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Abstract 
 
Glycobiology is the comprehensive study of the structure, biosynthesis, function and 
evolution of saccharides which are also named sugars or glycans. Glycosylation is a type of 
modification in which sugars are added to another molecule, such as a protein molecule or a 
ceramide. Abnormal glycosylation is frequently associated with diseases such as cancer and 
immune responses. Defining glycan structures is therefore important for understanding 
glycan function in health and disease. In addition, identification of glycan populations can 
provide essential information for further research on glycoproteins and glycolipids. In this 
thesis, glycomic experimental approaches were employed to characterize the structures and 
populations of glycans of glycoconjugates from HeLa cells, normal human dermal fibroblast 
(NHDF) cells, myoblasts, myotubes and trophoblasts. These approaches include sample 
preparation methodologies which were followed by the application of highly sensitive mass 
spectrometry, particularly MALDI-TOF MS, MALDI-TOF/TOF MS/MS and GC-MS. 
Ribosome inactivating proteins (RIPs) and lectins from elderberry are more toxic to HeLa 
cells than to NHDF cells. The difference in the cytotoxicity was hypothesized to be caused by 
the difference in the glycome patterns of HeLa and NHDF cells. To test the hypothesis, 
glycome patterns on both glycoproteins and glycolipids of HeLa and NHDF cells were 
investigated. Glycomic results have revealed that glycome patterns in HeLa cells and NHDF 
are different, and this gives a possible explanation for the difference observed in the 
cytotoxicity assay. 
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first enzyme of the 
hexosamine biosynthetic pathway which yields uridine diphosphate N-acetylglucosamine 
(UDP-GlcNAc), an essential substrate for protein glycosylation. N-glycan branching is 
especially sensitive to alterations in the concentration of this sugar nucleotide. Mutations in 
the gene GFPT1 can result in “limb-girdle CMS with tubular aggregates” which is a subtype 
of congenital myasthenic syndromes (CMS). To investigate whether protein glycosylation at 
the neuromuscular junction might be involved in this impairment, the N-glycomes of 
myoblasts and myotubes derived from healthy controls and patients were investigated. My 
result showed that global glycosylation is not significantly impaired in the muscle cells from 
the CMS patients caused by GFPT1 mutations.  
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The human fetoembryonic defense system hypothesis (hu-FEDS) is a hypothetical model 
depicting a way via which the human immune system is able to recognize foreign substances 
as "own species" as has been observed with maternal immune tolerance in pregnancy. The 
fundamental idea of this hypothesis is that glycoproteins existing in the reproductive system 
and exposed on gametes can either inhibit immune responses or prevent rejection of the 
foetus. This model has not been tested in human trophoblasts. My glycomic analyses of three 
trophoblast populations (CTB, STB and evCTB) revealed that functional glycan structures 
that are present on human gametes are also expressed on trophoblasts, and this provides 
further evidence for the hu-FEDS hypothesis. 
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1. Introduction 
 
1.1. Glycobiology 
 
Glycobiology is the comprehensive study of the structure, biosynthesis, function and 
evolution of saccharides in biological systems (Kiessling and Splain, 2010; Cummings and 
Pierce, 2014). It has only recently become a branch of molecular and cellular biology. The 
term glycobiology, formally coined in August 1988, is used to recognize the coming together 
of the traditional disciplines of carbohydrate chemistry and biochemistry (Blow, 2009). This 
union is a consequence of the dramatically increased understanding of glycans in molecular 
and cellular biology in the last 30 years. 
Glycans are compounds consisting of a series of glycosidically linked monosaccharides. Like 
amino acids and nucleic acids, glycans are also widely distributed in nature (Hart, 2013). All 
cells in nature are covered with a complex array of sugar chains, termed the glycocalyx 
(Varki, 2007). As an example, an erythrocyte surface glycocalyx in cross-section is shown in 
Figure 1.1. Consistent with the high glycan abundance on cells, genomic sequencing studies 
from eubacteria to eukaryotes show that approximately 1% of the genome contributes to 
sugar processing enzymes. Moreover, these glycan related genes are highly conserved 
(Coutinho et al., 2003; Kiessling and Splain, 2010).  
 
Figure 1.1 Electron microscopy: an erythrocyte surface glycocalyx 
The cell has been stained using special staining techniques. It is up to 1400 Å thick, and the 
oligosaccharide filaments are 12–25 Å in diameter. The glycocalyx is comprised of abundant 
carbohydrate-rich molecules, polysaccharides, proteoglycans, glycoproteins and glycolipids 
(Roseman, 2001; Voet and Voet, 2004). 
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It has long been known that carbohydrates serve as an energy source. However, a re-
evaluation of the biological role of glycans is required (Rademacher et al., 1988) because 
glycans have many other functions. For example, they were found to be the essence of 
antigenic determinants in the ABO blood group system (Cohen et al., 2009). In addition, 
glycans play a pivotal role in the attachment of the influenza virus to the host cells (Chu and 
Whittaker, 2004; Varki, 2007). Indeed glycans are involved in the recognition of host cells by 
most pathogens. Over the last 30 years a large amount of data has been assembled 
demonstrating the importance of glycans. In point of fact, for the most part, carbohydrates do 
not exist and function as simple sugars but as complex molecular conjugates. Thus glycans 
are usually found in covalent association with proteins and lipids via glycosylation 
(Rademacher et al., 1988). 
 
1.2. Glycosylation 
 
In biology, glycosylation is an enzymatic reaction that attaches glycans to proteins, lipids, or 
other organic molecules (Taylor and Drickamer, 2011; Freeze, 2006). In this thesis, the main 
focus is protein N- and O-glycosylation and glycosphingolipid glycosylation. 
 
1.2.1. Monosaccharides 
 
Monosaccharides are the basic constituents of glycans. Hexoses are monosaccharides which 
possess six carbons  designated carbon 1 (C1) to carbon 6 (C6) from the top which is an 
aldehyde group to the bottom which is a hydroxymethyl group (Figure 1.2). Four of these six 
carbons (C2, C3, C4 and C5) are chiral, which means each one has two configurations, so 
theoretically there are sixteen (24) potential structures, half of which are defined as L-hexoses 
and the remaining are termed D-hexoses. The difference between the D- and L- structure is 
determined by the configuration of C5. The structure of a D-monosaccharide is the mirror 
image of the structure of its corresponding L-form. Two stereoisomers (not identical) that are 
mirror images of each other are termed enantiomers. For instance, D-Glucose and L-Glucose 
are enantiomers. An alteration of configuration at each chiral carbon is called epimerization, 
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which will yield a new monosaccharide. For instance, epimerization at C4 of D-Glucose 
produces D-Galactose (Figure 1.2), and thus these two monosaccharides are termed epimers. 
 
Figure 1.2 Fischer projection of D-Glucose and D-Galactose, chair conformations of D-Glucose 
and Haworth representations of D-Glucose 
The D-Glucose linear structure is shown in the form of Fischer projection. It converted into D-
Galactose after the epimerization occurred at C4 (red frame) of the Glu. The ring structure of D-
Glucose is formed via the reaction of the hydroxyl group at C5 and the aldehyde group at C1 which 
are labelled using purple frames. C1 in α and β anomers of D-Glucose are emphasized in light blue 
frames.     
 
The hexose linear structure is transformed into the ring structure via reaction of the hydroxyl 
group at C5 with aldehyde group at C1 (Figure 1.2). In the ring structure, C1 becomes a 
chiral or “anomeric” carbon, and the different configurations of this carbon are known as α 
and β anomers. It is easy to distinguish these two anomers: in the Haworth representation of a 
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D-monosaccharide if the anomeric hydroxyl group is below the ring plane the 
monosaccharide is the α anomer; if the hydroxyl group is above the plane the 
monosaccharide is the β anomer.  
Other monosaccharides can be obtained from hexoses via some modifications. For instance, a 
deoxyhexose can be acquired via the removal of an oxygen from a hexose, and an N-
acetylhexosamine (HexNAc) can be produced by replacing a hydroxyl group with an 
acetylated amino group. In addition, HexNAcs can be further modified to yield acidic sugars.      
Monosaccharides are connected via glycosidic bonds to form oligo- and polysaccharides. 
Figure 1.3 displays a linkage between a glucose (Glc) and a galactose (Gal), which is formed 
via the reaction of the anomeric carbon C1 of the Gal and the hydroxyl group at C4 of the Glc. 
This disaccharide is called lactose. Because the oxygen in the hydroxyl group at the C1 
position of Gal is in the β configuration and this oxygen is linked to the C4 of Glc, the 
glycosidic bond is called a β1,4 linkage. In this newly formed disaccharide, there is a 
reducing end and a non-reducing end. The reducing end is actually a hemiacetal group, which 
can reduce inorganic ions like Cu2+ while the non-reducing end does not have this activity. It 
is conventional that the non-reducing end and the reducing end are drawn on the left hand 
side and right hand side, respectively. 
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Figure 1.3 The β1,4 linkage between a Gal and a Glc 
A β1,4 linkage is formed between a Gal and a Glc via the reaction of the anomeric carbon C1 of Gal 
and the hydroxyl group on the C4 of Glc. The product is lactose. The reducing end and the non-
reducing end of the project are labelled. Cartoon symbols for Gal and Glc are also shown. 
 
In addition, it is convenient to show a glycan, such as lactose, via symbolic representation; 
symbols such as these are used to represent the sequences of glycans in this thesis and are 
discussed in detail below. 
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Table 1.1 Seven common monosaccharides in humans 
The classification, name, abbreviation and structure of each monosaccharide are listed. 
 
 
In human glycoproteins and glycolipids there are 7 common monosaccharides (Table 1.1): 4 
neutral monosaccharides, 2 amino monosaccharides and 1 acidic monosaccharide (Goldberg 
et al., 2009). As shown in the table, Man and Gal are different from Glc at C2 and C4 
respectively. Fucose (Fuc) is different from other monosaccharides as its natural 
configuration is the L-stereoisomer while others are D-form. The difference between D-Gal 
and D-Fuc is that at C6 position there is a hydroxyl group in the former while in the latter the 
hydroxyl group is replaced by a hydrogen atom, and thus the Fuc can also be called 6-deoxy-
Gal. Replacing the hydroxyl group with an acetylated amino group at C2 in Glc and Gal 
forms N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc) respectively; 
both of which are amino monosaccharides. The acidic sugar (sialic acid) is more complicated: 
1. it possesses 11 carbon atoms, 2. it still forms a ring structure, but unlike previously 
mentioned monosaccharides, the ring structure is formed via the reaction of the carbonyl 
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group at C2 and hydroxyl group at C6, 3. it carries a carboxyl group at C1, an acetylamino 
group at C5 and a glycerol group at C6.   
Human glycoproteins have a limited repertoire of sugars; useful parameters of these glycans 
have been summarized in Table 1.2, which can be used as a reference for the glycomic data 
analysis.  
Table 1.2 Parameters of the seven common monosaccharides in humans 
The classification, abbreviation, symbol, mass, residue mass and permethylated residue mass of each 
monosaccharide are listed. The symbol is assigned to each monosaccharide according to the rules 
adopted by the Consortium for Functional Glycomics (CFG) (http://www.functionalglycomics.org/) 
and the Essentials of Glycobiology (http://www.ncbi.nlm.nih.gov/books/NBK1931/figure/ch1.f5/?r 
eport=objectonl) online textbook.     
Monosaccharide Symbol Mass Residue mass Permethylated residue mass 
Deoxyhexose Fuc   164 146 174 
Hexose Glc  
Gal  
Man  
 
180 
 
162 
 
204 
HexNAc GalNAc  
GlcNAc  
 
221 
 
203 
 
245 
Sialic acid NeuAc  309 291 361 
 
1.2.2. Protein glycosylation 
 
Protein glycosylation is ubiquitous in eukaryotes especially in extracellular matrices and 
cellular surfaces (Weerapana and Imperiali, 2006). It has been estimated that more than 50% 
of all proteins in nature are glycosylated (Apweiler et al., 1999). Glycosylation usually 
contributes to the maintenance of a protein structure; and therefore has an influence on the 
glycoprotein function. For instance, glycans contribute to the structure and stability of 
immunoglobulins, which is essential for their binding to receptors (Arnold et al., 2007; 
Schroeder and Cavacini, 2010). Sometimes, glycosylation-associated function is more 
dependent on the presence of the carbohydrates, rather than on the protein structure (Kent, 
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2004). For instance, the binding of human sperm to an ovum is regulated by a tetrasaccharide 
sialyl-Lewis X [NeuAcα2,3Galβ1,4(Fucα1,3) GlcNAc] on the zona pellucida (Pang et al., 
2011).  
As previously mentioned, glycans are attached to proteins by covalent bonds via 
glycosylation. There are two common glycosylation types: ‘N-linked’ to asparagine (Asn) 
residues and ‘O-linked’ to serine (Ser) or threonine (Thr) residues (Tissot et al., 2009; Taylor 
and Drickamer, 2011). 
 
1.2.2.1. N-glycosylation 
 
Most N-glycosylation occurs co-translationally, which means the glycosylation occurs before 
the protein is folded (Culyba, 2012). Intriguingly, unlike proteins which use DNA as template, 
no template is involved for the biosynthesis of N-glycans (Kiessling and Splain, 2010). 
 
Figure 1.4 Biosynthesis of the lipid-linked N-glycan precursor 
L, dolichol; PP, a pyrophosphate;  GlcNAc,  Man,  Glc. 
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The biosynthesis pathway of N-glycans can be divided into 3 steps:  
1. A lipid-linked 14-sugar (2 GlcNAc, 9 Man and 3 Glc) precursor is produced by a series of 
glycosyltransferases (Kornfeld and Kornfeld, 1985; Freeze, 2006). The lipid and the 
oligosaccharide are connected via a pyrophosphate linkage. The synthesis of the precursor 
occurs in two cellular locations (Figure 1.4): firstly on the cytoplasmic side of the 
endoplasmic reticulum (ER) membrane, the first GlcNAc from a uridine diphosphate (UDP)–
GlcNAc is attached to a dolichol via an enzyme, dolichyl-phosphate (UDP-N-
acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (DPAGT1), then the 
remaining 6 monosaccharides (1 GlcNAc and 5 Man) are synthesized using UDP–GlcNAc 
and guanosine diphosphate (GDP)–Man, after that this structure is translocated into the ER 
lumen via a flippase; secondly in the ER lumen another 7 monosaccharides (4 Man and 3 Glc) 
from dolichol phosphate Man and dolichol phosphate Glc are sequentially added to complete 
the synthesis of the precursor (Freeze et al., 2014). Defects in enzymes which are responsible 
for the biosynthesis of the 14-sugar (2 GlcNAc, 9 Man and 3 Glc) lipid-linked precursor 
oligosaccharide typically result in type 1 congenital disorders of glycosylation (CDG-1) 
(Freeze and Aebi, 2005; Freeze, 2006; Freeze et al., 2014).  
2. The oligosaccharide is entirely transferred to an N-glycosylation site of a polypeptide by 
the oligosaccharyltransferase (OST) in the ER (Figure 1.5A). In mammalian cells, it starts 
with the formation of a β-linkage between the oligosaccharide reducing terminal N-
acetylglucosamine (GlcNAc) and the amide nitrogen of asparagine (Asn) on a target 
polypeptide (Figure 1.5B) (Freeze, 2006; Lowe and Marth, 2003). The Asn is usually found 
in a conserved sequence Asn-B-Thr or Asn-B-Ser, in which B can be any amino acid except 
Proline (Pro), although Asn in other sequences, such as Asn-B-Cys (cysteine), can be 
glycosylated as well (Matsui et al., 2011). Pro cannot be the middle residue because it will 
prevent the formation of a loop which is essential for the glycan transfer.  
3. Following the transfer of the precursor to the target polypeptide, oligosaccharide 
processing is carried out initially in the ER and then in the Golgi apparatus (Aebi et al., 2010). 
The three Glc residues are firstly removed; the outer one is cleaved by ER glucosidase І and 
the inner two are removed by ER glucosidase ІІ. The remaining oligosaccharide is then 
processed by a series of mannosidases (ER mannosidase, Golgi mannosidases 1A, 1B and 1C) 
yielding a high mannose oligosaccharide (usually possessing 9 to 5 Man residues). The 
initiation of a hybrid or complex N-glycan begins with the action of GlcNAc transferase I 
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(GlcNAc-T I) on a heptasaccharide in the Golgi apparatus, the structure of which is 
Manα1,3(Manα1,3(Manα1,6Manα1,6))Manβ1,4GlcNAcβ1,4GlcNAc. After this, an 
octasaccharide is yielded. Hybrid glycans will be formed when mannosidases do not act on 
this octasaccharide. The two outer mannose residues in the octasaccharide are removed by α-
Mannosidase II generating a substrate for GlcNAc-T II (Figure 1.5A). A Fuc can be 
transferred from GDP-Fuc to the proximal GlcNAc via the action of fucosyltransferase VIII. 
The resulting N-glycan is extended by the addition of Gal to generate a complex N-glycan 
(Freeze et al., 2014; Schwarz and Aebi, 2011; Freeze, 2006; Takahashi et al., 2009).  
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Figure 1.5 A simplified biosynthesis pathway of N-glycans and the structure of a GlcNAc 
residue on an Asn 
A. The linkage in the precursor is labelled. The heptasaccharide (5 Man and 2 GlcNAc) is the core 
structure of both hybrid and complex N-glycans. In addition to these processes, others can also occur 
including biosynthesis of polylactosamine antenna, addition of Fuc, and other modifications; L, 
dolichol; PP, a pyrophosphate; the process highlighted in pink shadow is carried out in the ER and the 
process highlighted in green shadow is performed in the Golgi apparatus;  GlcNAc,  Man,  Glc,
 Gal,  Fuc,  NeuAc, OST, oligosaccharyltransferase. B. The structure of a GlcNAc (black) 
attached to an Asn (red) residue. The linkage between the GlcNAc and the Asn is β-form. 
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A GlcNAc attached to the 4-position of the β-linked core Man by GlcNAc-T III is considered 
as a bisecting structure which is not considered as an antenna (Figure 1.6). Addition of this 
GlcNAc requires the prior action of GlcNAc-T I. Bisecting GlcNAc cannot be further 
extended. In vitro, the presence of this structure prevents the actions of GlcNAc-T II, IV and 
V, α-mannosidase II and core α 1,6-Fuc-T (Schachter, 1991; Takahashi et al., 2009). 
However, in vivo GlcNAc T-III can act after core fucosylation and antennae initiation, so 
bisected structures can be core fucosylated as well as multiantennary (Hashii et al., 2009; 
Klisch et al., 2008). 
 
Figure 1.6 Branching of complex N-glycan 
The first antenna is initiated by GlcNAc-T I, GlcNAc-T II yields a biantennary glycan, GlcNAc-T III 
creates a bisecting glycan. More branched complex N-glycans can be produced via the action of 
GlcNAc-T IV, V and VI.  GlcNAc,  Man. 
 
Complex glycans can have more than four antennae in some vertebrates, but human N-
glycans usually possess four antennae at the most. These antennae can be modified with a 
variety of monosaccharides, such as Fuc and NeuAc. These modifications occur in the trans-
Golgi apparatus and lead to many terminal structures which can be functionally important. 
Figure 1.7 shows that an antenna in a biantennary glycan can be modified variously. In 
addition, the core of this biantennary glycan can also be modified with Fuc, which in 
mammals, is linked to the 6 position of the proximal GlcNAc. The order of monosaccharide 
addition and removal is not random but guided, and some enzymes are able to compete for 
the same substrate, which generates various N-glycans. Nearly all proteins that pass through 
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the ER–Golgi conduit are N-glycosylated, and a lack of this modification can be fatal in 
species ranging from yeast to mammals (Freeze, 2006).  
 
Figure 1.7 Common modifications of the antennae in N-glycans 
The antennae labelled in red frame are Lewis blood groups, their names are written in red under the 
structures. The antennae labelled in blue frame are ABO blood groups, their names are written in blue 
under the structures. S, sulphate group.  GlcNAc,  GalNAc,  Gal,  Man,  Fuc,   NeuAc.   
 
As previously mentioned, each antenna can be extended in the form of LacNAc (N-
acetyllactosamine), and then further decorated by Fuc, sialic acid and/or sulpho groups to 
yield many structures (see Figure 1.7) which could bear variable functional roles. For 
instance, with L-selectin, optimal recognition involves a sulphated type of sialyl Lewis X, in 
which the sulphate group is specifically at the 6 position of the GlcNAc residue (Varki, 2007). 
Since there are N-glycosylation consensus sites, a program named NetNGlyc 1.0 Server has 
been developed, which is widely used for looking for the consensus sequence and thus 
making a general N-glycosylation site prediction (Gupta and Brunak, 2002). 
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1.2.2.2. O-glycosylation 
 
Generally speaking, O-glycosylation is not as well understood as N-linked glycosylation. 
There are several types of O-glycans that are classified by the first carbohydrate residue 
which is added to the amino acid residue, such as O-fucosylation for fucose (Fuc), O-
glucosylation for glucose (Glc), O-mannosylation for mannose (Man) and O-GalNAcylation 
for N-acetylgalactosamine (GalNAc) (Wopereis et al., 2006; Martínez-Duncker et al., 2012; 
Gebauer et al., 2008). Some O-glycosylations can occur in conserved domains, for instance, 
in epidermal growth factor (EGF)-like domains O-fucosylation and O-glucosylation can 
occur in conserved sequences Cys-B-Ser-B-Pro-Cys and Cys-B-B-Gly-Gly-Thr/Ser-Cys 
respectively, in the conserved sequences B can be any amino acid (Harris and Spellman, 1993; 
Gebauer et al., 2008). However, some other O-glycosylation, such as the O-GalNAc 
glycosylation, does not occur in conserved sequences. This may be due to the fact that there 
are various transferases with overlapping but different substrate specificities.  
Unlike N-glycans, the biosynthesis of O-glycans is carried out after protein folding in the late 
ER or in one of the Golgi compartments (Wopereis et al., 2006; Spiro, 2002; Rapoport et al., 
1996). The biosynthesis of O-glycans does not start with the en-bloc transfer of a dolichol-
linked precursor, but with the attachment of a monosaccharide to the target peptide chain 
(Wopereis et al., 2006). 
 
1.2.2.2.1. O-GalNAc glycosylation 
 
GalNAc-linked O-glycans are often referred to as mucin type (Bergstrom and Xia, 2013). It 
has been considered as the most differentially and complex controlled type of protein 
glycosylation (Steentoft et al., 2013; Lira-Navarrete et al., 2015). 
O-GalNAc glycosylation is initiated in the Golgi apparatus by the addition of a GalNAc to 
the oxygen of the hydroxyl group of Ser or Thr forming an O-GalNAc linkage (Figure 1.8), 
and this reaction is catalysed by polypeptide N-acetylgalactosaminyltransferases (pp-
GalNAc-T) (Yoshimura et al., 2012; Ten Hagen et al., 2003). They feature two domains: a 
catalytic domain and a lectin domain (Lira-Navarrete et al., 2015). It is reported that in 
humans there are 20 pp-GalNAc-Ts (Bennett et al., 2012; Lira-Navarrete et al., 2015). These 
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enzymes can be classified into two categories, those that add a GalNAc to an unmodified 
peptide acceptor and those that favour acceptor peptides containing a GalNAc already (Ten 
Hagen et al., 2003; Lira-Navarrete et al., 2015). The underlying mechanism of how the 
GalNAc-T lectin domain contributes to glycopeptide specificity and catalysis is still not clear. 
Very recently, a group of scientists have presented the first crystal structures of GalNAc-T2 
in complex with defined GalNAc-glycopeptide substrates, and they also demonstrated a 
cooperative mechanism via which the GalNAc-T lectin domain enables unoccupied acceptor 
site binding of glycopeptides in the catalytic domain (Lira-Navarrete et al., 2015). 
 
Figure 1.8 The structure of a GalNAc attached to a Ser or a Thr 
The linkage between the GalNAc (black) and the Ser or Thr (red) is α-type. R=H in Ser, R = CH3 in 
Thr. 
 
O-GalNAc, the simplest mucin O-glycan, is also termed the Tn antigen (Gill et al., 2011). 
This antigen and its sialylated form (NeuAcα2,6GalNAc) are usually observed in mucins 
from tumours but not normal tissues or cells (Brockhausen et al., 1995; Julien et al., 2012). 
Further addition of one or two monosaccharides to the Tn antigen creates 8 core structures of 
O-glycans (Figure 1.9), 4 of which are most common: core 1 (T antigen), core 2, core 3 and 
core 4. The T antigen is derived from O-GalNAc by a core 1 β1,3-galactosyltransferase 
(β1,3Gal-T). In many glycoproteins, the antigen is usually sialylated at the C3 position of the 
Gal or GlcNAcylated at the C6 position of the GalNAc by a β1,6-N-
acetylglucosaminyltransferase creating the core 2 structure. In another pathway the core 3 
structure can be created by a core 3 β1,3-N-acetylglucosaminyltransferase. The core 4 
structure is yielded by adding a GlcNAc to the core 3 GlcNAc in a β1,6 linkage. The core 5 
to core 8 structures show restricted expression: core 5 has been found in human meconium 
and intestinal adenocarcinoma tissue, core 6 has been detected in human intestinal mucin and 
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ovarian cyst mucin, core 8 has been reported in human respiratory mucin, and core 7 has only 
been found in bovine submaxillary mucin (Brockhausen, 1999; Wopereis et al., 2006; Varki, 
2009; Chai et al., 1992). 
Antennae on O-glycans can be extended in a similar mode to that described in the N-glycan 
biosynthesis in section 1.2.2.1.  
 
Figure 1.9 Eight Core structures of mucin type O-glycans  
The enzymes involved in the synthesis of these core structures are labelled in blue. These structures 
may be further modified by other glycosyltransferases.  GlcNAc,  GalNAc,  Gal. 
 
Although there is no O-GalNAcylation (mucin type) consensus sequence, statistical studies 
have shown several general rules for the mucin type glycans, such as O-GalNAcylation 
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preferring sequences rich in Ser, Thr and Pro (Elhammer et al., 1993). Based on these rules, a 
program called NetOGlyc 4.0 Server has been developed and it is now available on the 
Internet and is able to predict approximately 75% of mucin-type glycosylated residues 
correctly (Julenius et al., 2005; Wopereis et al., 2006). 
 
1.2.3. Glycolipid glycosylation 
 
In addition to being attached to proteins, glycans can also be added to lipids, and this type of 
glycoconjugate is termed glycolipid. Glycolipids play pivotal roles in cell membrane 
structure, cell-cell interaction, cell-molecule interaction and modulating the function of 
membrane proteins (Varki, 2009; Lahiri and Futerman, 2007). Based on the locus of the lipid 
parts, glycolipids can be divided into two categories: glycosphingolipids (GSLs) which are 
built on a ceramide and glycophospholipids which are located at a phosphatidylglycerol core 
(Taylor and Drickamer, 2011). GSLs can be found in virtually all plasma membranes of 
mammalian cells (Yamashita et al., 1999; Kolter and Sandhoff, 1998). In this thesis, the main 
focus is the glycosylation of GSL. 
 
1.2.3.1. Glycosphingolipid glycosylation 
 
GSLs are composed of ceramide (Cer), which contains a fatty acid portion and a sphingosine 
portion and one or more attached saccharides (Figure 1.10). GSL is a functionally important 
group of glycolipids found in the membranes of cells from bacteria to humans (Jia et al., 2014; 
Varki, 2009). It functions either like membrane glycoproteins which are involved in cell-cell 
interactions or in the formation of membrane domains (Taylor and Drickamer, 2011). For 
instance, one type of glycosphingolipid, gangliosides, can function as toxin receptors (Lahiri 
and Futerman, 2007). 
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Figure 1.10 The structure of a Glc residue attached to ceramide 
The ceramide (Cer) of glycosphingolipids is composed of a long-chain amino alcohol, sphingosine 
(red), in amide linkage to a fatty acid (green). 
 
Based on the first sugar attached to the sphingosine, GSLs can be divided into two subgroups: 
when the first sugar is a Gal, the GSL belongs to galactosphingolipid subgroup, when the first 
sugar is a Glc, the GSL is a member of the glucosphingolipid subgroup (Sillence, 2007). In 
mammals only Glc and Gal can be added to the Cer directly. GalCer can be sulphated, and its 
sulphated derivatives are termed sulfatides. The sulfatide is abundant in myelin (Merrill, 2011; 
Gault et al., 2010). It is reported that the sulfatide plays an important role in the maintenance 
of CNS myelin and axon structure in mice (Marcus et al., 2006). GlcCer serves as the 
precursor for complex glycosphingolipids while GalCer is simpler (Merrill, 2011). In this 
thesis, the glucosphingolipid subgroup is the focus. 
The biosynthesis of glucosphingolipids starts with the synthesis of Cer in the ER (D'Angelo 
et al., 2013; Merrill, 2002; Kolter et al., 2002). The sugar addition is initiated in the Golgi: 
the Cer moves to the cis-Golgi, probably via vesicular transport (Gault et al., 2010), and the 
addition of the first Glc residue from a nucleotide sugar donor UDP-Glc to the Cer occurs at 
the cytosolic surface of the Golgi apparatus. This reaction is catalysed by ceramide 
glucosyltransferase which was initially detected in an embryonic chicken brain in 1968 
(D'Angelo et al., 2013; Funakoshi et al., 2000; Ichikawa et al., 1996; Basu et al., 1968). After 
this the GlcCer is transferred by a poorly defined GlcCer transporter to trans-Golgi network. 
This is proposed to be operated by a protein termed four-phosphate adaptor protein 2 (FAPP2) 
which also controls vesicular trafficking from the Golgi apparatus to the plasma membrane 
(D'Angelo et al., 2012; D'Angelo et al., 2007). Additional sugars are added from nucleotide 
sugar donors in the Golgi apparatus. Firstly, lactosylceramide (Galβ1,4GlcβCer) is produced 
by addition of Gal, catalysed by a β1,4 galactosyltransferase (GalT) (Lannert et al., 1994; 
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D'Angelo et al., 2013). Further modifications of this structure can yield a series of core 
structures (Figure 1.11).  
 
Figure 1.11 Several core structures of glycosphingolipids (GSLs) 
GSLs have lacto-, neolacto-, ganglio- and globo-core structures. As shown in the figure, the lacto-
series GSLs are based on the core structure Galβ1,3GlcNAcβ1,3Galβ1,4GlcβCer, whereas neolacto-
type is built on core structure Galβ1,4GlcNAcβ1,3Galβ1,4GlcβCer, ganglio-series is constructed on 
Galβ1,3GalNAcβ1,4Galβ1,4GlcβCer, globo-type is formed on GalNAcβ1,3Galα1,4Galβ1,4GlcβCer. 
 GlcNAc,  GalNAc,  Glc,  Gal. 
 
A group of glycosphingolipids were extracted from ganglion cells, and based on this fact this 
group of glycosphingolipids were called gangliosides. This term was coined by the German 
biochemist Klenk (Kolter, 2012).  
In gangliosides the core is extended by a β1,4 N-acetylgalactosaminyltransferase (GalNAc-T) 
transferring a GalNAc to the Galβ1,4GlcβCer described previously. In addition, ganglioside 
biosynthesis involves the activities of Gal and NeuAc transferases, the abbreviations of which 
are Gal-T and Sia-T shown in Figure 1.12. The ganglioside-glycans are synthesised when 
they travel through Golgi as the enzymes required are attached at the membrane of the Golgi 
and function sequentially. 
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Figure 1.12 Biosynthesis pathway, structure and nomenclature of brain gangliosides 
The ganglioside is labelled via Svennerholm nomenclature which is complicated: the G is the abbreviation of ganglioside. The second capital character stands 
for the sialylation state of every glycans: A means asialylated, M stands for monosialylated, D is short for disialylated, T is the abbreviation of trisialylated 
and so forth. The number here assigned to individual glycan refers the migration order of this glycan in a certain chromatographic system (Svennerholm, 
1963).  GalNAc,  Glc,  Gal,  NeuAc.   
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As shown in the figure, in some ganglioside-glycans, such as GD1b, GD3 and GT3, there is 
α2,8 linked NeuAc (Figure 1.12). This linkage has been observed in disialosyl motifs on 
human O-glycans but not in N-glycans (Traving and Schauer, 1998; Fukuda et al., 1987). 
This can be explained by an in vitro study, the result of which showed that the hST8Sia VI 
recombinant enzyme has substrate specificity; this enzyme needed the trisaccharide 
Neu5Acα2,3Galβ1,3GalNAc to produce disialosyl motifs particularly on O-glycans 
(Teintenier-Lelievre et al., 2005). 
 
1.3. Biological importance of glycans in glycoproteins and GSLs  
 
Since glycoproteins and GSLs are commonly found on cell membranes, they play important 
roles in cell-cell and cell-molecule interactions.  
It has long been realized that proteins with various glycosylation have varied biological 
properties. Although the glycan portion is considered as a decoration on the proteins, some 
glycans are also important (Bateman et al., 2010; Yoshida-Moriguchi et al., 2010). For 
instance, the binding of human sperm to the zona pellucida (ZP) which is the extracellular 
matrix coating of the oocyte is regulated by the oligosaccharide sialyl-Lewis X 
[NeuAcα2,3Galβ1,4(Fucα1,3)GlcNAc] on the ovum surface but not Lewis X 
[Galβ1,4(Fucα1,3)GlcNAc] (Pang et al., 2011).  
GSLs are considered to be integral for many vital cell membrane biological events, including 
cellular interactions, signalling, and trafficking (Yamashita et al., 1999). GSLs are capable of 
forming microdomains on membranes, and these microdomains are believed to be involved 
in recognition events and cell signalling (Hakomori, 2004; Gupta and Surolia, 2010). It is 
known that some growth factor receptors, such as the epidermal growth factor receptor and 
the nerve growth factor receptor are located in membrane microdomains and there is 
evidence that signalling functions are considerably regulated by glycolipids (Hakomori, 
2003). It has also been reported that in the mouse, in the absence of GSL synthesis, 
embryogenesis proceeded well into gastrulation with differentiation into primitive germ 
layers and patterning of the embryo but was finally ceased by an apoptotic process 
(Yamashita et al., 1999).  
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The following table gives a few more examples to show the biological importance of glycans. 
Table 1.3. A few more examples showing that N-, O- and GSL glycans are biologically 
important 
Glycan type Related enzyme/gene Results 
 
 
N-glycan 
 
Phosphomannose 
isomerase 
Mutations in this gene could cause deficient N-glycan 
biosynthesis, which could result in congenital disorder of 
glycosylation type Ib (Lonlay and Seta, 2009). 
Fuc-T VIII Fut8-knockout mice displayed severe growth retardation, 
and 70% of the mice died within a few days after birth 
(Zhao et al., 2008). 
 
 
O-glycan 
Core 1 β1,3Gal-T Genetic ablation of this enzyme in mice results in 
defective angiogenesis and fatal brain hemorrhages 
(Guzman-Aranguez and Argueso, 2010). 
Core 2 GlcNAc-T I Mutations in this gene lead to defective leukocyte P-
selectin ligand activity (Ellies et al., 1998). 
 
GSL glycan 
GM2 (see Figure 
1.12 for the GM2 
structure) synthase 
Mice display severe neurological pathology and die soon 
after birth once the GM2 synthase is deleted (Lingwood, 
2011). 
  
Furthermore, the 2012 National Academy Sciences report has demonstrated that a better 
understanding of glycoscience is essential for advancement of human health and 
sustainability on the earth (Hart, 2013). 
Even the 2014 FDA Guidance for Industry implies the importance of glycans (FDA, 2014): 
“For proteins that are normally glycosylated, use of a cell substrate production system and 
appropriate manufacturing methods that glycosylate the therapeutic protein product in a 
nonimmunogenic manner is recommended ”. 
All these indicate that the glycosylation and glycans play vital roles in biological processes. 
 
1.4. Glycomics 
 
Since the importance of glycans has been highlighted in the previous section, it is now 
necessary to introduce glycomics.   
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1.4.1. Introduction to glycomics 
 
Glycomics is the comprehensive study of all glycan structures in a provided organism, tissue 
or cell cluster (Varki, 2009). Glycomic experimental approaches had been employed in all the 
projects. The term ‘glycomics’ is composed of two parts: the prefix ‘glyco-’ which means 
sweetness, and the suffix"-mics" which relates to a field of study in biology for example 
genomics and proteomics. Like genomics and proteomics  are focused on genes and proteins, 
respectively, glycomics seeks to illustrate the importance of glycans in biological systems 
(Cummings and Pierce, 2014). It is believed that the increased understanding of glycan 
functions is beneficial for drug discovery and disease treatments as there are more than 100 
human genetic disorders which are related to deficiencies in the different glycosylation 
pathways (Freeze et al., 2015). Additionally, some scientists are now paying attention to how 
carbohydrates affect neuromuscular junction disorders and immune tolerance in the human 
female reproductive tract (Senderek et al., 2011; Clark and Schust, 2013; Cummings and 
Pierce, 2014). New findings in these promising areas will be a significant step in biomedical 
research. 
Based on the ‘omics’ research trend from DNA to proteins of the past decade, it is expected 
that the next ten years will see a move towards greater exploitation of glycomics. 
 
1.4.2. Difficulties in a glycomic study 
 
Glycosylation is a complicated process. A single protein can be glycosylated heterogeneously. 
Here the ‘heterogeneously’ has two meanings, it either means that a glycosylation site is 
occupied by different glycans or a protein has more than one glycosylation site, but not all of 
the sites are occupied. For instance, there are two N-glycosylation sites in human transferrin, 
the locations of which are Asn-432 and Asn-630 respectively (Spik et al., 1975). In normal 
healthy people, these two sites are primarily occupied by two disialylated N-glycans, 
however in congenital disorders of glycosylation (CDG) type I patients only one site is 
primarily glycosylated, and in CDG type II patients two sites are fully occupied by 
underglycosylated (immature) structures (Freeze et al., 2015; Freeze, 2006). In addition, 
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unlike DNA and proteins which only have linear structures, glycans usually have antennae, 
which also complicate the research. 
Although traditional biological approaches such as gene knock out and Western blot are able 
to analyse glycan-related genes and the products, certain glycan-related information may be 
not clear. For instance, the glycan structures cannot be determined and it is not clear whether 
the glycosylation sites are fully occupied. In addition, it is also difficult to know the 
glycosyltransferases and glycosidases which are responsible for transferring and cleaving 
monosaccharides during glycan biosynthesis. Therefore glycomic research requires 
continuous development of new techniques which can overcome these difficulties. One of 
these techniques is mass spectrometry. 
 
1.5. Mass spectrometry 
 
Mass spectrometry (MS) is a technique that measures the mass-to-charge ratios of ions 
(Calvete, 2014). A mass spectrometer can be used to determine masses of molecules, analyse 
chemical compounds, and profile the structure of a molecule. MS has played an important 
role in the “Omics” Era (Di Girolamo et al., 2013). The apparatus is composed of three parts: 
an ion source, a mass analyser and a detector (Calvete, 2014).  
Although MS has been demonstrated since World War I, it could only be used to analyse 
small molecules due to the undeveloped technology (Keith, 1999). In 1960s, electron 
ionization was already used for the structural elucidation of di- and trisaccharides (Kochetkov 
et al., 1968). At that time it was difficult to analyse more complex oligosaccharides as the 
analyte should be sufficiently volatile and increased molecular weight of the analyte resulted 
in decreasing volatility. In addition, the mass range of the mass spectrometer also limited the 
analysis of the oligosaccharides with higher molecular weight. In the early 1970s, the 
Forssman glycolipid hapten of horse kidney was characterized using mass spectrometry 
(Karlsson et al., 1974). In this MS analysis, the signals of the molecular ions in the high mass 
range were generally small or absent, and thus its usefulness was limited. In late 1970s, mass 
spectrometry was firstly employed in glycoprotein sequencing (Morris et al., 1978; Dell and 
Morris, 2001). In addition, Dell and Morris carried out the first structural determination of 
glycans using Fast-atom-bombardment mass-spectrometry (Dell et al., 1983a). These indicate 
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that MS can be used in glycan related analysis. In the 1980s, the molecular weight of ions 
that mass spectrometers can deal with did not exceed 10,000 (Keith, 1999). Nowadays, with 
the development of related technology, MS hardware has been significantly improved. For 
instance, the employing of matrix-assisted laser desorption ionization tandem time-of-flight 
(MALDI-TOF/TOF) instrumentation permits the analysis of carbohydrates and proteins with 
masses up to hundreds of thousands (North et al., 2009). It is therefore considered to be a 
potent tool for expeditiously and precisely investigating high-mass and fragile molecules.  
 
1.5.1. Ion source techniques 
 
All mass spectrometry experiments require the analyte to be ionized before being analysed in 
the mass spectrometer. The ionization is achieved either via electron ejection or capture, or 
protonation/cationization or deprotonation. When choosing an ionization technique, the 
physicochemical properties of the analyte need to be considered. 
In the early days, electron impact or electron ionization (EI) and chemical ionisation (CI) 
were used (Munson, 1966; Rudge, 1968). However, these techniques are not so suitable for 
high molecular weight and non-volatile molecules. Since then new techniques, such as fast-
atom-bombardment (FAB) and matrix-assisted laser desorption ionization (MALDI), were 
developed, making direct ionisation and desorption of non-volatile substances possible. Here 
three ionization techniques EI, FAB and MALDI are introduced in detail as they are either 
closely related to my glycomic technologies or directly employed in my experiments.   
 
1.5.1.1. Electron ionization (EI) 
 
Electron ionization (EI), also known as electron impact, is an ionization technique in which 
accelerated electrons collide with volatile atoms or molecules to produce ions (Wittmann, 
2007; Horning et al., 1977). For ionizing small molecules, EI is widely used due to its 
advantages: it is a well-understood technique (Rudge, 1968); the ion source is inexpensive 
compared to others; it is easy to construct as basically it requires a small gap between two 
electrodes. This ion source is usually connected with gas chromatography (GC).  
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EI requires the analyte to have volatile and thermally stable properties (Dell and Morris, 
2001). During the ionization process (Figure 1.13) a beam of high-energy electrons strikes 
the analyte and knocks one electron out of the electron cloud of the analyte. Due to the loss of 
the electron, a singly charged cation M+· is formed. This ion has obtained a large amount of 
energy from the strike, as a result of which it fragments subsequently, yielding fragment ions 
with various relative abundances, which provides a 'fingerprint' for the analyte structure 
(Wittmann, 2007; Busch, 1995).  
 
Figure 1.13 Schematic view of the EI ion source 
The red M stands for an analyte molecule; Uacc is the electron accelerating potential, GC is short for 
gas chromatography. The efficiency of this technique and the yield of fragments are mainly 
determined by the property of the analyte and the energy of the electron beam. If the energy of the 
electrons is much lower than required, the interaction between the electron and the analyte is not able 
to transfer adequate energy, as a result of which the ionization will not occur. If the energy of the 
electron is much higher than the required, the ionization will not occur either. Only when the energy is 
around the required value does the De Broglie wavelength of the electron match the length of the 
chemical bonds in the analyte, and maximum energy can transfer to the analyte, resulting in ionization. 
 
Although this technique works well for volatile analytes, it causes substantial fragmentation, 
as a result of which the molecular ions are usually absent or very weak. Thus EI is considered 
as a ‘hard’ (it causes the ion to fragment) ionization technique (Hejazi et al., 2009; Horning et 
al., 1977; Dell and Morris, 1974; Sutton-Smith and Dell, 2006). 
50 
 
 
1.5.1.2. Fast atom bombardment (FAB) 
 
FAB has become a potent structural analysis tool since the reports of its application in 1981 
(Dell et al., 1981; Barber et al., 1981a; Barber et al., 1981d; Morris et al., 1981b). This 
ionization technique is usually coupled with a magnetic sector mass analyser. It has been 
employed to analyse inorganic ion clusters to mass 25800 Da and peptides to mass 5700 Da 
in the early 1980s (Rinehart, 1982). In FAB (Figure 1.14), the sample to be analysed was 
mixed with a viscous and non-volatile matrix (usually thioglycerol) and bombarded in 
vacuum by a high energy beam of ions or atoms (Rinehart, 1982; Barber et al., 1981c; Dell 
and Morris, 2001). The bombardment transfers energy to the sample molecule in the matrix, 
which allows the molecule to sputter out of the matrix and into the vacuum of the ion source 
(Dell and Morris, 2001). In this process the majority of the molecules couple with a single ion 
such as H+ and produce a singly charged cation such as [M+H]+ (Barber et al., 1981c; Barber 
et al., 1981b; Dell and Morris, 2001). The aim of using a matrix is to minimise sample 
damage by the atom or ion beam and to absorb spare energy from the beam and thus to 
prevent extensive fragmentation of the sample. 
The main advantage of using FAB in glycan mixture analysis is that an individual FAB-MS 
experiment is able to give both sequence and compositional information which are obtained 
from fragment ions and molecular ions, respectively. Thus it has been used to determine 
structures of interest within a complex mixture of glycans such as biologically functional 
terminal epitopes (Dell and Morris, 2001; Dell, 1987). For instance, the presence of sialyl-
Lewis X on leukocytes was first observed using FAB (Fukuda et al., 1984). In addition, 
compared to EI it is not limited to analysing volatile samples.  
When FAB began a revolution in the MS analysis of glycoconjugates, it was soon recognized, 
via research at Imperial College London in the early 1980s, that permethylation enhanced its 
versatility (Bern et al., 2013; Oates et al., 1985; North et al., 2009). This procedure remains 
unaltered from that used nearly 30 years ago, and it is still applicable to MALDI-MS 
nowadays (North et al., 2010). This is due to the fact that glycan permethylation significantly 
improves sensitivity of detection, and the fragment ions yielded from the permethylated 
glycans are more reproducible than those derived from their native counterparts (Sutton-
Smith and Dell, 2006; Dell et al., 1983b).  
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Due to the limited availability of many biological samples, and their high molecular weights, 
high sensitivity and extended mass ranges became increasingly important. From the end of 
the 1990s, FAB was replaced by more sensitive techniques, notably MALDI, which were 
capable of analysing much larger molecules. 
 
Figure 1.14 Schematic view of the FAB ionization source 
 
1.5.1.3. Matrix-assisted laser desorption ionization (MALDI) 
 
MALDI is currently one of the most sensitive ionization methods for glycan analysis (Loo et 
al., 1999; Varki, 2009; Kailemia et al., 2014). This ionization technique is usually coupled 
with time-of-flight (TOF) mass analysers. The wide application of MALDI in the biological 
area has especially promoted innovation in the design of TOF analysers (see section 1.5.2.2), 
which results in enhanced mass resolution and sensitivity (Radionova et al., 2015). 
In 1963 the laser desorption ionization technique was introduced by Honig and Woolston 
(Honig and Woolston, 1963) and later improved by Posthumus and employed in 
biomolecular studies (Posthumus et al., 1978). In the 1980s, this technique was further 
developed by Hillenkamp and Tanaka (Tanaka et al., 1988; Karas et al., 1985). The 2002 
Nobel Prize in chemistry was awarded to the latter due to his contribution to the soft 
desorption ionisation techniques in MS. 
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As indicated in the term MALDI, a matrix is involved in the ionization process: the analyte is 
mixed with a large excess of low molecular weight matrix which can absorb laser energy, and 
this prevents fragmentation of the sample molecules. The analyte and matrix mixture is 
loaded onto a metal plate. The analyte co-crystallises with the matrix when the mixture is 
dried. When the laser is fired at the dried mixture under vacuum conditions, a large amount of 
energy from the laser is absorbed by the matrix, as a result of which desorption of sample and 
matrix molecules at the surface layer occurs and a plume forms. Finally, the analyte 
molecules are ionized (Glish and Vachet, 2003). The velocity that the ions obtained in 
MALDI is independent of their molecular mass (Beavis and Chait, 1991). High voltage is 
applied to the metal plate, which accelerates the resulting ions out of the ion source into the 
mass analyser, which is usually a time-of-flight (TOF) analyser. Unlike EI, the processes of 
volatilization and ionization in MALDI are intimately related (Busch, 1995). However, the 
mechanism of the ionization is still poorly understood, but it is widely accepted that the 
energy from the laser promotes the ion formation by proton transfer in the matrix plume and 
chemical reactions between the excited matrix and the analyte (Zenobi and Knochenmuss, 
1998; Knochenmuss, 2006). Figure 1.15 shows a schematic view of the most widely accepted 
ion formation mechanism in MALDI. 
The analyte molecule ionized by MALDI forms mainly monocharged ions which are denoted 
as [M+H]+ or [M+Na]+ (Zaia, 2004), thus it is rapid and convenient for the determination of 
the analyte molecular weight.  
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Figure 1.15 Schematic view of the most widely accepted ion formation mechanism in MALDI 
The red M stands for an analyte molecule, the black spots are matrix molecules, the blue triangle can 
be either H or Na.  
 
The resolution of the MALDI mass spectrum can be improved by “delayed extraction” which 
is basically a time delay between ion generation and ion extraction from the source. The high 
voltage applied to accelerate the ions is not continuous but pulsed. To some extent this 
narrows the initial kinetic energy distribution and corrects the energy dispersion of the ions, 
as a result of which the ions fly with more uniform kinetic energies improving resolution 
(Kaufmann et al., 1996; Vestal et al., 1995; Vestal and Campbell, 2005; Signor and Erba, 
2013).  
 
1.5.2. Mass analysers 
 
The ions need to be separated once they have been produced. A mass analyser is a part of a 
mass spectrometer that takes control of ionized microscopic particles and separates these 
particles based on their mass to charge ratios. This form of separation method was originally 
discovered by Joseph John Thomson who discovered the electron and measured its mass-to-
charge ratio and thus won the 1906 Nobel Prize in Physics. Mass analysers employ either 
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electric or magnetic fields or a combination of both to achieve the separation. Three types of 
mass analyser will be introduced in detail as they are either more commonly coupled with the 
previously mentioned ionization techniques or utilised in my projects. 
 
1.5.2.1. Magnetic sector  
 
Magnetic fields have been employed in MS since A.J. Dempster developed the first 
spectrometer with a sector-shaped magnet in 1918 (Münzenberg, 2013). The development of 
high-field magnets in the 1970s, pioneered by Morris (Morris et al., 1981a), had a profound 
effect on biological MS. Thus, employing a combination of FAB and high field magnet 
technology allowed MS of analytes whose molecular weight could go up to 6000 Dalton (Da) 
(Dell and Morris, 1982). Approximately 15 years ago researchers in our laboratory still used 
a magnetic sector mass analyser coupled with FAB. Although magnetic mass analysers are 
expensive, they are still popular in certain type of work, for example, it can be employed in 
environmental sciences for the analysis of dioxins and furans (Hernandez et al., 2012) as well 
as mass separation of rare isotopes at accelerator facilities (Münzenberg, 2013).   
The passage of analyte ions through a magnetic sector analyser is as follows: the ions 
generated from the ion source are accelerated via a relatively high potential (Figure 1.16), 
usually the accelerating potential U is 7-8 keV. The kinetic energy (Ek) that an ion gains is 
equal to the potential loss, which means that Ek=mv2/2=Uq (m is the mass of the ion, q stands 
for the charge of the ion, v is the velocity of the ion). Once the ions pass this acceleration 
region, they come into a magnetic field, in which they will be separated according to their 
mass to charge ratios (m/z). In this magnetic field there is a flight tube with a bend of fixed 
radius r permitting only the ions possessing a required mass-to-charge ratio to travel through. 
Once the ions enter the magnetic field, they obtain a magnetic force FB=qvBsinθ (because the 
B is applied perpendicular to the velocity direction, sinθ=sin90º=1). This magnetic force 
make the ions fly in a circular trajectory with the radius r, thus FB is equal to the centrifugal 
force, which means qvB=mv2/r=2Uq/r. Finally the equation can be written as m/q=r2B2/2U 
(m/q is the mass to charge ratio m/z), which provides the theoretical basis for separating ions 
according to their m/z. Only the ion with selected m/z can be transmitted to the detector, 
those ions with higher or lower m/z will be deflected. By scanning the magnetic field 
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(m/q=r2B2/2U, fixing r and altering either U or B) ions with different m/z ions are detected, 
as a result of which a mass spectrum can be obtained (Glish and Vachet, 2003). 
 
Figure 1.16 Schematic of the magnetic sector analyser 
 
However, due to the initial kinetic energy (Ek) difference the analyte ions with the same m/z 
can be dispersed by the magnetic field as r=(2mEk)1/2/qB. In order to overcome this, the Ek 
difference needs to be controlled. To achieve this, an electrostatic sector can be incorporated 
with the magnetic sector (Nier, 1955). The electrostatic sector functions as an energy 
focusing device, which is able to increase the resolution of the instrument. This two-sector 
instrument is called double focusing as in this instrument both the energies and the angular 
dispersions are focused (Münzenberg, 2013). 
 
1.5.2.2. Time-of-flight (TOF) 
 
The concept of a time-of-flight mass analyser was initially mentioned by William in 1946 at 
MIT (Stephens, 1946). This mass analyser separates ions with different m/z by the flight time 
difference due to their various velocities in a flight tube without the use of an external field 
(Cameron and Eggers, 1948; Guilhaus, 1995).  
The travelling of ions via a TOF mass analyser can be described as follows. Analyte ions are 
produced in the ion source. These ions are accelerated via a known potential U. In this 
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electric field, the electric potential energy of one ion will be converted into its kinetic energy, 
Uq =Ek=mv2/2 (m is the mass of the ion, v is the velocity of the ion, U is the accelerating 
potential, q stands for the charge of the ion). After the acceleration, this ion will travel 
linearly in the flight tube at constant velocity to the detector. The time that the ion requires to 
travel is t=L/v=L(m/q)1/2(1/2U)1/2 (L is the length of tube). As shown in the equation, t, time 
of flight is directly proportional to (m/q)1/2 (L and U are held constant, m/q is m/z) (Guilhaus, 
1995). If all other factors are equal, the equation also shows that, the smaller the mass of an 
ion, the shorter the time it requires to reach the detector. 
Theoretically, this type of mass analyser does not have upper mass limit. In 1996 a sample 
with mass over 333 kDa was measured using MALDI-TOF (Moniatte et al., 1996).  
Historically poor mass resolution was a drawback of the TOF analyser. The resolution is 
mainly limited by the existence of a spread in the initial velocities of analyte ions formed in 
the source (Mamyrin et al., 1973). Although velocity filters were used to increase the 
resolution, they also reduced the sensitivity. With the development of numerous techniques, 
such as the application of a reflectron, the resolution of the TOF mass analyser has been 
improved. 
The reflectron was initially proposed by Mamyrin in 1973 (Mamyrin et al., 1973). The 
principle of a reflectron is that a retarding field created by the reflectron functions as an ion 
mirror to deflect the ions penetrating the field and send them back to reach the detector. It 
corrects the kinetic energy of dispersion of the analyte ions; both fast and slow ions with the 
same m/z reach the detector simultaneously rather than at different time, which narrows the 
peak width of the output signal, thus improving the resolution (Figure 1.17).  
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Figure 1.17 Schematic of a TOF mass spectrometer equipped with a reflectron  
○ represents the ion with greater energy which travels deeper in the reflectron and follows the full line 
trajectory; ● the ion with smaller energy travels shallower in the reflectron and follows the dotted line 
trajectory. These two ions arrive at the detector simultaneously via the adjusting voltages and fields. 
 
The resolution can also be improved via decreasing the accelerating potential. However, 
decreasing the potential is not workable as it leads to lower sensitivity.  
It is widely acknowledged that the TOF mass spectrometer has a number of advantages over 
other mass spectrometers: the ability of obtaining a broad mass range spectrum in 
microseconds; the theoretically unlimited mass range for the ions analysed and the possibility 
of displaying both the full mass spectrum and the individual section of interest (Mamyrin et 
al., 1973). 
TOF is usually coupled with MALDI. A main reason for this is that MALDI delayed 
extraction (see section 1.5.1.3) is ideally suitable for TOF analysis. The following MALDI-
TOF mass spectrometer, Voyager-DETM STR (Figure 1.18), is the instrument mainly 
employed in my projects to collect the MS data. When the instrument operates in linear mode, 
the linear detector collects the ions. However, when the instrument runs in reflectron mode, 
the reflectron is switched on and it deflects the ions to the reflected detector. The linear mode 
is usually employed in intact protein studies as it does not lose efficiency for large molecules 
while the reflectron mode does.     
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Figure 1.18 Schematic of the Voyager-DETM STR  
Delayed extraction (variable-voltage grid and ground grid) and a reflectron are applied in this 
instrument. Practically the reflection angle is less than 2°, which makes the displacement along the y 
axis smaller.  In the above figure, a much greater angle has been used for clarity in the drawings. The 
TOF analyser with a reflectron allows the ions to travel longer, which is able to improve the 
resolution of ions with similar masses as the longer the ions travel the greater their arrival time 
difference will be. 
 
1.5.2.3. Quadrupole (Q) 
 
This type of mass analyser was described by Paul and Steinwedel in 1953 at Bonn University, 
and later they patented this apparatus (Paul and Steinwedel, 1960; Keith, 1999). 
As the term implies this mass analyser is made up of four parallel metal rods which are 
circular or ideally, hyperbolic. It is an instrument which sorts ions according to their m/z 
ratios using the stability of the trajectories in oscillating electric fields (Paul and Steinwedel, 
1960). As shown in Figure 1.19, one rod is paired with the diagonally opposite rod, and thus 
there are two pairs in total. Each pair is electrically connected; a direct current (DC) potential 
is imposed positively on one pair of rods and negatively on the other, then a radio frequency 
(RF) voltage is superimposed on the DC potential, as a result of which one pair of rods is 
positively charged and the other is negatively charged. These potentials generate a total 
electric field which has an influence on ions travelling in the quadrupole between the metal 
rods. Since there is an RF voltage, the generated electric field varies as time goes by and it 
only allows an ion with a stable trajectory to travel through the quadrupole (Figure 1.19). For 
instance, when a positive ion enters the analyser, it undergoes an electric field force which 
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pulls it to a negative rod. If the potential changes sign, the ion will change direction and not 
hit the rod. The path of the ion will be stable if it never reaches the rod. Ion oscillations 
depend on the total electric field; only an ion with a specific m/z travelling in a stable 
trajectory is able to pass through the analyser (Glish and Vachet, 2003).  
A mass spectrum is built up via the scan of RF taking ions of successively higher to lower 
m/z values into focus on the detector. Consequently, the rods function as a mass filter. The 
quadrupole mass analyser has a number of advantages, including robustness and low cost 
(Wittmann, 2007). It is compatible with the EI source, and is the most common analyser in 
GC-MS (Glish and Vachet, 2003). 
 
Figure 1.19 The path of ions travelling through a quadrupole mass analyser 
Two ions are generated from the ion source. The blue line is a stable trajectory of an ion passing 
through the analyser, the red dotted line stands for an unstable trajectory of an ion which is 
intercepted by a rod and thus this ion cannot reach the detector.   
 
1.5.3. The detector 
 
The detector is the final element of a mass spectrometer. Once the ions pass through the mass 
analyser and then reach the detector, they will be converted into usable signals. The detector 
either provides a direct measurement of ion charges or amplifies the signal. There are two 
types of detectors: some detectors are manufactured to count ions with a single mass at a time 
and thus they count all the ions in sequence at one point (point detectors); other detectors, 
such as photographic plates and image current detectors, are designed to count ions with 
different masses at the same time and detect the arrival of these ions in the same plane (array 
detectors) (Barnes and Hieftje, 2004). 
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The microchannel plate electron multiplier, a type of array detector, consists of a group of 
parallel and small channels which are covered with a secondary electron emitting 
semiconductor substance and drilled into a plate. Electron multiplication is achieved via this 
substance giving off secondary electrons. The characteristic of this detector is the short 
response time resulting from the short path of the secondary electron inside the channel, and 
this is well suited to the TOF analyser which requires precise arrival time. However, this 
detector has some disadvantages; it is fragile, sensitive to air and expensive. 
 
1.5.4. Tandem mass spectrometry (MS/MS) 
 
As mentioned in section 1.5.1.3, MALDI is a soft ionization technique, producing very 
limited fragment ions. Therefore, it is suitable for glycan profiling. However, to further 
analyse monosaccharide composition and sequence of each glycan, fragmentation of the 
glycan ion is required. The fragmentation allows rigorous sequencing which usually includes 
glycan branch determination and terminal epitope confirmation. This fragmentation can be 
achieved by employing two mass analysers in tandem. The term MS/MS refers to this type of 
coupling.  
In this technique, there are two mass analysers which are separated by a collision cell. The 
first mass analyser functions as a ‘filter’ to choose a precursor molecular ion of interest from 
the ion cluster yielded at the source. The chosen ion then enters a collision cell filled with an 
inert gas such as argon and encounters collision induced dissociation (CID). This collision 
facilitates fragmentation of the precursor ion; in which the cleavage of glycosidic bonds 
occurs. The fragments produced in this process continue flying towards the second analyser, 
which separates these fragments thus generating a fingerprint pattern of the precursor ion. 
This fingerprint contains sequence informative fragment ions which provide vital structural 
information. These two mass analysers could be the same or different, for instance they could 
be tandem time-of-flight (TOF/TOF) analysers or a combination of quadrupole and time-of-
flight (Q-TOF) (Morris et al., 1997; Morris et al., 1996b; Vestal and Campbell, 2005). 
Tandem MS has now become a potent tool for characterizing components in glycans. All the 
MS/MS data mentioned in the thesis were obtained using an Applied Biosystems SCIEX 
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MALDI-TOF/TOF mass spectrometer. Therefore it is necessary to introduce TOF/TOF in 
detail.   
 
1.5.4.1. Tandem time-of-flight (TOF/TOF) 
 
The schematic of the MALDI-TOF/TOF mass spectrometer, Applied Biosystems SCIEX 
4800, used in my Ph.D. study is shown (Figure 1.20). This MALDI-TOF/TOF instrument is 
composed of a linear delayed extraction MALDI-TOF, a time ion selector (TIS), a collision 
cell and one more TOF analyser. In the MS mode, ions produced are directly guided to the 
detector. However, in the MS/MS mode, ions need to pass through the first TOF and then are 
selected by the TIS. Only ions of interest can pass through. The collision energy is adjustable. 
The adjustment is achieved by modulating the ion source potential to that of the collision cell, 
in which the inert gas pressure is managed to make the fragmentation acceptable. The mass 
spectrometer is able to yield CID fragment ions at both high and low energies, and the 
resolution and sensitivity of the single TOF can be ensured simultaneously (Vestal and 
Campbell, 2005). Fragment ions yielded in the collision cell are then re-accelerated towards a 
reflectron which deflects the ions to a reflected detector.  
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Figure 1.20 A schematic illustration of 4800 MALDI TOF/TOF analyser in MS/MS mode 
Ions yielded in the source are flying upwards. The time ion selector (TIS) selects the ion of interest 
which will be firstly decelerated by the deceleration stack and then fragmented in the collision cell 
which is blue in the figure. 
 
1.5.4.2. Fragmentation patterns of permethylated glycans 
 
To interpret the MS/MS spectrum, it is necessary to know the fragmentation patterns of 
glycans. Currently most of the knowledge concerning glycan fragmentation patterns is 
originally from the work carried out using FAB (Dell, 1987; Dell et al., 1983a; Egge et al., 
1983). All the MS/MS data in this thesis were obtained via MALDI, but carbohydrate 
fragmentation patterns established by FAB are still valid. 
Compared to a native glycan, a permethylated glycan yields a limited number of fragment 
ions, which makes the data interpretation easier. In addition, its fragmentation is more 
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reliable (Sutton-Smith and Dell, 2006; Dell, 1990; Yu et al., 2006). Therefore glycans in my 
projects were permethylated prior to being analysed. 
The fragmentation of glycans in MS/MS is mainly due to glycosidic bond breakage between 
two monosaccharide rings. This breakage can be achieved via a cleavage termed β-cleavage 
in which a hydrogen transfer is involved. This cleavage does not yield any charge. The 
charge on the fragment ion is produced via protonation or cationization (e.g. sodiation). The 
fragment ion can be either reducing or non-reducing, and this depends on which of the two 
bonds to the middle oxygen is cleaved (Figure 1.21) (Dell et al., 1994; Dell, 1987). 
 
Figure 1.21 β-cleavage occurring at a glycosidic bond can result in either a reducing ion (top 
panel) or a non-reducing ion (bottom panel) 
R1 is the non-reducing end, R2 is the reducing end. R stands for the ‘remainder’ of the chemical group. 
 
In addition to β-cleavage, there is another type of cleavage, A type-cleavage, which also leads 
to glycan fragmentation (Dell, 1987). The cleavage occurs at the left side of the middle 
oxygen, it produces an oxonium ion (Figure 1.22). This cleavage favours occurring at the 
amino sugar residues. In addition, it is sometimes accompanied by a further fragmentation in 
which the substituent at the 3 position of the ring is eliminated (Dell et al., 1994). 
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Figure 1.22 A type-cleavage yields an oxonium ion (top panel), β-elimination of the 3 position of 
the oxonium ion (bottom panel) 
R1 is the non-reducing end, R2 is the reducing end. R stands for the ‘remainder’ of the chemical group. 
 
1.5.5. Applications in glycomic analysis 
 
The development of modern mass spectrometry, especially the revolution which occurred in 
the 1980s when MS could readily be used to analyse non-volatile samples, has facilitated 
glycomic analysis (Bern et al., 2013; Oates et al., 1985; North et al., 2010). Usually there are 
two goals in the glycomic analysis: structural determination and semi-quantitative analysis. 
These two goals can be achieved via the applications of MS. 
 
1.5.5.1. Structural analysis 
 
Not only can the structures of glycoproteins be determined by mass spectrometry (Dell and 
Morris, 2001; Morris et al., 1978), but also the glycans (Dell et al., 1983a; Babu et al., 2009; 
Jia et al., 2014). To determine structures of glycans in a sample, firstly the m/z values of 
these glycans are measured via MS. For MALDI-TOF instrumentation, the ions yielded are 
usually monocharged, therefore the m/z values obtained from the MS are actually the 
molecular weight of the glycans. Since the molecular weight is clear, possible 
monosaccharide compositions can be deduced. Moreover, the number of potential glycan 
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structures can be minimised either by using mass spectrometers with high mass accuracy or 
by the knowledge of the glycan biosynthesis pathway which has been well characterized (see 
sections 1.2.2 and 1.2.3) (Schwarz and Aebi, 2011; Varki, 2009; Weerapana and Imperiali, 
2006; Dell et al., 2010).  
N-glycan data from a glycomic paper is described below as an example of how to apply mass 
spectrometry in glycan structural analysis. 
The N-glycan profile of ferret lung was obtained via MS analysis and glycans of interest were 
noted. For instance, one of the glycans, the m/z of which is 3252.4, has been determined to 
have the following composition Fuc1Hex4HexNAc6NeuAc2. The composition implies that 
the glycan may contain an Sda epitope (NeuAcα2,3(GalNAcβ1,4)Galβ1,4GlcNAc). Since 
MS analysis could not check the presence of the Sda, further investigation was carried out by 
breaking the glycan into fragment ions and then measuring the m/z of each fragment using 
MS/MS. The principle of MS/MS is that various glycans will yield different groups of 
fragment ions, and these fragments constitute a fingerprint of particular glycan structures. As 
shown in Figure 1.23, the most abundant fragment ion at m/z 2387.3 arose from cleavage of 
amino sugar glycosidic bonds. The signal at m/z 2183.2 corresponds to a loss of the 
tetrasaccharide constituent of the Sda capping group. Its concurrent ion is also observed at 
m/z 1092.5. This demonstrates the presence of Sda epitope (Jia et al., 2014). In addition, to 
make the result more accurate Jia et al. have also carried out GC-MS analysis on partially 
methylated alditol acetates derived from the permethylated glycans. The expression of the 
Sda epitope was confirmed by the presence of terminal GalNAc together with 3,4-linked Gal 
(Jia et al., 2014). Taken together, the results of MS, MS/MS and GC-MS have confirmed the 
presence of the Sda capping group in the sample.   
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Figure 1.23 MALDI-TOF/TOF MS/MS spectrum of permethylated glycan at m/z 3252 which 
was derived from the ferret lung 
Data were acquired in the form of [M+Na]+ ions. The number indicated above the peak is the m/z 
value of the fragment ion (resulting ion) that has been detected by the mass spectrometry. Peaks were 
annotated with putative fragment ions according to the molecular weight (Jia et al., 2014).  GlcNAc, 
 GalNAc,  Man,  Gal,  Fuc,  NeuAc. 
 
1.5.5.2. Semi-quantitative analysis 
 
The reason why analysis is called semi-quantitative is that the MS spectrum shows relative 
abundance of each glycan but not the absolute amount. Although it is not fully quantitative, it 
has been reported that relative quantitation based on signal abundances of permethylated 
glycans investigated by MALDI-TOF MS is a reliable approach, especially when making a 
comparison of signals over a small mass range between glycans with similar structures within 
the same spectrum (Haslam et al., 2008; Wada et al., 2007). 
In our laboratory, the most commonly used strategy in quantitative analysis is called label 
free. The label free approach together with mass spectrometry has been extensively employed 
in glycomic and proteomic studies (Neilson et al., 2011; Wada et al., 2007; Babu et al., 2009; 
Kailemia et al., 2014). MS spectra show not only m/z values of glycans but also their relative 
abundance. The relative abundance of different glycans is determined by label free 
quantification via comparing their molecular ion signals. It has been demonstrated that 
relative quantitation based on signal intensities of permethylated glycans analyzed by 
MALDI-TOF MS is a reliable method (Wada et al., 2007; Bateman et al., 2010). The 
permethylation leads to more consistent ionization due to the fact that chemical groups –OH, 
–COOH and –NHCOCH3 on glycans have been replaced by –OCH3, –COOCH3 and –
NCH3COCH3 respectively. In addition, for those sialic acids containing glycans which easily 
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lose sialic acids in MS in-source fragmentation, permethylation makes them more stable.  
A glycomic study of neutrophils demonstrated the reliability of quantitative analysis of 
permethylated glycans: although the two normal samples are from two different countries, 
their glycan profiles are similar (Babu et al., 2009).  
For semi-quantitative analysis of a mixture of glycan isomers, the characteristic fragment 
ions of each isomer can be observed during MS/MS analysis. In this case, the greater the 
percentage of an isomer in this mixture is, the higher the intensity of its characteristic ion will 
be, and this implies the relative abundance of the characteristic ions can be used to compare 
the amount of the isomers (North et al., 2010).  
In this thesis I am employing mass spectrometry strategies in three projects which are 
comparative glycomic profiling of HeLa cells and normal human dermal fibroblast (NHDF), 
investigation of glycosylation in patients with muscular diseases, and glycomic profiling of 
human trophoblasts. Details of these projects are introduced successively in the following 
sections. 
 
1.6. Ribosome-inactivating proteins (RIPs) and lectins from elderberry 
 
1.6.1. RIPs  
 
Ribosome-inactivating proteins (RIPs) are a group of proteins that function as protein 
synthesis inhibitors that enzymatically act at the ribosome (Stirpe, 2004; Stirpe, 2013). Since 
1970 it has been reported that RIPs are less toxic to normal cells than cancer cells (Lin et al., 
1970). Therefore RIPs have received a lot of attention as they may be potential antitumor 
therapeutic medicines. However, not all RIPs are suitable for being medicine candidates. 
Some RIPs, such as ricin and abrin, are not acceptable as they show powerful cytotoxicity 
towards mammalian cells, but some other RIPs are suitable as they possess strong protein 
synthesis inhibition activity in vitro but they are approximately 103-105 less toxic than ricin 
towards animal cells (Ferreras et al., 2011; Tejero et al., 2015). These less toxic RIPs include 
RIPs from Sambucus. Recently Van Damme and Shang at Ghent University found that lectins 
from Sambucus nigra (elderberry) are also less toxic to normal cells (Shang et al., 2015). 
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Although not all of the mechanism of cytotoxicity triggered by RIPs and lectins is completely 
clear, at least the well-studied RIPs can provide further impetus to study the physiological 
activities of RIPs and lectins on mammalian cells. More importantly, the way that RIPs and 
lectins from Sambucus nigra employed to show their cytotoxicity may be initiated by binding 
to cells, and this binding is probably achieved via their lectin chains.  
The most intensively studied RIP by far is ricin. Hitherto, RIPs have been generally divided 
into two groups (Figure 1.24): type 1 RIPs, consisting of a single peptidic chain, the 
molecular weight of which is approximately 30 kDa, and type 2 RIPs which are composed of 
an enzymatically active A chain which is similar to type 1 RIPs, connected by a single 
disulphide bond to a B chain which has specific lectin properties (Stirpe, 2004; Lord et al., 
1994; Stirpe, 2013; Tejero et al., 2015).  
A RIP enzymatically cleaves one adenine base from the sugar-phosphate backbone of the 
rRNA via the N-glycosidase activity of the A chain, thus inhibiting protein synthesis (Endo 
and Tsurugi, 1987). Only specific adenines are targeted by the RIP. For example, if it is in rat 
liver, the adenine should be adenine 4324 which is located on a big loop of the 28S rRNA 
(Endo et al., 1987). 
 
 
Figure 1.24 Schematic representation of the structures of two different types of RIP 
The red bar stands for the one chain in type 1 RIP; the black bar is the chain B which has specific 
lectin properties. After one adenine (A) is removed, the r-RNA becomes inactivated. 
 
In this project the RIPs that I focused on are SNA-I, SNA-V and SNALRP, which are 
classified as type 2 RIPs. Here SNA is short for Sambucus nigra agglutinin. For historical 
reasons the proteins are usually termed as SNA followed by Roman numbers attributed in 
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chronological order of their discovery (Shang and Van Damme, 2014). The full name of 
SNLRP is Sambucus nigra lectin related protein and this is due to the fact that it is closely 
related to type 2 RIP but it does not show agglutination activity (Van Damme et al., 1997a; 
Shang and Van Damme, 2014).  
SNA-I is obtained from the storage parenchyma cells of elderberry bark and it is the most 
widely studied so far (Tejero et al., 2015). This protein can be extracted via affinity 
chromatography using immobilised fetuin. Analysis of SNA-I has demonstrated that this 
protein exists as a tetramer which is composed of four subunits, and each of the four subunits 
contains two disulphide bond linked chains. The molecular weight of the subunit is 
approximately 60kDa. Each subunit possesses eight putative N-glycosylation sites (Van 
Damme et al., 1997b; Shang and Van Damme, 2014). A main biological function of SNA-I is 
the RNA N-glycosidase activity. As its name implies, it can agglutinate animal and human 
erythrocytes. In addition, it also prevents protein synthesis and development of some insects. 
For instance, it has been reported that in the insect midgut SNA-I can trigger caspase 3-like 
protease-induced cell apoptosis (Van Damme et al., 1997b; Shahidi-Noghabi et al., 2011; 
Van Damme et al., 1998). 
SNA-V, also termed Nigrin b, also exists in elderberry bark. This glycoprotein can be 
purified using affinity chromatography with immobilized GalNAc. It is a dimer which 
contains two [A-s-s-B] subunits, and each of them possesses six putative N-glycosylation 
sites. SNA-V also has RNA N-glycosidase activity, and thus can result in agglutination of 
rabbit and human erythrocytes (Van Damme et al., 1998; Tejero et al., 2015). 
SNLRP is a predominant lectin in elderberry bark. It is a monomer which contains an 
enzymatically active A chain and a not fully active B chain, and thus it possesses RNA N-
glycosidase activity but no agglutination activity. It has five potential N-glycosylation sites. 
This is probably due to the fact that there are several amino acid substitutions in the B chain 
sugar binding sites, and these substitutions have affected the binding affinity (Van Damme et 
al., 2001). 
The parameters of the above three type 2 RIPs are summarized in the following table (Shang 
and Van Damme, 2014).  
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Table 1.4 Overview of type 2 RIPs from Sambucus nigra 
Name  Source Structure Molecular 
weight 
Protein synthesis 
inhibition 
Agglutination 
activity 
SNA-I Bark Tetramer 
[A-s-s-B]4 
240kDa 
(4×60kDa) 
+ + 
SNA-V Bark Dimer 
[A-s-s-B]2 
120kDa 
(2×60kDa) 
+ + 
SNLRP Bark Monomer 
[A-s-s-B] 
62kDa + - 
 
1.6.2. Lectins  
 
Lectins are specific carbohydrate-binding proteins. They are ubiquitous, being identified in 
microorganisms, plants and animals (Berg et al., 2002b). Sambucus nigra lectins can be 
classified as R-type which is a superfamily of glycan-binding proteins that contain a 
carbohydrate-recognition domain which is structurally similar to that in ricin (Varki, 2009). 
The difference between the lectin from Sambucus nigra and the RIP is the former only has a 
lectin chain.   
In this project the lectins that I am interested in are SNA-II and SNA-IV. An overview of 
these two lectins is shown in Table 1.5 (Shang and Van Damme, 2014). The nomenclature of 
these lectins is the same as the one used in the RIPs.  
SNA-II is one of the most abundant lectins in elderberry bark. It can be purified using affinity 
chromatography with immobilized asialoglycophorin. This SNA actually shares a precursor 
with SNA-V. The precursor is processed in two different ways, as a result of which two 
different products, SNA-II and V, are yielded. SNA-II is a homodimer containing two B 
chains which are the same as the B chain in SNA-V without the initial eight amino acids. 
Each of the B chain has four putative N-glycosylation sites (Shahidi-Noghabi et al., 2011). 
Due to the lack of an A chain, SNA-II is not able to show RNA N-glycoside activity and thus 
it cannot inhibit protein synthesis (Van Damme et al., 1998; Maveyraud et al., 2009). 
Unlike SNA-II, SNA-IV is a predominant lectin in the elderberry fruit. It can be purified 
using affinity chromatography with immobilized GalNAc. Like SNA-II, it shows 
agglutination activity but it does not exhibit RNA N-glycosidase activity and cannot inhibit 
protein synthesis. There are three putative N-glycosylation sites in each B chain.  
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Table 1.5 Overview of lectins from Sambucus nigra  
Name  Source Structure Molecular 
weight 
Protein synthesis 
inhibition 
Agglutination 
activity 
SNA-II Bark Dimer 
[B]2 
60kDa 
(2×30kDa) 
- + 
SNA-IV Fruit Dimer 
[B]2 
64kDa 
(2×32kDa) 
- + 
 
Lectins of the ricin B chain form are composed of two β-trefoil domains which are the 
binding domains and contain 3 subdomains, α, β and γ. The amino acid residues that form the 
glycan-binding site in ricin have been determined via cocrystalization of ricin with several 
glycan structures (Montfort et al., 1987). It has been reported that the α-subdomain of the first 
β-trefoil domain and the γ-subdomain of the second β-trefoil domain are involved in the 
glycan binding (Rutenber and Robertus, 1991).  
The result of sequence alignment of the ricin B chain and the RIP B chains and lectins from 
Sambucus nigra shows that in both subdomain-Iα and subdomain-IIγ three of five residues 
which form the carbohydrate binding site are conserved between ricin and all SNAs (Table 
1.6) (Shang and Van Damme, 2014). This suggests that in respect of glycan binding the B 
chains of SNAs show similarity to that of ricin. 
Table 1.6 Comparative analysis of the residues forming the carbohydrate binding sites of the 
five SNA lectin chain and ricin lectin chain  
RIP B chain/lectin Subdomain-Iα Subdomain-IIγ 
SNA-I Asp26, Gln39, Arg41, Asn48, Gln49 Asp231, Ile243, Tyr245, Asn252, Gln253 
SNA-II Asp16, Gln29, Trp31, Asn38, Gln39 Asp227, Ile239, Phe241, Asn248, Gln249 
SNA-IV Asp18, Gln31, Trp33, Asn40, Gln41 Asp229, Ile241, Phe243, Asn250, Gln251 
SNA-V Asp24, Gln37, Trp39, Asn46, Gln47 Asp235, Ile247, Phe249, Asn256, Gln257 
SNLRP Asp23, Gln36, Leu38, Ser45, Gln46 Glu230, Ile242, Tyr244, Asn251, Gln252 
Ricin Asp15, Gln27, Trp29, Asn39, Gln40 Asp227, Ile238, Tyr241, Asn248, Gln249 
 
1.6.3. Glycan binding 
 
Van Damme and Shang have carried out glycan array analyses of these five proteins. The 
result showed that SNA-I exhibited strong binding affinity to glycans containing α2,6 linked 
terminal sialic acid, and all strongly interacting glycans contain at least one this sialic acid. 
SNA-I exhibited the strongest binding to the glycan array among all SNAs, and this is 
consistent with its very strong interaction with cells and glycoproteins. SNA-II, IV and V all 
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interacted with glycans possessing Gal or GalNAc. Unlike SNA-II and V, SNA-IV also binds 
to sialylated Gal residues. SNLRP binds to glycans containing GlcNAc (Shang and Van 
Damme, 2014). The top three glycan motifs that reacted with these five SNAs have been 
summarized in the following table (Shang and Van Damme, 2014) to show the SNA binding 
preference. 
Table 1.7 Top three glycan motifs that reacted with Sambucus nigra type 2 RIPs and lectins  
 GlcNAc,  GalNAc,  Glc,  Gal,  NeuAc,  Fuc.   
 
 
1.7. Muscular diseases caused by gene mutations 
 
Gene mutations are changes occurring in the genetic sequence, and they can have different 
consequences. One of the consequences is that gene mutations can result in various diseases, 
such as muscular diseases. According to the clinical features of the muscular diseases 
mentioned in the papers (Guergueltcheva et al., 2012; Senderek et al., 2011; Palace, 2012; 
Palace et al., 2007; Downham et al., 2008; van der Ploeg and Reuser, 2008), this group of 
mutations can be classified as ‘loss of function’ type, the effect of which is that the gene 
products are complete or partial loss of function. The phenotypes connected with these 
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mutations are usually recessive. Many of the genes, such as GFPT1, DPAGT1, ALG2 and 
ALG14, play important roles in the synthesis of dolichol-linked oligosaccharide, and the 
mutations in these genes result in congenital myasthenic syndromes (Freeze et al., 2015; 
Senderek et al., 2011; Cossins et al., 2013; Belaya et al., 2012). Although the gene mutation 
sites and most of carbohydrate metabolism have already been detected, our knowledge and 
understanding of these diseases is limited, especially in the glycobiology field. For instance, 
it is unknown why, although the phenotypes of CDG and myasthenic patients are different, 
they could be caused by mutations in a same gene, such as GFPT1 (Freeze et al., 2015). 
 
1.7.1. Congenital myasthenic syndromes (CMS) caused by GFPT1 mutations 
 
In the past few years mutations in genes encoding protein glycosylation enzymes, or enzymes 
synthesising the building blocks for protein glycosylation, have been identified to cause a 
neuromuscular transmission defect named congenital myasthenic syndromes (CMS) which 
are autosomal recessive diseases that characterized by a limb-girdle pattern of muscle 
weakness and usually accompanied by the presence of tubular aggregates in muscle biopsies 
(Senderek et al., 2011; Guergueltcheva et al., 2012). The first of these genes to be correlated 
with CMS was GFPT1 (glutamine-fructose-6-phosphate transaminase 1), which has been 
recently identified by a group of researchers including Lochmuller and Mueller at Newcastle 
University using classical positional cloning (Senderek et al., 2011; Guergueltcheva et al., 
2012). Subsequently, mutations in two genes (ALG2 and ALG14), encoding enzymes of the 
protein N-glycosylation pathway were also found to cause CMS (Cossins et al., 2013). CMS 
caused by GFPT1 mutations is a type of neuromuscular junction disorder in which the 
synapses that form between motorneurons and skeletal muscle fibres that transmit the 
impulse resulting in muscle contraction have impaired function (Senderek et al., 2011; Sanes 
and Lichtman, 1999; Martin, 2002; Guergueltcheva et al., 2012). Synapses are the 
fundamental units of the human nervous system (Martin, 2002; Senderek et al., 2011), which 
implies that synapses could play an important role in the function of the neuromuscular 
junction. Research from 40 years ago suggested that some glycoproteins, such as 
acetylcholine receptors and acetylcholinesterase, are concentrated at neuromuscular synapses 
(Sanes and Cheney, 1982; Conti-Tronconi and Raftery, 1982; Massoulie and Bon, 1982), and 
this implies that glycoproteins are essential for synaptic function or development. In addition, 
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many vital neuromuscular proteins are glycosylated, such as agrin and dystroglycan 
(Senderek et al., 2011; Martin, 2002). Thus attention should be paid to the glycosylation in 
the neuromuscular junction. However, most neurobiologists usually ignored the glycosylation 
when they were thinking about synapses, thus research on synaptic function has been carried 
out using approaches in which glycans were not considered (Martin, 2002), as a result of 
which they would narrowly miss an opportunity to discover something of interest in the 
synapse. Nowadays, some neurobiologists have realized this problem. 
 
Figure 1.25 A simplified hexosamine biosynthesis pathway  
Usually less than 5 % of the fructose-6-phosphate isomerized takes part in hexosamine pathway. The 
first and rate-determining step is coupling of an amino group from glutamine (Gln) to fructose-6-
phosphate. This reaction is catalysed by GFPT1 or GFAT1. The product Glucosamine-6-phosphate 
then reacts with acetyl-CoA to form N-acetylglucosamine-6-phosphate. After that, an isomerase 
change N-acetylglucosamine-6-phosphate into N-acetylglucoseamine-1-phosphate. Finally, the latter 
reacts with UTP, producing UDP-N-acetylglucosamine (UDP-GlcNAc) which acts as a precursor for 
amino sugar used for synthesis of proteoglycans, glycoproteins, glycolipids and O-GlcNAc (Senderek 
et al., 2011). 
 
GFPT1 (glutamine-fructose-6-phosphate transaminase 1), also named GFAT1 (glutamine-
fructose-6-phosphate aminotransferase 1), is the first enzyme of the hexosamine biosynthesis 
pathway which has been shown in Figure 1.25 (UniProtKB, 2012; Senderek et al., 2011). It 
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transfers an amino group from glutamine to fructose-6-phosphate to yield glucosamine-6-
phosphate, providing the precursor for uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc) synthesis. UDP-GlcNAc is an essential substrate for all mammalian glycosylation 
biosynthesis pathways and N-glycan branching is especially sensitive to alterations in the 
concentration of this sugar nucleotide (Senderek et al., 2011; UniProtKB, 2012; Freeze et al., 
2015).  
In GFPT1, there are two sugar isomerase (SIS) domains and one glutamine amidotransferase 
domain (UniProtKB, 2012; Senderek et al., 2011). The active site of this protein is still 
unclear though there is a prediction about the active site (UniProtKB, 2012). GFPT1 has two 
isoforms: isoform 1 and isoform 2 which are composed of 699 amino acids and 681 amino 
acids, respectively. The sequence difference between isoform 1 and isoform 2 is that peptide 
229-246 is missing in the latter (UniProtKB, 2012). 
In 2011, 16 CMS patients caused by GFPT1 mutations were reported (Senderek et al., 2011). 
In the next year, more CMS patients were discovered and the clinical features of all these 
patients were further documented (Guergueltcheva et al., 2012). In 2013, 12 novel mutations 
in CMS patients were identified (Selcen et al., 2013). The details of the GFPT1 CMS patients 
that are associated with this project are listed in the following table. The mutation sites in the 
other four patients are not clear. 
Table 1.8 The country of origin, gene mutation sites and the amino acid changes caused by the 
mutations 
CMS Country of origin Nucleotide change Amino acid changes 
GFPT1 patient 1 Germany 595G>T Val199Phe 
GFPT1 patient 2 Spain 1475T>C Met492Thr 
GFPT1 patient 3 Spain 1475T>C Met492Thr 
 
Having discovered that some of their CMS patients had mutations in GFPT1, Lochmuller et 
al. had found that these patients have a recognizable pattern of weakness of shoulder and 
pelvic girdle muscles, and defects in ocular or facial muscles showing a favourable treatment 
response to acetylcholinesterase (AChE) inhibitors. They discovered that the enzymatic 
activity of control GFPT1 did not change too much compared that of the mutants (Figure 
1.26A). The comparison of GFPT1 amounts in patients and the control showed that the 
amount of GFPT1 in the two patients reduced to 51% and 22% of the GFPT1 amount in the 
control (Figure 1.26B) (Senderek et al., 2011). In addition, they also set up an animal model 
using zebrafish. The result from the animal model showed that low expression level of 
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GFPT1 resulted in delayed neuromuscular junction development and abnormal muscle 
morphology (Senderek et al., 2011), GFPT1 was found to be essential for events in 
neuromuscular transmission. GFPT1 knockout mice are not available yet.  
A 
 
B    
 
Figure 1.26 Analysis of the enzymatic activity of GFPT1 mutants (A), Western blot analysis of 
GFPT1 expression in myoblasts (B) 
In A, HEK293 cells were transfected with either wild type or mutant GFPT1 constructs. Enzyme 
activity of GFPT1 was measured in cell lysates with the glutamate dehydrogenase method 48 h after 
transfection. The enzymatic activity of every mutant was normalized to GFPT1 protein amounts 
determined by western blot analysis of cell lysates used for activity measurements. Triplicate 
experiments were carried. Error bars indicate ± SD; significant differences from wild type **P < 0.01; 
***P < 0.001. n.s., not significant (Senderek et al., 2011). In B, cell lysates of cultured myoblasts and 
differentiated myotubes of patients 3 and 5 (shown in Table 1) and one healthy control donor were 
immunoblotted with an anti-GFPT1 antibody (upper panel). Actin was used as a control. GFPT1 band 
intensities were normalized to actin bands in the same lane (Senderek et al., 2011). 
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Since they have not carried out any glycomic investigation on GFPT1 patients, and GFPT1 
plays an essential role in synthesizing UDP-GlcNAc which is involved in the initiation of N-
glycan antennae (Figure 1.27), we hypothesized that mutations in GFPT1 may cause N-
glycan branching variations and thus have an influence on protein glycosylation. This 
hypothesis can be tested via a  systematic glycomic study on GFPT1 patients. Additionally, 
samples from DOK7 CMS patient and other muscular disease patients were also investigated. 
This was to check if there was a glycosylation variation and whether this variation was 
unique in the GFPT1 CMS patients. 
 
Figure 1.27 UDP-GlcNAc is involved in the initiation of N-glycan antennae 
 GlcNAc,  Man, the numbers in the brackets under the enzyme are the Km values (Lau et al., 2007). 
 
1.7.2. Muscular diseases caused by other gene mutations 
 
Mutations occurring in other genes which are not encoding protein glycosylation enzymes, or 
enzymes synthesising the building blocks for protein glycosylation can also result in 
muscular diseases. 
 
1.7.2.1. CMS caused by DOK 7 mutations 
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DOK7 encoded by DOK7 is a postsynaptic protein involved in the acetylcholine receptor 
(AChR) clustering pathway (Palace, 2012). It functions as an activator of muscle, skeletal 
receptor tyrosine kinase (MuSK) via dimerization (Bergamin et al., 2010). It is likely that it 
plays an important role in neuromuscular synaptogenesis. 
In 2006, DOK7 mutation was firstly reported as a cause of CMS (Beeson et al., 2006). One 
year later, this type of mutation has been further shown to underlie a recessive CMS 
associated with small simplified neuromuscular junctions but normal acetylcholine receptor 
and acetylcholinesterase function (Palace et al., 2007). Onset of DOK7 CMS tends to occur at 
the ages of two to three years (Palace, 2012). The characteristic of the onset is that patients 
show difficulty in walking development after normal motor milestones (Palace et al., 2007). 
Proximal muscles were severely affected, resulting in weakness in limb-girdle. It is common 
that the symptoms become worse in adulthood, particularly impacting respiratory function. 
Treatment with ephedrine or oral salbutamol can result in a slow, steady, and often dramatic 
improvement over months (Palace, 2012). These characteristics of DOK7 CMS are different 
from limb-girdle myasthenia associated with tubular aggregates, in which GFPT1 mutations 
were detected and patients showed positive response to anticholinesterase treatments (Palace 
et al., 2007; Senderek et al., 2011).  
It has been reported that DOK7 mutation is the third most common cause of CMS in the UK 
(Palace, 2012). Our knowledge and understanding of this disease is limited, thus investigation 
will help clinical diagnosis and potential treatment. 
 
1.7.2.2. Muscular disease caused by MTND5 mutations  
 
MTND5 is short for mitochondrial NADH dehydrogenase 5 gene which encodes the subunit 5 
of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I). Like 
the position of GFPT1 in hexosamine pathway, Complex I is the first enzyme in the 
mitochondrial electron transport chain (Liolitsa et al., 2003). In eukaryotes, Complex I is 
situated in the inner membrane of the mitochondria. It functions as a catalyst to transfer 
electrons from NADH to coenzyme Q10. 
It has been reported that mutations in MTND5 can result in neurodegenerative disorders, such 
as Leigh syndrome and Parkinson's disease (Parker and Parks, 2005; Bannwarth et al., 2013; 
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Petruzzella et al., 2003). However, researchers also find that MTND5 mutations can lead to 
muscular diseases, such as myopathies (Alston et al., 2010; Downham et al., 2008).  
Recently a young girl with defect in Complex I in muscle caused by a mutation, 
m.12425delA, within the MTND5 gene was reported. This single deletion was not detected in 
her mother but identified in some tissues from her proband, which implies that this is a de 
novo mutation. Her cardinal symptoms are renal failure and myopathy (Alston et al., 2010).  
 
1.7.2.3. Limb girdle muscular dystrophy type 2A (LGMD2A) caused by CAPN3 mutations 
 
LGMD2A is considered to be the most common form of recessive LGMD. It is an autosomal 
recessive disorder caused by mutated CAPN3 gene which encodes deficient calpain-3 protein 
(calcium-activated neutral protease 3). Calpain-3 protein is a cysteine protease belonging to 
the intracellular calpain family (Rocha and Hoffman, 2010; Richard et al., 1995). It is a 
muscle-specific enzyme. Although the role of this enzyme plays in normal skeletal muscle 
physiology and in LGMD2A pathophysiology is not clear (Richard et al., 1995; Fanin and 
Angelini, 2015), a study suggests that it is important for a physiological process in muscle 
termed “sarcomere remodelling” (Kramerova et al., 2005).   
Currently the way to diagnose LGMD2A is detecting calpain-3 protein deficiency in muscle 
and then identifying the causative mutations. Other biochemical tests are not sensitive (Fanin 
and Angelini, 2015; Rocha and Hoffman, 2010).   
 
1.7.2.4. Pompe disease caused by GAA mutations 
 
Pompe disease is a disorder of glycogen accumulation. It is caused by mutations in the gene 
GAA which encodes acid α1,4 glucosidase, a lysosomal enzyme. This enzyme plays an 
essential role in the decomposition of glycogen in lysosomes. Its deficiency mainly results in 
lysosomal glycogen over storage, usually in cardiac and skeletal muscles, due to the 
incapacity of breaking down glycogen into Glc (Matalon et al., 2006; Turaca et al., 2015). 
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In the process of translation, lysosomal enzymes enter the ER where glycosylation occurs co-
translationally (Hermans et al., 1993). Research shows that a suitable protein conformation is 
indispensable for recognition and glycosylation of a site (Bause and Legler, 1981). After the 
three terminal Glc residues are removed from the 14-sugar (2 GlcNAc, 9 Man and 3 Glc) 
precursor in the ER, a Man-6-phosphate recognition marker is acquired as a lysosomal 
targeting sign by most of the lysosomal enzymes. This is achieved by transferring GlcNAc-1-
phosphate from UDP-GlcNAc to a specific mannose residue, and subsequently the phosphate 
is released by a phosphodiesterase. Combining with the mannose 6-phosphate receptor this 
process is vital for lysosomal targeting. The enzyme is then shipped to the endosomes in 
which a pH decrease results in the dissociation of the ligand and the receptor. The enzyme 
continues its way to the lysosome and the receptor goes back to the Golgi apparatus 
(Hermans et al., 1993). It is known that the acid α1,4 glucosidase will follow this pathway 
and undergo modification with Man-6 phosphate substituted N-glycans. It possesses 7 N-
glycosylation sites. Importantly, removal of the second glycosylation site at Asn-233 affects 
significantly the formation of mature enzyme (Hermans et al., 1993). However, it is not clear 
whether the mutation occurring in this gene had altered the cell glycome.  
 
1.8. The protection of the embryo/foetus from the maternal immune system 
 
1.8.1. Background 
 
In 1953 Sir Peter Medawar raised a question 'how can the mother nourish a foetus which is 
similar to a "foreign organ" (paternal contribution to its half genome) within itself for several 
months but not reject it?' He gave three possible explanations: the antigenicity of the foetus is 
immature; maternal immunological indolence or inertness, and anatomical separation from 
the mother (Medawar, 1953). However, Medawar’s hypotheses could not be supported by 
subsequent investigations. Immunity can be induced in skin transplantation tests when 
injecting foetal tissue (Billingham et al., 1956), arguing against the first possible explanation; 
the mother shows response to pathogens in pregnancy (Head and Billingham, 1986), which 
means the second one has been denied; the extravillous cytotrophoblast (evCTB) can invade 
the maternal decidua and myometrium and remodel the uterine arteries for the foetus 
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(Handschuh et al., 2007; Clark and Schust, 2013; Benirschke, 1994), and this is in conflict 
with the last one.  
 
1.8.2. The human fetoembryonic defense system hypothesis (hu-FEDS) 
 
To address the question, in 1996 Gary F. Clark et al. raised a hypothesis termed the human 
fetoembryonic defense system hypothesis (hu-FEDS) (Clark et al., 1996), and later it was 
renamed as eutherian fetoembryonic defence system hypothesis (eu-FEDS) to apply more 
broadly. It is a hypothetical model depicting a way via which the human immune system is 
able to recognize foreign substance as "own species" as has been observed with maternal 
immune tolerance in pregnancy. The fundamental idea of this hypothesis is that glycoproteins, 
which exist in the reproductive system and are exposed on gametes can either inhibit immune 
responses or prevent rejection of the foetus (Clark et al., 2001). Biomolecules in human 
seminal plasma and the pregnant uterus had been shown to suppress immune responses in 
vitro (Bolton et al., 1987; Kelly and Critchley, 1997), but the idea that human gametes could 
have an influence on immune responses was novel. This model has been intensively tested 
since it was conceived, and an increasing amount of supportive evidence for this model has 
been collected (Kui Wong et al., 2003; Pang et al., 2007). The following section talks about 
the gametes, from which the foetus initially develops.    
 
1.8.3. Human gametes and maternal immune responses 
 
In humans the gametes are sperm and eggs. Most of the information available suggests that 
sperm and eggs do not express detectable amounts of human leukocyte antigens (HLA) on 
the surface (Hutter and Dohr, 1998; Clark, 2014). If they did, the mother would reject the 
paternal sperm as a foreign organ transplant. The genes encoding HLA antigens are located 
on chromosome 6p21. HLA class I genes have been divided into two types, class Ia and class 
Ib which contains HLA-A, -B, -C, and HLA-E, -F, and -G, respectively. HLA class II (HLA-
D) genes are not translated in human trophoblast cells (Murphy and Tomasi, 1998; Hunt et al., 
2005; Apps et al., 2009). The cytotoxic T lymphocyte (CTL) is responsible for this HLA 
rejection as it kills cells with foreign HLA. Since sperm does not express detectable amounts 
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of HLA, it is ‘invisible’ to CTL. However, in the mother there are other immune cells, such 
as natural killer (NK) cells, which can eliminate cells without detectable HLA class I 
molecules (Karre, 2002; Jaeger and Vivier, 2012). Therefore, it is likely that the sperm will 
be killed by NK cells. However, studies have shown that human sperm express bisecting type 
N-glycans which could inhibit NK cell cytotoxicity (Pang et al., 2007; Patankar et al., 1997). 
Indeed, multiple pieces of evidence have shown that bisecting type N-glycan can suppress 
NK cell cytotoxicity. For instance, human K562 erythroleukaemic cells are easily killed by 
natural killer cells. However, stable transfection of K562 cells with the gene that encodes 
GlcNAc-transferase III which is responsible for transferring a GlcNAc to the bisecting site 
could produce NK cell resistant transformants (Patankar et al., 1997; Yoshimura et al., 1996). 
It is therefore likely that the sperm can evade these two major immune cells via glycan-
mediated processes. 
Recent studies also suggest that mechanisms to avoid the human immune system used by 
gametes, tumour cells and pathogens may have something in common. To some extent, they 
display molecular mimicry which is the expression of surface structures similar to those 
found in the host (Kui Wong et al., 2003; Pang et al., 2007; Clark, 2014).  
 
1.8.4. Human foetus and maternal immune responses 
 
A zygote forms as a result of fertilization, and then it becomes an embryo which develops 
into a foetus. The foetus floats in the amniotic fluid in the uterus, and it communicates with 
the mother via an interface termed placenta. Foetal development in utero requires a functional 
placenta that mediates the transport of nutrients and gases from the maternal blood which are 
essential for maintaining foetal viability. In addition to this, its development also requires the 
protection of the embryo/foetus from the maternal immune system. The blood circulations of 
the foetus and the mother are separate (Hunt et al., 2005). The foetus is like a foreign 
transplant organ for the latter due to the fact that it expresses paternal HLA molecules 
(Guleria and Sayegh, 2007). The pregnant uterus yields two major glycoprotein molecules, 
CA125 and glycodelin-A (GdA), which can suppress the potential maternal immune response 
against the foetus (Lee et al., 2009; Kui Wong et al., 2003; Clark and Schust, 2013), so the 
foetus is safe. Clinically, the major part of the placenta is composed of foetal elements; only a 
very small amount of maternal decidua will be shed at delivery (Benirschke, 1998). This 
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suggests that for the mother the placenta is foreign. Anatomically, a placenta is composed of 
three principal parts: trophoblasts, connective tissue with chorionic membrane and blood 
vessels, and the amnion (Benirschke, 1998). Among these 3 parts, the trophoblast is in very 
intimate contact with the maternal blood in which the immune cells can circulate (Benirschke, 
1998; Juch et al., 2012), which suggests that it is the placenta trophoblast that would be the 
target for the maternal immune cells. The attack would normally be expected to result in 
immune responses, and this could trigger severe pregnancy complications. However, the fact 
is that most pregnant women do not suffer these pregnancy complications, which implies that 
the immune response has been suppressed. The underlying mechanism of how the immune 
response is suppressed at the placenta trophoblasts remains unknown. It is therefore 
necessary to pay attention to the trophoblasts. 
Placenta trophoblasts (TB) are originally derived from the trophectoderm, the outter layer of 
a blastocyst (Georgiades et al., 2002; Paria et al., 2002). They are considered to be 
trophoblastic stem cells as they can differentiate into two different types of cells: the villous 
cytotrophoblast (CTB) and the extravillous cytotrophoblast (evCTB). The former fuses with 
each other, forming syncytiotrophoblasts (STB) which are multinucleated. CTB and STB stay 
on the foetal side (Figure 1.28), and they cover the chorionic villi and are responsible for the 
exchange of gases and nutrients between the mother and the foetus via the blood (Tarrade et 
al., 2001; Georgiades et al., 2002; Handschuh et al., 2007; Ji et al., 2013). The latter, evCTB, 
extravasates and invades the maternal decidua and myometrium where they act with decidual 
NK cells to remodel uterine arteries into flaccid conduits. Thus evCTB cells are spread out on 
the maternal side (Figure 1.28). Defects in the invasion can result in pregnancy complications, 
including late miscarriage and preeclampsia (Handschuh et al., 2007; Clark and Schust, 2013; 
Benirschke, 1994; Robson et al., 2012; Parham, 2004).  
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Figure 1.28 Human placental plate structure after 12 weeks of gestation: the placenta has a 
foetal and a maternal side 
The foetal part is composed of branched villous structures which are soaked in maternal blood for 
nutrition and gas exchange. The maternal decidua is full of stromal and immune cells and is traversed 
by spiral arteries which pump blood into the intervillous space. The placental villi are covered by an 
inner layer of mononucleated villous cytotrophoblasts (CTB) and an outer layer of fused 
syncytiotrophoblasts (STB). The extravillous cytotrophoblasts (evCTB) are extravasated (green spots) 
and then spread out in the maternal part (Clark and Schust, 2013).  
 
1.9. Aims of this thesis 
 
The main aim is to investigate biomedically important glycosylation using mass 
spectrometric approaches. 
There are three specific aims: 
• Glycomic analysis of HeLa cells and NHDF for developing potential antitumor 
therapeutic medicines (Chapter 3).  
• Glycomic investigation of CMS caused by GFPT1 mutations and other muscular 
diseases caused by other gene mutations (Chapter 4).  
• To further understand the role of glycans in human fetoembryonic defence system by 
structurally characterizing trophoblast N-glycans using mass spectrometry (Chapter 5). 
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Chapter 2 
 
Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
86 
 
2. Materials and methods 
 
2.1.  Materials 
 
2.1.1. General chemicals and reagents 
 
The ultra-pure water (Neptune Purite water purification system, Purite Ltd, Oxfordshire, UK), 
nitrogen and argon (BOC, Guildford, UK), sodium chloride (NaCl) (Rose Chemicals Ltd, 
London, UK) and 3,4-diaminobenzophenone (DABP) (Acros Organics, Geel, Belgium). 
Methanol, ammonia, dimethylsulphoxide (DMSO), propan-1-ol, acetic acid, acetonitrile, 
chloroform, butanol, sodium hydroxide and trifluoroacetic acid (TFA) are from Romil 
(Cambridge, UK). Idoacetic acid (IAA), tris(hydroxymethyl)aminomethane (Tris), α-cyano-
4-hydroxycinnamic acid, sodium cholate, hexane, potassium borohydride (KBH4), 2,5-
dihydroxybenzoic acid (DHB) and sodium borodeuteride (NaBD4) are from Sigma-Aldrich 
(Poole, UK). Ammonium bicarbonate (AMBIC, NH4HCO3), 3-(N-Morpholino)-
propanesulfonic acid (MOPS), manganese chloride 4-hydrate, UDP-Gal, sodium acetate 
(CH3COONa), ethylenediaminetetraacetic acid (EDTA), potassium hydroxide (KOH), formic 
acid and Dowex 50WX8 beads are from Fluka (Polle, UK). 3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate hydrate (CHAPS) and dithiothreitol (DTT) are from 
Roche (East Sussex, UK). Acetic anhydride and methyl iodide are from Alfa Aesar 
(Lancaster, UK). 
 
2.1.2. Standards and enzymes 
 
Calibration standards for MS and MS/MS are 4700 calibration standard kit (AB Sciex, 
Warrington, UK), glycan standards (Dextra, Reading, UK). 
Porcine pancreas trypsin (Sigma-Aldrich, Poole, UK), PNGase F (Flavobacterium 
meningosepticum, recombinant from E. coli, Roche, East Sussex, UK), rEGCase II (E. coli 
encoding the gene of this enzyme yielded by Rhodococcus sp., Takara, Saint-Germain-en-
Laye, France), β1,4-galactosyltransferase (Merk, Darmstadt, Germany), endo-β-galactosidase 
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(Escherichia freundii, AMSBIO, Oxford, UK), sialidase S (expressed in E. coli, recombinant 
from Streptococcus pneumonia, Prozyme, Cambridge, UK) and sialidase A (expressed in E. 
coli, recombinant from Arthrobacter ureafaciens, Prozyme, Cambridge, UK). 
 
2.1.3. Biological samples 
 
All samples were kindly provided by my collaborators, the samples were then subjected to 
glycomic analysis in our laboratory. 
 
2.1.3.1. NHDF (normal human dermal fibroblasts) and HeLa cells 
 
Two batches of NHDF and HeLa cells were cultured in vitro by Professor Els Van Damme 
and Miss Chenjing Shang at Ghent University, Belgium. 
  
2.1.3.2. Myoblasts and myotubes 
 
Three batches of samples were provided by Professor Hanns Lochmuller and Dr. Juliane 
Mueller at Newcastle University. The first two batches are myoblasts; the last batch is the 
myotube. 
In the first batch there were five myoblast cell lines which were derived from the muscle 
biopsies obtained from five separate patients and then immortalised in vitro. These patients 
are one DOK7 patient, one MTND5 patient, GFPT1 patients 1, 2 and 3. Each cell line except 
GFPT1 patient 3 has three pellets which were harvested from myoblasts cultured in the 
skeletal muscle cell growth medium containing 5%, 10% and 15% foetal calf serum (FCS). 
The GFPT1 patient 3 cells grew extremely slowly and they only grew in the medium with 15% 
FCS.  
In the second batch, there were nine myoblast cell lines. In addition to the five mentioned in 
the first batch, the other four cell lines were derived from the muscle biopsies obtained from 
four separate people and then immortalised in vitro. These four people are healthy controls 1 
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and 2, one LGMD2A (limb girdle muscular dystrophy type 2A) patient and one Pompe 
disease patient. Samples from two healthy controls were obtained via orthopaedic surgery. 
These myoblasts were cultured in the medium containing 15% FCS.  
In the third batch, there were nine myotube cell lines. These myotubes were differentiated 
from myoblasts which were derived from the muscle biopsies obtained from patients and 
healthy controls and then immortalised in vitro. The myotubes were cultured in the medium 
containing 15% FCS.  
The total number of the sample is shown in section 4.2. 
 
2.1.3.3. Trophoblasts 
 
There were four sets of primary human trophoblasts isolated from four separate patients who 
had undergone an uncomplicated pregnancy and requested Cesarean section delivery. These 
trophoblasts were cultured in vitro. Four cytotrophoblast (CTB) and four syncytiotrophoblast 
(STB) samples were received in duplicate from Professor Gary F. Clark at University of 
Missouri. The STB was differentiated from the CTB.  
Two batches of extravillous cytotrophoblast (evCTB) samples were provided by Dr. Sandra 
M. Blois at University Medicine Berlin, Germany.  
 
2.2. Methods  
 
To acquire N-, O- and glycolipid glycans, samples were processed following an established 
protocol which has been summarized in Figure 2.1 (Jang-Lee et al., 2006; North et al., 2010; 
Jia et al., 2014; Parry et al., 2007). 
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Figure 2.1 An overview of the glycomic approaches 
 
2.2.1. Sonicator cleaning 
 
It is important to clean the sonicator (VC130PB, Sonics & Materials, Inc.) that will be used in 
the homogenisation step as mass spectrometry is a very sensitive technique and any 
contaminant left on the sonicator could have an influence on the experiment result. 
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To clean the sonicator, firstly, the tip of the sonicator was dipped into ultra-pure water in a 
clean beaker and sonicated in continuous mode (10 seconds, 20 Amps). The first step was 
repeated with a solution containing 33.33% (volume percent) methanol, 33.33% formic acid 
and 33.33% ultra-pure water. After that the tip of the sonicator was immersed in ultra-pure 
water and kept in an ultrasonic bath (FS200, Decon) 10 minutes. The first step was repeated 
with following solutions: ultra-pure water, methanol, methanol chloroform mixture (v: v=1: 
1), methanol, ultra-pure water (twice). Finally the sonicator was activated at 40 Amps in an 
empty Falcon tube for 1 minute.  
 
2.2.2. Homogenisation 
 
In order to extract the glycoproteins and glycolipids from cells, homogenisation is required to 
mechanically disrupt cells. However, because glycoproteins and glycolipids have different 
properties, different extraction approaches were employed. 
 
2.2.2.1. Glycoprotein extraction   
 
Lyophilized cell pellets were suspended in 1ml homogenization buffer (150 mM NaCl, 25 
mM Tris, 5 mM EDTA and 1% CHAPS (volume percent), pH 7.4), sonicated in continuous 
mode for 10 seconds at 40 Amps. This was repeated 5 times pausing on ice for 15 seconds 
between each sonication.  
Lysed sample was transferred into a dialysis cassette (3.5K MWCO, 0.5 - 3 ml, Thermo 
Scientific) and dialysed against the 4.5 L dialysis buffer (50 mM ammonia bicarbonate, pH 
7.5) at 4 °C for 48 hours. Constant stirring was used during the dialysis process, the dialysis 
buffer was changed regularly (approximately every 12 hours). After dialysis, the sample was 
transferred into a 15 ml Falcon tube, covered with perforated Parafilm (Bemis) and 
lyophilized using a freeze dryer (Modulyod-230, Thermo Fisher). 
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2.2.2.2. Glycolipid extraction 
 
Lyophilized cell pellets were suspended in 2 ml ice cold ultra-pure water and then transferred 
into a 15 ml Falcon tube. The sample was sonicated on ice in continuous mode (10 seconds, 
40 Amps). This was repeated 2-3 times pausing on ice for 15 seconds between each 
sonication. Then the tube was taken into fume hood, in which 2.67 volumes of methanol 
(2.67 × volume of the ice cold ultra-pure water) was added and mixed fully. After that 1.33 
volumes of chloroform (1.33 × volume of the water) was added and mixed fully. The mixture 
was centrifuged (IEC Centra CL3 centrifuge, Thermo) at 3000 rpm for 10 minutes (100 µl 
0.6 M Tris buffer was added when the protein did not precipitate, and then the mixture was 
centrifuged again). The final supernatant (glycolipid fraction) was collected and its volume 
was measured. Then 0.173 volume of ultra-pure water (0.173 × volume of the supernatant) 
was added and mixed fully. The mixture was centrifuged (3000 rpm, 15 minutes). The 
mixture was divided into two layers which were collected separately: up layer is polar 
glycolipid; bottom layer is nonpolar glycolipid.  
 
2.2.3. Reduction and carboxymethylation 
 
Tris buffer (0.6 M, pH 8.5) was freshly made; pH was adjusted using acetic acid. The buffer 
was degased by bubbling gently nitrogen at the bottom of the buffer for 30 minutes.   
The lyophilized sample from section 2.2.2.1 was suspended in 200 µl degased Tris buffer. 
Then 200 µl 10 mg/ml DTT (prepared from the degased Tris buffer) was added. The mixture 
was incubated (37 °C, 90 minutes). After the incubation the sample was centrifuged shortly. 
200 µl 60 mg/ml IAA (prepared from the degased Tris buffer) was then added, this mixture 
was incubated at room temperature in dark (approximately 20 °C, 90 minutes). The reaction 
was terminated by transferring the sample into a dialysis cassette. The mixture was dialysed 
in 4.5 L dialysis buffer (see section 2.2.2.1) at 4 °C for 48 hours. Constant stirring was also 
used during the dialysis process; the dialysis buffer was changed regularly as mentioned 
previously (see section 2.2.2.1). After dialysis, the sample was transferred into a clean 
disposable glass tube (GPI 15-415, 13x100mm, Corning), covered with perforated Parafilm 
and lyophilized. 
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2.2.4. Tryptic digestion and glycopeptide purification 
 
Ammonium bicarbonate (AMBIC) buffer (50 mM, pH 8.4) was freshly made; pH was 
adjusted using ammonia solution.  
The lyophilized sample from section 2.2.3 was dissolved in 100 µl AMBIC buffer, then 200 
µl 1 mg/ml trypsin (prepared from the AMBIC buffer) was added. The mixture was incubated 
(37 °C, 14-16 hours). After the incubation the sample was centrifuged shortly. The tryptic 
digestion was terminated by heating the sample (100 °C, 2 minutes). 1 drop of acetic acid 
was added to neutralize the sample. The sample was then preceded to the purification step. 
A purification cartridge (Oasis HLB Plus, Waters) was attached to a 5 ml glass syringe 
(Samco) and then conditioned by eluting successively with 5 ml methanol, 5 ml 5% acetic 
acid (volume percent), 5 ml propan-1-ol, and 15 ml 5% acetic acid. The sample was loaded 
dropwise onto the cartridge. In order to avoid losing sample, the tube was washed 1-2 times 
using 5% acetic acid, the washing solution was also loaded onto the cartridge. The cartridge 
was washed using 20 ml 5% acetic acid, 4 ml 20% propan-1-ol solution (volume percent, 20% 
propan-1-ol in 80% 5% acetic acid), 4 ml 40% propan-1-ol solution, 4 ml 100% propan-1-ol. 
All propanol fractions were collected while the 5% acetic acid fraction was discarded as it 
contained hydrophilic contaminants. The volume of the fractions was reduced in a 
concentrator centrifuge, SpeedVac (SPD121P-230, Thermo) until these fractions could be 
combined into a single tube. Finally, the sample was covered with perforated Parafilm and 
lyophilized. 
 
2.2.5. Polar glycolipid recovery 
 
The step was carried out in the fume hood due to the use of chloroform. A purification 
cartridge (tC18, Sep-Pak, Waters) was attached to a 5 ml glass syringe (Samco) and then 
conditioned by eluting successively with 5 ml methanol, 5 ml methanol water mixture (v: v=1: 
1), 5 ml methanol chloroform mixture (v: v=1: 1), and again 15 ml methanol water mixture. 
The polar glycolipid fraction from section 2.2.2.2 was loaded dropwise onto the cartridge. 
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The cartridge was washed using 15 ml methanol water mixture, 5 ml methanol and 5 ml 
methanol chloroform mixture. The methanol containing fractions were collected, combined 
and dried under nitrogen.  
 
2.2.6. Release of glycans from glycoconjugates and purification of released glycans 
 
As previously mentioned in sections 1.2.2.1, 1.2.2.2 and 1.2.3.1, N-, O- and glycolipid 
glycans are linked to proteins and lipids in different patterns, the approaches that employed to 
release these glycans are various. 
All N-glycans were cleaved by peptide-N-glycosidase F (PNGase F). PNGase F is an 
endoglycosidase that cleaves the linkage between the N-glycan inner most GlcNAc and the 
amine group of the GlcNAc linked Asn residue on glycoproteins (Varki, 2009; Tarentino et 
al., 1985). This cleavage did not cause any change on the glycan portion but resulted in 
variation on the protein backbone: the Asn residue is substituted by an aspartic acid (Asp) 
residue.  
All O-glycans were released by alkaline borohydride treatment (alkaline elimination) (Wada 
et al., 2010; Varki, 2009). Although O-glycosidase is also available, but it only cleaves some 
simple core 1 glycans, thus a chemical method, alkaline elimination, was used to release O-
glycans. The reaction was performed under reducing environment which is helpful for 
preventing 'peeling reaction' of the released glycans via reducing the terminal GalNAc to its 
alditol form, thus it is also termed reductive elimination. This elimination was usually carried 
out after N-glycan release; otherwise it would cleave both N- and O-glycans, which would 
complicate subsequent data analysis.   
The glycolipid glycans were released using ceramide glycanase (Recombinant 
endoglycoceramidase II). Like PNGase F, this enzyme is also an endo-enzyme which cuts in 
the chain between the glycan and the ceramide (see section 1.2.3.1) (Izu et al., 1997).  
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2.2.6.1. Release of N-glycans and purification of released N-glycans 
 
AMBIC buffer was freshly made (see section 2.2.4 for details). PNGase F cleaves N-glycan 
chains from glycoproteins/glycopeptides. However, it cannot cleave the glycan chain which 
carries an α1,3-linked core fucose residue at the innermost GlcNAc (Tretter et al., 1991; Parc 
et al., 2015).  
The lyophilized sample from section 2.2.4 was dissolved in AMBIC buffer (200-300 µl, 
depends on the amount of the sample), then 4 U of PNGase F was added (the amount of the 
enzyme added is determined by the amount of the sample) and incubated (37 °C, 24 hours, 
another 4 U of PNGase F after the first 12-hour incubation). After incubation the sample was 
covered with perforated Parafilm and lyophilized. The lyophilized sample was proceeded to 
purification. 
A classic C18 Sep-Pak cartridge (Waters) was attached to a 5 ml glass syringe and then 
conditioned as previously mentioned in section 2.2.4. The sample was loaded dropwise onto 
the cartridge. The cartridge was washed using 5 ml 5% acetic acid, followed by 4 ml 20% 
propan-1-ol solution, 4 ml 40% propan-1-ol solution, 4 ml 100% propan-1-ol. The 5% acetic 
acid fraction was collected as it contained released N-glycans. All propanol fractions were 
also collected as they contained the remaining peptides and O-glycopeptides. The volume of 
the fractions was reduced in SpeedVac until the fractions could be combined into a single 
tube. Finally, both 5% acetic acid fraction and propanol fraction were covered with 
perforated Parafilm and lyophilized. 
 
2.2.6.2. Release of O-glycans and purification of released O-glycans 
 
KOH solution (50 ml, 0.1 M) was made, and it is used for KBH4 solution (1 M) preparation. 
The lyophilized propanol fraction from section 2.2.6.1 was dissolved in KBH4 solution (400 
μl), and then incubated (45 °C, 20–24 hours). After incubation, acetic acid was added 
dropwise until there was no bubbling. The sample was briefly centrifuged and proceeded to 
the next step. 
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A small amount of glass wool was filled at the narrow end of a Pasteur pipette, and the 
narrow end was inserted into a section of silicone tube, the internal bore diameter of the tube 
is 1–2 mm. A screw-adjustable switch was attached close to the tip of the tube. This Pasteur 
pipette was fixed by a retort stand. The pipette was filled with 5% acetic acid, and then the 
switch was opened to make the acid run out slowly. At the same time, the pipette was refilled 
with ion-exchange Dowex 50W-X8 beads which were used to remove peptides and cationic 
salts. The beads were washed using 5% acetic acid (20 ml). The switch was employed to 
control flow to keep the level of the acid above the bead level. The sample was loaded 
dropwise into the pipette. The acid should be controlled to pass slowly the pipette. The beads 
were washed using 2 × 3 ml 5% acetic acid. The two 3 ml acetic acid fractions were collected 
though usually the first 3 ml contains released O-glycans. The volume of the fractions was 
reduced in SpeedVac to approximately 1 ml, and then covered with perforated Parafilm and 
lyophilized. However, the borates could not be removed by beads, thus an extra step, 
coevaporation, was required: after lyophilisation 0.5 ml methanolic acetic acid (volume 
percent, 10% acetic acid in 90% methanol) was added to the lyophilized sample, the mixture 
was dried under nitrogen, and this was repeated 3-4 times. 
 
2.2.6.3. Release of glycolipid glycans and purification of released glycolipid glycans 
 
Sodium acetate buffer (50 mM, pH 5.5) was freshly made, pH was adjusted using 5% acetic 
acid, sodium cholate was finally added to the buffer make its concentration as 0.2% (v/w). 
The lyophilized sample from section 2.2.5 was resuspended in the sodium acetate buffer (200 
µl). Then 25 mU ceramide glycanase was added to the sample and the mixture was incubated 
(37 °C, 24 hours). After this another 25 mU of the enzyme was added and the incubation was 
carried out for another 24 hours. After incubation, ultra-pure water was added to the sample 
to make the total volume 2 ml. Then 2 ml butanol was added. The mixture was centrifuged 
vigorously, the up layer was discarded. This step was repeated 1-2 times. Trace of butanol 
that left in the remaining liquid fraction was removed via drying under nitrogen.    
A classic C18 Sep-Pak cartridge was attached to a 5 ml glass syringe and then conditioned by 
eluting successively with 5 ml methanol, 5 ml 5% acetic acid, 5 ml acetonitrile and 15 ml 5% 
acetic acid. The sample was loaded dropwise onto the cartridge, the cartridge was then 
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washed using 5 ml 5% acetic acid. The acetic acid fraction was collected using a clean glass 
culture tube.  
This sample was further purified using Hypercarb column (Thermo Scientific) 
chromatography. The column was conditioned by eluting successively with 3 column 
volumes of 80% acetonitrile in 0.1% TFA (volume percent, the remaining 19.9% is ultra-pure 
water) and 3 column volumes of ultra-pure water. The sample was loaded dropwise onto the 
cartridge, the cartridge was then washed using 3 column volumes of ultra-pure water and 2 
column volumes of 25% acetonitrile in 0.05% TFA (volume percent, the remaining 74.95% is 
ultra-pure water). The acetonitrile fraction was collected. The volume of the fractions was 
reduced in SpeedVac until the fraction volume was approximately 1 ml. Finally, the sample 
was covered with perforated Parafilm and lyophilized. 
 
2.2.7. Other enzymatic digestions and digested glycan purification 
 
Released glycans from glycoproteins and glycolipids can be digested by enzymes, such as 
sialidase S, sialidase A, β1,4-galactosyltransferase and endo-β-galactosidase. These 
digestions can provide extra structural information.     
 
2.2.7.1. Sialidase S digestion 
 
Sialidase S is an enzyme which specifically removes non-reducing terminal unbranched α2,3 
linked sialic acid from glycoconjugates (Corfield et al., 1983). Sodium acetate buffer was 
freshly made as mentioned in section 2.2.6.3. 1 unit sialidase S powder was dissolved in the 
buffer (200 µl) to make 5mU/µl enzyme solution. 
The sample from previous was dissolved in the buffer (200 µl). 20 µl of enzyme solution was 
added to the sample, then the sample was incubated (37 °C, 24 hours, another 20 µl of the 
enzyme solution was added to the sample after the first 12 hours). After incubation, the 
sample was briefly centrifuged and proceeded to the purification step. 
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2.2.7.2. Sialidase A digestion 
 
Sialidase A is an enzyme which can specifically cleave all non-reducing terminal sialic acid 
from glycoconjugates (Ohta et al., 1989). 1 unit sialidase A powder was made into solution 
following the procedure in section 2.2.7.1. 
The sample from previous section was treated with sialidase A following the procedure that 
described in section 2.2.7.1. 
 
2.2.7.3. β1, 4-galactosyltransferase reaction 
 
β1,4-galactosyltransferase is the enzyme which can transfer a Gal from a UDP-Gal to a 
GlcNac producing a disaccharide unit, Galβ1,4GlcNac. However, if a GlcNac is bisected (see 
section 1.2.2.1), it will not be modified by this enzyme (Qasba et al., 2008; Narasimhan et al., 
1985). 3-(N-Morpholino) - propanesulfonic acid (MOPS) solution (50 mM, pH 7.4, contains 
45 uM UDP-Gal) was freshly made, pH was adjusted using ammonia, and then manganese 
chloride 4-hydrate was added to make its final concentration as 20 mM. 1 unit β1,4-
galactosyltransferase was dissolved in the solution (200 µl). 
The sample from previous section was dissolved in the enzyme solution (50 µl), then the 
sample was incubated (37 °C, 24 hours, another 50 µl of the enzyme solution was added to 
the sample after first 12 hours). The sample was briefly centrifuged and proceeded to the next 
step. 
 
2.2.7.4. Endo- β-galactosidase digestion 
 
Endo-β-galactosidase is an enzyme which hydrolyses internal β1,4 galactosidic linkage in 
this favoured repeating unit [GlcNAcβ1,3Galβ1,4]n (Scudder et al., 1983). Sodium acetate 
buffer (100 mM, pH 5.8) was freshly made; pH was adjusted using 5% acetic acid. 0.1 unit 
endo-β-galactosidase powder was dissolved in the buffer (100 µl). 
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The sample from previous section was dissolved in the sodium acetate buffer (150 µl). 20 µl 
of enzyme solution was added to the sample, then the sample was incubated (37 °C, 48 hours, 
another 20 µl of the enzyme solution was added to the sample after first 24 hours). The 
sample was briefly centrifuged and proceeded to the separation step. 
 
2.2.7.5. Digested glycan purification 
 
A purification classic C18 Sep-Pak cartridge (Waters) was attached to a 5 ml glass syringe 
and then conditioned as described in section 2.2.4. The sample was loaded dropwise onto the 
cartridge. The cartridge was washed using 5 ml 5% acetic acid. The 5% acetic acid fraction 
was collected as it contained glycans required. The volume of the fractions was reduced to 
about 1 ml by SpeedVac. Finally, the fraction was covered with perforated Parafilm and 
lyophilized.   
 
2.2.8. Permethylation of released glycans  
 
3-5 sodium hydroxide pellets and 3 ml dimethyl sulfoxide (DMSO) were added in a mortar 
and ground with a pestle. The pellet should be ground into slurry. The slurry (about 1 ml) was 
added to the glass tube which contained lyophilized sample from previous section. Then 
methyl iodide (about 0.6 ml) was added into the tube. The tube was capped and fixed on an 
automatic vortexer (VX-2500, VWR) and vortexed (15-20 minutes, 20 °C). The reaction was 
terminated by addition of ultra-pure water dropwise until there was no bubbling. Then 1 ml 
chloroform was added, ultra-pure water was added to make the final volume of the mixture 5 
ml. The mixture was centrifuged (2500 rpm, 30 seconds), the up layer was discarded. This 
step was repeated 4 times. The bottom layer was chloroform layer which contained 
permethylated glycans. It was dried under a gentle stream of nitrogen.  
Figure 2.2 shows the reducing end (OR), the non-reducing end (R) and the method of how to 
calculate the mass of a permethylated glycan.  
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Figure 2.2 The method used to calculate the mass of a permethylated glycan residue 
 
2.2.9. Purification of permethylated glycans  
 
1.5 ml, 3.5 ml, 5 ml and 7.5 ml acetonitrile was mixed with 8.5 ml, 6.5 ml, 5 ml and 2.5 ml 
ultra-pure water respectively to make 10 ml 15%, 35%, 50% and 75% acetonitrile solution. 
A classic C18 Sep-Pak cartridge (Waters) was attached to a 5 ml glass syringe and then 
conditioned by eluting successively with 5 ml methanol, 5 ml ultra-pure water, 5 ml 
acetonitrile, and 15 ml ultra-pure water. The sample from section 2.2.8 was dissolved in 
methanol/ultra-pure water (200 µl, v:v=1:1) and then loaded dropwise onto the cartridge. The 
cartridge was washed using 5 ml ultra-pure water following by 3 ml 15%, 35%, 50% and 75% 
acetonitrile solution. All acetonitrile fractions were collected. The volume of the fractions 
was reduced to about 1 ml by SpeedVac. Finally, the fractions were covered by perforated 
Parafilm and lyophilized.  
 
2.2.10. Mass spectrometry 
 
The mass spectrometric techniques used are matrix assisted laser desorption ionization time-
of-flight (MALDI-TOF), matrix assisted laser desorption ionization time-of-flight/time-of-
flight (MALDI-TOF/TOF) and gas chromatography mass spectrometry (GC-MS).  
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2.2.10.1. MS data acquisition and analysis 
 
The MS matrix, 2,5-dihydroxybenzoic acid (DHB) (20 mg/ml) in methanol/water mixture 
(v:v=7:3), for permethylated glycans was freshly made. The MS matrix, α-cyano-4-
hydroxycinnamic acid (10 mg/ml) in acetonitrile/TFA/water mixture (v:v:v=500:1:499), for 
calibration standard was freshly made. 
Purified permethylated glycans from section 2.2.9 was dissolved in methanol (10 µl). 1 µl of 
the sample was combined with 1 µl of DHB matrix and then loaded onto a metal plate. In 
addition, prepared calibration standard (AB Sciex) mixed with calibration matrix was also 
spotted on the plate. After the sample and calibration standard were dried, the plate was put 
into a Voyager-DE STR MALDI workstation (Applied Biosystems) mass spectrometer, via 
which the calibration was carried out and the MS data could be acquired. The Voyager was 
run in the reflectron positive ion mode and its accelerating voltage was set as 20kV. 
Obtained MS data was processed using Data Explorer Software version 4.9 (Applied 
Biosystems). Generally, the MS spectrum was baseline corrected with the default setting and 
then smoothed with the noise filter at a correlation factor of 0.7. The processed spectrum was 
annotated using a glycoinformatic tool, GlycoWorkBench (Ceroni et al., 2008) and a graphic 
design software, CorelDraw X3. 
 
2.2.10.2. MS/MS data acquisition and analysis 
 
The MS/MS matrix, 3,4-diamino-benzophenone (DABP) (10 mg/ml) in acetonitrile/water 
mixture (v:v=7:3), for permethylated glycans was freshly made. The MS/MS matrix for 
calibration standard is the same as the MS matrix for calibration standard described in section 
2.2.10.1. 
Previous dissolved sample from section 2.2.10.1 was dried and then redissolved in methanol 
(10 µl), 1 µl of the sample was combined with 1 µl of DABP matrix and then loaded onto a 
metal target plate. In addition, prepared calibration standard (AB Sciex) mixed with 
calibration matrix was also spotted on the plate. After the sample and calibration standard 
were dried, the plate was loaded into a 4800 MALDI-TOF/TOF mass spectrometer (AB 
SCIEX), via which the calibration was carried out. MS spectrum was firstly obtained, and 
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then peaks of interest were selected for MS/MS analyses and the MS/MS data could be 
acquired. The 4800 instrument was also run in the reflectron positive ion mode. The collision 
energy was set to 1 kV with argon as the collision gas.  
Obtained MS/MS data was also processed using the same method described in section 
2.2.10.1. 
 
2.2.10.3. GC-MS  
 
GC-MS requires the analyte to be volatile but the permethylated glycans are not volatile, 
therefore, permethylated glycans cannot be analysed directly. Further treatment of these 
glycans is required.  
 
2.2.10.3.1. GC-MS sample preparation 
 
TFA solution (2 M) was made freshly using ultra-pure water. NaBD4 solution (10 mg/ml) 
was freshly made using 2 M ammonia.   
TFA solution (200 µl) was added to the sample left in previous step and incubated (121 °C, 2 
hours). After the incubation, the sample cooled down to the room temperature, briefly 
centrifuged and then dried under a gentle stream of nitrogen. NaBD4 solution (200 µl) was 
added to the dried sample and incubated (room temperature, 2 hours). The incubation was 
terminated by adding acetic acid dropwise until there was no bubbling. The sample was 
redried under nitrogen. Because borates were introduced, coevaporation was required (see 
section 2.2.6.2). After coevaporation, acetic anhydride (200 µl) was added to the sample and 
then the mixture was incubated for acetylation (100 °C, 1 hour). Then the sample was briefly 
centrifuged and redried under nitrogen. 1 ml chloroform was added to the dry sample and 
then ultra-pure water was added to make the total volume 5 ml, the mixture was vortexed and 
then allowed it to separate into two layers, the up layer was discarded. This washing step was 
repeated 4 times. The bottom chloroform fraction was finally dried under a gentle stream of 
nitrogen. The final partially methylated alditol acetates (PMAA) were ready for analysis. 
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2.2.10.3.2. GC-MS data acquisition and analysis 
 
A blank (usually hexane) was injected into RTX-5MS column (Restek Corp.) which was 
fitted in Perkin Elmer Clarus 500 GC-MS. This was performed to make sure the column was 
clean and the instrument  was in good condition (could be used in the experiment). A glycan 
standard was firstly run and then the sample; retention times of the standard would be 
compared with the sample and would help us determine the compound of the sample. Sample 
from section 2.2.10.3.1 was usually dissolved in hexane (usually 50 µl, depends on the 
amount of the sample), and then 2 µl of dissolved sample was injected. All injections were 
carried out after the oven temperature reached 60 °C. Running a blank was required before 
every sample running.  
A list of retention times and characteristic ions were prepared for comparison. Obtained GC-
MS data, the gas chromatographic profiles and electron ionization spectra were processed 
using TurboMass version 4.5.0 (Perkin Elmer Instruments). 
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normal human dermal fibroblast (NHDF) 
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3. Comparative glycomic profiling of HeLa cells and normal human 
dermal fibroblast (NHDF) 
 
3.1. Introduction to the project 
 
This project is in collaboration with Professor Els Van Damme and Miss Chenjing Shang at 
Ghent University.  
In addition to performing glycan array analyses of the five SNAs (Shang and Van Damme, 
2014) mentioned in section 1.6.3, Van Damme and Shang have carried out cytotoxicity assay 
of these five SNAs using HeLa and NHDF cells, and found that all the SNAs are more toxic 
towards HeLa than NHDF cells. They have also performed in vivo luciferase (internalization) 
assay of SNAs using HeLa cells and found that the SNAs could get into the cell (Shang et al., 
2015). All these made us hypothesize that HeLa and NHDF cells could express glycans that 
the SNAs can bind to and the patterns of the glycans in these cells would be different leading 
to the different cytotoxicities, and thus glycomic analysis of these two types of cells were 
carried out to check the hypothesis. Specifically, MS and MS/MS analyses provided general 
structural information of the glycans; the result of the glycan array analyses suggested the 
determination of sialic acid linkages in the glycans as the five SNAs favoured different 
glycan motifs (see section 1.6.3); quantification of nonsialylated (gal-terminated) and 
sialylated glycans may provide a possible explanation for the result of the cytotoxicity assay 
of these five SNAs. 
The glycome patterns on both glycoproteins and glycolipids of HeLa and NHDF cells (see 
section 3.2) were analysed using MS to test the hypothesis. 
 
3.2. Sample details and sample processing 
 
Two batches of HeLa and NHDF cells were cutured in the same media (Shang et al., 2015) 
but on different days. The cells were sent to our laboratory once being harvested. The detail 
of two batches of NHDF and HeLa cells is shown in Table 3.1. 
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Table 3.1 Detail of NHDF and HeLa cells received from Ghent University 
First batch 
Cell type Cell number 
NHDF Approximately 4 million 
HeLa cells Approximately 7.5 million 
NHDF Approximately 7.5 million 
HeLa cells Approximately 10 million 
Second batch 
Cell type Cell number 
NHDF Approximately 4 million 
HeLa cells Approximately 21 million 
NHDF Approximately 7.3 million 
HeLa cells Approximately 30 million 
 
All samples were analysed using glycomic methodologies which have been described in 
section 2.2.  
 
3.3. Results 
 
3.3.1. HeLa and NHDF N-glycans 
 
3.3.1.1. MALDI-TOF MS analysis of the N-glycans of HeLa and NHDF cells 
 
Duplicate analyses of N-glycans were carried out to check the reproducibility (Figure 3.1) 
and whether combining the duplicate for the more detailed structural research would be valid.    
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Figure 3.1 MALDI-TOF MS spectra of permethylated N-glycans (m/z 2200-5680) from two 
batches of HeLa cells (top) and two batches of NHDF cells (bottom)  
The MS spectra of the cells from the first batch are black; the MS spectra of the cells from the second 
batch are red. The black spectra are overlaid on the red spectra with an offset of approximately 8 Da. 
In HeLa cells, the average peak variation between the spectra from different batches is approximately 
33%. In NHDF cells, the average peak variation between the spectra from different batches is 
approximately 19%. The result shows that there is no significant difference in the N-glycan profile of 
biological replicates.  
 
High quality MALDI data were obtained for the N-glycans from the HeLa and NHDF cells. 
Here ‘high quality’ means: 1. The spectrum does not show 14 dalton smaller 
underpermethylated peaks which could be due to the fact that the hydrogen of one of the 
hydroxyl groups in the glycan is not replaced by a methyl group (Morris et al., 1996a); 2. 
When zoom in the spectrum, the isotope peaks observed in the spectrum can be clearly 
distinguished; 3. The signal to noise ratio (S/N) of the spectrum is acceptable, which means 
the signal peaks of analyte ions do not merge with the baseline ("noise") and can be 
distinguished. S/N is a measure of a peak signal intensity relative to the "noise" level 
(Williams et al., 2003; Krutchinsky and Chait, 2002). Representative MALDI-TOF MS 
spectra of their N-glycans are shown in Figure 3.2 and Figure 3.3. Molecular ions were 
observed up to approximately m/z 5700 indicating that very good sensitivity was being 
achieved. The spectra show that high mannose and complex glycans are present in both cell 
types. Non-core fucosylated glycans, such as m/z 2792 and 3603, are more evident in HeLa 
cells. The dominant complex N-glycans in both HeLa and NHDF are sialylated with NeuAc 
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or are terminated with uncapped Gal. The result of a more detailed comparison of the glycan 
profiles of these two cell types has been summarized in section 3.3.1.7.   
 
Figure 3.2 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2200-3900) 
from HeLa (top) and NHDF cells (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. Putative structures are based on the molecular weight, N-glycan biosynthesis pathway and 
MS/MS data. Due to the presence of heterogeneous multiantennary structures with extended LacNAc 
(Gal-GlcNAc) repeats, the annotations are simplified throughout by using biantennary structures with 
the extensions or sugars listed outside a bracket.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
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Figure 3.3 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 3900-5680) 
from HeLa (top) and NHDF cells (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
 
3.3.1.2. MALDI-TOF/TOF MS/MS analyses of the N-glycan at m/z 3143 of HeLa and NHDF 
cells 
 
Peaks of interest were chosen for further characterization via MALDI-TOF/TOF MS/MS 
analysis. This analysis was used to distinguish isobaric glycans with different sequences as 
well as glycans of similar masses whose isotope clusters were overlapping. 
Here the MS/MS data for the molecular ion clusters centred at m/z 3142 in two cells are 
described as an example of the latter. In HeLa cells the isotope peaks of the glycan(s) at m/z 
3143 span a wider mass range than predicted for a single glycan composition, while the 
isotope pattern in NHDF is more akin to that expected for a glycan at that molecular weight 
(Figure 3.4). This implies that this peak cluster may include a LacNAc containing glycan as 
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well as a potential sialyl-Lewis X containing glycan which differ by 2 Da. This situation has 
been reported in dendritic cells and neutrophils (Babu et al., 2009; Bax et al., 2007). 
  
 
Figure 3.4 Isotope peak cluster is wider in HeLa cells than that in NHDF 
The isotope peaks of m/z 3141 and 3143 are overlapping in spectra from HeLa cells, as a result of 
which the peak cluster is wider than in the NHDF data. 
 
In order to confirm the presence of potential sialyl-Lewis X and LacNAc and their relative 
abundance, MS/MS analyses were carried out for the two samples. As shown in Figure 3.5 
(top) the fragment ions at m/z 2679, 2230 and 1781 correspond to loss of LacNac, LacNac2 
and LacNac3 respectively, and their concurrent ions are also observed at m/z 486 and 1385. 
This demonstrates the presence of oligo-LacNAc containing glycans, in accordance with the 
isotope pattern of the molecular ion cluster (Figure 3.4). The third most abundant fragment 
ion at m/z 2142 and its concurrent ion at m/z 1021 are attributable to a sialylated, fucosylated 
glycan. Fuc is confirmed to be 3-linked as the signal at m/z 2934 corresponds to the loss of a 
Fuc from the C3 position of GlcNAc via beta elimination. These provide evidence of the 
presence of potential sialyl-Lewis X. The abundance of the fragment ions corresponding to 
potential sialyl-Lewis X containing glycan suggests that it is minor compared to the LacNAc 
containing glycan in HeLa cells. In contrast to the HeLa data, MS/MS of m/z 3142 from 
NHDF cells showed fragment ions that correspond solely to oligo-LacNAc antennae (Figure 
3.5 bottom), which is consistent with its isotope pattern.   
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Figure 3.5 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated N-glycan peak 
centred at m/z 3142 in HeLa cells (top) and NHDF cells (bottom) 
Assignments of the fragment ions are indicated on the cartoons and on the spectra the horizontal red 
arrows show antennae losses whilst antennae-derived fragment ions are annotated with their 
sequences. The number indicated above the peak in the spectra is the m/z value of the fragment ion 
(resulting ion) that has been detected by the mass spectrometer. Data were acquired in the form of 
[M+Na]+ ions. The glycan molecule and its corresponding fragment ions are labelled in the same 
colour (red or black). Due to the presence of heterogeneous multiantennary structures with extended 
LacNAc repeats, the annotations are simplified throughout by using biantennary structures with the 
extensions listed outside a bracket.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
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3.3.1.3. Sialidase S digestion of the N-glycans of HeLa and NHDF cells 
 
It is necessary to know the linkage of the NeuAc because NeuAc linkage differences might 
cause the carbohydrate binding differences. To determine the NeuAc linkages, the glycans 
were digested with sialidase S and sialidase A, which cleave α2,3 linked and all non-reducing 
terminal NeuAc residues, respectively. 
Digestion of HeLa and NHDF cells with sialidase S resulted in partial desialylation, and with 
sialylated N-glycans at m/z 2431, 2605, 3055 and 3504 being observed (Figure 3.6 and 
Figure 3.7). The comparison of Figure 3.2 (top) and Figure 3.3 (top) to Figure 3.6 (top) and 
Figure 3.7 (top) showed that the relative abundances of many sialylated glycans in HeLa cells 
were decreased, the most obvious decrease was observed in the glycans at m/z 2966, 3416, 
3777, 3865, 4226 and 4587 which completely disappeared; simultaneously, the relative 
abundance of nonsialylated glycans was increased, the most obvious increase being observed 
in the glycans at m/z 2244, 2693 and 3143 which increased approximately 1004.9%, 1937.6% 
and 2152.5% respectively. Similarly, the comparison of Figure 3.2 (bottom) and Figure 3.3 
(bottom) to Figure 3.6 (bottom) and Figure 3.7 (bottom) also showed that the relative 
abundance of many sialylated glycans decreased in NHDF cells, the most obvious decreases 
were observed in the glycans at m/z 2966, 3416, 3865, 4226 and 4587 which completely 
disappeared; simultaneously, the relative abundance of nonsialylated glycans increased, the 
most obvious increases were observed in the glycans at m/z 3143, 4041 and 4490 which were 
increased approximately 2080.7%, 2617.0% and 745.1% respectively. In addition, sialyl 
Lewis X disappeared after the desialylation (see section 3.3.1.4 for evidence). This indicated 
that both HeLa and NHDF contain a mixture of α2,3 and α2,6 linked NeuAc. The ratio of 
desialylated glycans in HeLa cells is slightly higher than that in NHDF cells (see section 
3.3.1.7 for details). 
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Figure 3.6 Annotated MALDI-TOF MS spectra of permethylated sialidase S treated N-glycans 
(m/z 2200-3900) from HeLa (top) and NHDF cells (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.   GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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Figure 3.7 Annotated MALDI-TOF MS spectra of permethylated sialidase S treated N-glycans 
(m/z 3900-5680) from HeLa (top) and NHDF cells (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.   GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
 
3.3.1.4. MALDI-TOF/TOF MS/MS analysis of glycan cluster at m/z 3143 of HeLa cells after 
sialidase S digestion 
 
After sialidase S digestion, the isotope peak of the glycan at m/z 3143 in HeLa cells is akin to 
that predicted. This implies that this peak only includes one glycan, probably the LacNAc 
containing glycan. In order to confirm this, MS/MS analysis was carried out. The presence of 
fragment ions at m/z 2230, 1781 and 1385 (Figure 3.8) demonstrated the presence of an 
oligo-LacNAc containing glycan only. 
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Figure 3.8 Annotated MALDI-TOF/TOF MS/MS spectrum of permethylated sialidase S treated 
N-glycan at m/z 3143 in HeLa cells 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of 
assignments.  GlcNAc,  Man,  Gal,  Fuc. 
 
3.3.1.5. Sialidase A digestion of the N-glycans of HeLa cells and NHDF 
 
The glycan profiles are similar between the two cell types after sialidase A digestion. 
Treatment with sialidase A resulted in a complete desialylation of the N-glycans (Figure 3.9 
and Figure 3.10), for instance, the sialyl Lewis X containing glycan at m/z 3141 in Figure 3.2 
(top) became the glycan at m/z 2418 in Figure 3.9 (top). LacNAc or polyLacNAc containing 
glycans, such as m/z 2244, 2693 and 3143, were the main products of the enzymatic reaction. 
With the disappearance of sialylated N-glycans, glycans at 2244, 2693 and 3143 increased 
approximately 2309.5%, 3119.7% and 2208.7% in HeLa cells respectively, 100.9%, 145.1% 
and 1632.2% in NHDF cells respectively. In addition, some novel nonsialylated N-glycans 
which were not observed in Figure 3.2 were shown in Figure 3.9. For instance, glycans at m/z 
2867 in HeLa cells and glycan at m/z 2418 in NHDF cells were only observed after sialidase 
A digestion. All these glycans (m/z 2418, 2592, 2867, 3317, 3766, 4215, 4664 and 5114) 
possessed more than one Fuc. Within the displayed mass range, the completely desialylated 
form of the glycan peaks annotated in Figure 3.2 and Figure 3.3 could all be found in Figure 
3.9 and Figure 3.10.    
These confirmed that in both HeLa and NHDF cells the complex glycans contained terminal 
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Gal and NeuAc as well as fucosylated antennae. 
 
Figure 3.9 Annotated MALDI-TOF MS spectra of permethylated sialidase A treated N-glycans 
(m/z 2200-3900) from HeLa (top) and NHDF cells (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc. 
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Figure 3.10 Annotated MALDI-TOF MS spectra of permethylated sialidase A treated N-glycans 
(m/z 3900-5680) from HeLa (top) and NHDF cells (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc. 
 
3.3.1.6. Quantification of the N-glycans 
 
Since terminal Gal and NeuAc play important roles in the carbohydrate binding, it is 
necessary to quantify the Gal and NeuAc and then make a comparison. Quantification of 
terminal Gal and terminal NeuAc on glycan antennae of each cell type was carried out via 
comparing the relative abundance of LacNAc (Gal-GlcNAc) antenna and sialylated LacNAc 
antenna.  
The following figure shows the quantification method. According to the Figure 3.11A, the 
glycan at m/z 3055 is a mixture of biantennary and triantennary. The ratio of the two 
structures in the mixture was calculated by dividing the relative intensity sum of the 
corresponding characteristic ions. The assumption was made that the probabilities of losing 
one LacNAc and one sialylated LacNAc in biantennary structure are 50% and 50% 
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respectively, and the probabilities of losing one LacNAc and one sialylated LacNAc in 
triantennary structure are 67% and 33% respectively. Therefore the expected values of losing 
one LacNAc and one sialylated LacNAc are 0.51 and 0.49 respectively. Since the relative ion 
count of the glycan at m/z 3055 is 4452.7 (Figure 3.11B); it is possible to calculate the 
individual ion abundance of the LacNAc and sialylated LacNAc. 
A 
 
B 
 
Figure 3.11 Annotated MALDI-TOF/TOF MS/MS spectrum of permethylated N-glycan at m/z 
3055 in NHDF cells (A), the relative intensity of the same glycan in the MALDI-TOF MS 
spectrum (B) 
Data were acquired in the form of [M+Na]+ ions. See legends to Figure 3.2 and Figure 3.5 for 
explanation of structure assignments. In Panel A, only peaks of interest were labelled, the biantennary 
(bi) and triantennary (tri) characteristic ions are labelled in red and black frame respectively, RI is 
short for relative intensity. In B, the isotope peak of the glycan at m/z 3055 has been magnified.  
GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
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3.3.1.7. Summary 
 
Complex N-glycans in both HeLa and NHDF cells have been quantified using the above 
method; the result (Figure 3.12) showed that before sialidase S digestion, the proportion of 
the glycan terminated with Gal was approximately 54% in NHDF cells, which is higher than 
that in HeLa cells (approximately 30%). After sialidase S treatment, the percentage of the 
glycan terminated with α2,6 linked NeuAc in HeLa cells is around 17%, which is 
significantly higher than the 3% shown in NHDF cells; sialidase A digestion removed all 
NeuAc residues supporting the glycomic assignments.  
 
Figure 3.12 A comparison of the relative intensities of LacNAc antenna and sialylated LacNAc 
antenna in all complex glycans in HeLa and NHDF (A), sialidase S digested (B) and sialidase A 
digested (C) 
Black colour stands for relative intensity of α2,3 and α2,6 sialylated LacNAc antenna; blue colour 
stands for relative intensity of LacNAc antenna; red colour stands for relative intensity of α2,6 
sialylated LacNAc antenna.  GlcNAc,  Gal,  NeuAc. 
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3.3.2. HeLa and NHDF O-glycans 
 
3.3.2.1. MALDI-TOF MS analysis of the O-glycans of HeLa cells and NHDF 
 
Duplicate analyses of O-glycans were also carried out to check the reproducibility and 
whether combining duplicates for the more detailed structural research would be valid. High 
quality MALDI data were obtained for the O-glycans from HeLa and NHDF cells. 
Representative MALDI-TOF MS spectra of HeLa and NHDF cell O-glycans are shown in 
Figure 3.13. The profile showed that in HeLa cells the glycan structures are core 1 
(Galβ1,3GalNAc-O) type; monosialylated and disialylated core 1 were observed at m/z 895 
and 1257 respectively. While in NHDF cells the glycan structures are core 1 
(Galβ1,3GalNAc) and core 2 (Galβ1,3(GlcNAcβ1,6)GalNAc) types: in addition to observing 
monosialylated and disialylated core 1 at m/z at 895 and 1257 respectively, three core 2 
derived glycans m/z 984, 1345 (monosialylated) and 1706 (disialylated) were also detected. 
In NHDF cells, core 1 derived glycans account for approximately 79.5% of all the O-glycans. 
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Figure 3.13 Annotated MALDI-TOF MS spectra of permethylated O-glycans in Hela (top) and 
in NHDF cells (bottom) 
Profiles were obtained from the 35% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. Putative structures are based on the molecular weight, O-glycan biosynthesis pathway and 
MS/MS data.  GalNAc,  GlcNAc,  Gal,  NeuAc. 
 
According to the O-glycan biosynthesis pathway, all O-glycan structures displayed in Figure 
3.13 are unambiguous except the structures of the glycans at m/z 895 and 1345. The NeuAc 
in the glycan at m/z 895 can be either linked to the Gal or to the GalNAc. The NeuAc in the 
glycan at m/z 1345 glycans can be either linked to the Gal or to the Gal-GlcNAc. The 
position of sialylation was established by MS/MS where there were ambiguities. 
As shown in Figure 3.14, in both HeLa and NHDF cells the Gal was confirmed to be 3-linked 
to the GalNAc as the signal at m/z 620 corresponds to an eliminated ion O-Gal-NeuAc which 
was derived from the elimination occurring at the C3 position of GalNAc. The presence of 
the fragment ion at m/z 620 and the absence of the fragment ions at m/z 259 (losing a single 
Gal via elimination) and 659 (the product of loss of a single Gal via elimination) showed that 
the NeuAc in the glycan at m/z 895 is linked to the Gal.  
121 
 
 
 
Figure 3.14 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated O-glycan at m/z 
895 in HeLa cells (top) and NHDF cells (bottom) 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GalNAc,  Gal,  NeuAc. 
 
As shown in Figure 3.15, in NHDF cells the Gal was confirmed to be 3-linked to the GalNAc 
as the signal at m/z 620 corresponds to an eliminated ion O-Gal-NeuAc which was derived 
from the elimination occurring at the C3 position of GalNAc, its concurrent ion at m/z 747 
was also observed. In addition, the fragment ion at m/z 881 corresponds to a loss of LacNac, 
this demonstrates the presence of LacNAc. All these implied that the NeuAc was linked to 
the Gal. However, the molecular ion at m/z 520 corresponds to a loss of sialylated LacNac, 
this showed that the NeuAc was linked to the Gal-GlcNAc. Taken together, the MS/MS data 
provided evidence that the NeuAc was linked to either Gal or Gal-GlcNAc, which is 
indicated by drawing this NeuAc outside the bracket. 
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Figure 3.15 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated O-glycan at m/z 
1345 in NHDF cells 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GalNAc,  GlcNAc,  Gal,  NeuAc. 
 
3.3.2.2. Sialidase S digestion of the O-glycans of HeLa and NHDF cells 
 
Sialidase S digestion was carried out on O-glycans to determine the NeuAc linkage. 
Digestion of both HeLa and NHDF cells with sialidase S resulted in partial desialylation 
(Figure 3.16). The core 1 structure (m/z 534) and monosialylated core 1 structure (m/z 895) 
shown in HeLa cells (Figure 3.16 top) were originally from the glycans at m/z 895 and 1257 
in Figure 3.13 (top) respectively. A similar phenomenon was also observed in Figure 3.13 
(bottom) and Figure 3.16 (bottom). In addition, the core 2 structure (m/z 984) shown in 
NHDF cells (Figure 3.16 bottom) was derived from the glycans at m/z 984, 1345 and 1706 in 
Figure 3.13 (bottom). 
This indicated that both HeLa and NHDF contain α2,3 linked NeuAc. The following figure 
showed that a small amount of core 2 containing glycan (m/z 984) was observed in HeLa 
cells after sialidase S digestion, but this type of glycan was not detected prior to sialidase S 
treatment due to its low abundance.  
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Figure 3.16 Annotated MALDI-TOF MS spectra of permethylated sialidase S treated O-glycans 
in Hela cells (top) and NHDF (bottom) 
Profiles were obtained from the 35% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.13 for explanation of structure assignments.  GalNAc,  GlcNAc, 
 Gal,  NeuAc. 
  
3.3.2.3. Sialidase A digestion of the O-glycans of HeLa and NHDF cells 
 
Treatment with sialidase A led to a complete desialylation of the O-glycans in both cell types. 
Both core 1 and core 2 type glycans were observed after the desialylation (see Table 3.2). 
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Table 3.2 O-glycan structures observed in the MALDI-TOF MS spectra of Hela and NHDF af-
ter sialidase A digestion 
Glycans were obtained from the 35% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. Glycan structures and linkages are drawn based on the molecular weight, O-glycan 
biosynthesis pathway and MS/MS data. The rough percentage of the glycan relative abundance to the 
whole group is also indicated.  GalNAc,  GlcNAc,  Gal. 
 
m/z 
 
Structure 
After sialidase A digestion 
HeLa cells (percentage) NHDF cells (percentage) 
 
534 
 
 
 
 
96.0% 
 
60.4% 
 
 
984 
 
 
 
 
4.0% 
 
 
39.6% 
 
 
3.3.2.4. Summary 
 
In both HeLa and NHDF cells the O-glycans are either terminated with NeuAc or with 
uncapped Gal. Comparison of the relative abundances of the O-glycans (Table 3.3) showed 
that in HeLa cells O-glycans were sialylated, the monosialylated core 1 glycan accounted for 
approximately 22.9% of all the O-glycans, the remaining was the disialylated core 1 glycan. 
A small amount of core 2 containing glycan was only observed after sialidase digestions (see 
sections 3.3.2.2 and 3.3.2.3). It also showed that in NHDF cells, the relative abundances of 
non- mono- and disialylated glycans accounted for 35.7%, 37.4% and 26.9% of all the O-
glycans respectively. The relative abundance of disialylated glycans is greater in HeLa cells. 
After sialidase A digestion, the abundances of cores 1 and 2 (containing) glycans accounted 
for 60.4% and 39.6% respectively. 
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Table 3.3 O-glycan structures observed in the MALDI-TOF MS spectra of Hela and NHDF 
All glycans are permethylated and [M+Na]+. Glycan structures and linkages are drawn based on the 
molecular weight, O-glycan biosynthesis pathway and MS/MS data. ND, not detected. The ratio of 
the glycan relative abundance to the whole group is indicated using *; *=minor (<20%), **=medium 
(20-50%), ***=major (>50%).   GalNAc  GlcNAc,  Gal,  NeuAc. 
 
 
3.3.3. HeLa and NHDF glycolipid glycans 
 
3.3.3.1. MALDI-TOF MS analyses of the glycolipid glycans of HeLa cells and NHDF 
 
The glycolipid glycans were obtained following the procedure described in section 2.2. High 
quality MALDI data were obtained for the glycans from HeLa and NHDF cells. MALDI-
TOF MS spectra of HeLa and NHDF cell glycolipid glycans are shown in Figure 3.17 and 
Figure 3.18. The spectra show that nearly all glycans detected in both HeLa and NHDF are 
sialylated with NeuAc. In HeLa cells glycolipid glycans with m/z 855, 943, 1101, 1305 and 
1666 were detected in the 35% acetonitrile fraction. Their relative abundances are 
approximately 6.5%, 1.4%, 67.9%, 22.3% and 1.9% respectively. In addition, glycolipid 
glycans with m/z 1101, 1305 and 1666 were observed in the 50% acetonitrile fraction 
126 
 
(relative abundances 2.4%, 3.2% and 94.4% respectively). In NHDF cells glycolipid glycans 
with m/z 855, 943, 1217 and 1305 were detected in the 35% acetonitrile fraction, their 
relative abundances accounted for approximately 66.8%, 0.3%, 29.9% and 3.1% respectively. 
Additionally, glycolipid glycans with m/z 855, 1217, 1305 and 1666 were observed in the 50% 
acetonitrile fraction, their relative abundances accounted for 27.8%, 69.4%, 1.7% and 1.1% 
respectively. The glycan at m/z 1101 terminated with HexNAc is only observed in HeLa cells 
(see Table 3.4 for a compact summary). 
 
Figure 3.17 Annotated MALDI-TOF MS spectra of deuteroreduced, permethylated glycolipid 
derived glycans from Hela (top) and NHDF (bottom) 
These profiles were obtained from the 35% acetonitrile fractions from a C18 Sep-Pak column. All 
glycans are deuteroreduced (DR) and in the form of [M+Na]+. Putative structures are based on the 
molecular weight, glycolipid glycan biosynthesis pathway and MS/MS data.  GalNAc,  Glc,  Gal, 
 NeuAc. 
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Figure 3.18 Annotated MALDI-TOF MS spectra of deuteroreduced, permethylated glycolipid 
derived glycans from Hela (top) and NHDF (bottom) 
These profiles were obtained from the 50% acetonitrile fractions from a C18 Sep-Pak column. All 
glycans are deuteroreduced (DR) and in the form of [M+Na]+. See legend to Figure 3.17 for 
explanation of structure assignments.  GalNAc,  Glc,  Gal,  NeuAc. 
 
Peaks of interest were chosen for further characterization via MALDI-TOF/TOF MS/MS 
analysis. For instance, the glycan at m/z 1305 (the position of the NeuAc could not be 
determined). 
As shown in Figure 3.19 (top), the presence of the fragment ion at m/z 847 and its concurrent 
ion at m/z 480 showed that the NeuAc is linked to the terminal Gal. The presence of the 
fragment ion at m/z 486 and the presence of its concurrent ion at m/z 841 showed that the 
NeuAc is linked to the internal Gal. In addition, the presence of the double-cleavage ion at 
m/z 466 could also support this. All these showed that the glycan at m/z 1305 in HeLa cells 
possessed two structures; the NeuAc is either linked to the terminal Gal or to the internal Gal. 
In contrast to the HeLa data, MS/MS of m/z 1305 from NHDF cells showed fragment ions 
that correspond solely to one structure (Figure 3.19 bottom), in which the NeuAc is linked to 
terminal Gal. 
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Figure 3.19 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated glycolipid glycan at 
m/z 1305 in HeLa cells (top) and NHDF cells (bottom) 
Data were acquired in the form of [M+Na]+ ions. DR, deuteroreduced. See legend to Figure 3.5 for 
explanation of structure assignments.  GalNAc,  Glc,  Gal,  NeuAc. 
 
The following table summarises the structural conclusions which are extracted from the MS 
and MS/MS analyses, taking into account glycolipid glycan biosynthetic considerations. 
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Table 3.4 Structures of glycans derived from glycolipids observed in the MALDI-TOF MS 
spectra of Hela and NHDF cells 
All glycans are deuteroreduced (DR), permethylated and in the form of [M+Na]+. Glycan structures 
are drawn based on the molecular weight, glycolipid glycan biosynthesis pathway and MS/MS data; 
ND, not detected. The ratio of the glycan relative abundance to the whole group is indicated using *. 
*=minor (<20%), **=medium (20-50%), ***=major (>50%).  GalNAc,  Glc,  Gal,  NeuAc.   
 
 
3.3.3.2. Sialidase digestion of the glycolipid glycans of HeLa cells 
 
Sialidase digestions were only carried out on the glycolipid glycans from HeLa cells due to 
the fact that the amount of NHDF cells was limited. A new batch of HeLa cells was used for 
this enzymatic digestion. High quality MALDI data were obtained. As shown in Figure 3.20, 
digestion of the glycans with sialidase S resulted in partial desialylation. Thus the sialylated 
glycan at m/z 1101 was still observed while the glycan at m/z 1666 was absent. One structure 
giving the original signal at m/z 1305 was absent, whilst the other was still observed. A new 
glycan, the m/z of which is 943, was detected. All these confirmed the α2,3 linkage of the 
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peripheral NeuAc in glycans at m/z 1305 and 1666. Sialidase A digestion resulted in a 
complete loss of NeuAc supporting the glycomic assignments. 
 
Figure 3.20 Annotated MALDI-TOF MS spectra of deuteroreduced, permethylated glycolipid 
derived glycans from Hela cells, untreated (top), sialidase S treated (middle), sialidase A treated 
(bottom)  
These profiles were obtained from the 35% acetonitrile fractions from a C18 Sep-Pak column. All 
ions are [M+Na]+. See legend to Figure 3.17 for explanation of structure assignments.  GalNAc,  
Glc,  Gal,  NeuAc. 
 
The result of glycomic analyses showed similar sialylation in the glycolipid glycans in the 
two cell types. 
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3.4. Discussion 
 
Although Van Damme and Shang had investigated these SNAs using glycan array and HeLa 
and NHDF cells, they did not determine the cell glycomes; this is essential as it could bridge 
what they did determine (glycan array result, SNA cytotoxicity result (Table 3.5), etc.) 
(Shang et al., 2015; Shang and Van Damme, 2014) and form a more complete story on these 
SNAs. Therefore, the glycomic analysis was carried out. 
Table 3.5 Comparison of LC50 values for the S. nigra proteins in HeLa and NHDF cell lines 
Data are shown as means ± SE based on 4 replications per treatment, and each experiment was 
repeated 3 times. LC50, lethal concentration that kills half of the sample population. The 
concentration of SNAs used for the cell viability test is in the range of 0.1-2 µM. The concentrations 
(>2 µM) were obtained via calculated according to the trend of the dose response curve. Since these 
predict LC50 concentrations (>2 µM) were not tested, accurate values were not given. Therefore, this 
conclusion, " the LC50 value is > 2 µM ", was made (Shang et al., 2015). 
 
 
The glycomic analyses of HeLa cells and NHDF cells demonstrated a clear correlation with 
the results from cytotoxicity and internalization studies, which indicates the importance of 
protein-carbohydrate interactions for the proteins entering the cells. Particularly, the result of 
N- and O-glycomic analyses showed that compared to NHDF cells the overall sialylation 
level of N- and O-glycans in HeLa cells is greater (see Figure 3.12 and Figure 3.13), which 
could explain why SNA-IV was more toxic towards HeLa cells. Similarly, significantly more 
α2,6 linked NeuAc residues in the glycoprotein glycans from HeLa cells (see Figure 3.12) 
could explain the greater cytotoxicity of SNA-I to HeLa cells. In addition, SNA-II and SNA-
V also showed more cytotoxicity to the HeLa cells (see Table 3.5), which was possibly due to 
the fact that these two SNAs preferred binding to O-glycan core 1 glycan (see Table 1.7). 
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Moreover, compared to other SNAs, SNA-V is the only protein that revealed remarkable 
cytotoxicity to NHDF cells (see Table 3.5), and this could be caused by the higher abundance 
of terminal Gal residues in these cells. As shown in Table 1.7, SNLRP prefers binding to the 
structure GlcNAcβ1,4GlcNAc which is the chitobiose core moiety (Barry et al., 2013). 
Therefore, this SNA should interact with all N-glycans as this disaccharide is a core structure 
for all N-glycans. However, the LC50 values in the cytotoxicity experiment for SNLRP are 
very great (see Table 3.5), implicating low binding to the cell surface. More importantly, this 
was consistent with the result of the SNA internalization experiment performed using HeLa 
cells. In the experiment the amount of SNLRP internalized by HeLa cells was extremely low 
(Shang et al., 2015), and this suggested that the binding of SNLRP to the chitobiose core 
moiety is probably blocked as the structure GlcNAcβ1,4GlcNAc is cryptic due to capping 
structures.  
Although the MS data provided glycan profiles of HeLa and NHDF cells and new insights on 
potential carbohydrate binding sites which associate with cell binding/uptake for SNAs, it is 
evident that this interaction is complicated and not adequate to explicate the cytotoxicity of 
the proteins under study. For instance, although the amount of terminal Gal on HeLa cells is 
obviously lower than that of sialic acid, the reason why the SNA-V and SNA-II are more 
toxic to HeLa cells than SNA-I is still unknown. A possible explanation for this could be 
differential intracellular trafficking of the proteins. It has been reported that the cytotoxicity 
of some type 2 RIPs, such as ricin and abrin, relies on the binding of the B chain to 
glycoconjugates at the cell surface, as such promoting cellular uptake of the RIPs (Sandvig et 
al., 1978; Lannoo and Van Damme, 2014; Shang et al., 2015). Incubation of mammalian cells 
with ricin leads to it being endocytosed and then transported to the trans-Golgi network, 
followed by retrogradely transported from the Golgi to the ER in which the disulphide bond 
is cleaved, after that the A chain gets into the cytoplasm where it finally refolds and inhibits 
protein synthesis via removing a key adenine from the 28S ribosomal subunit (Sandvig et al., 
1991; Lord and Roberts, 1998; Spooner and Lord, 2015). However, the intracellular 
trafficking of SNA V is different; it enters the cytosol without passing the Golgi and ER 
(Barbieri et al., 2004; Battelli et al., 1997; Shang et al., 2015). Therefore, it is possible that 
these SNAs follow different intracellular trafficking and exhibit the cytotoxicity via different 
ways. 
It has been reported that RIPs are able to induce cell death via apoptosis (Das et al., 2012). 
Since SNA-I, SNA-V and SNLRP are type-2 RIPs, they should be able to cause cell 
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apoptosis. In addition, it has been reported that SNA-II can cause apoptosis (Shahidi-Noghabi 
et al., 2010), and both SNA-II and SNA-IV possess one lectin chain, this implies that SNA-
IV is probably able to cause apoptosis as well. Therefore, all these SNAs are able to cause 
apoptosis via which HeLa and NHDF cells could be killed in the experiment. However, it is 
not clear that how SNAs trigger the apoptosis. It is reported that SNA-I and SNA-II could 
trigger caspase-3 like activities in cells (Shahidi-Noghabi et al., 2010), and caspase-3 is a cell 
death protease and it plays an essential role in apoptosis (Porter and Janicke, 1999). It is 
therefore possible that the binding of SNAs to cells yields a stimulus which subsequently 
activates the caspase pathway resulting in apoptosis. 
Sambucus species have been used for medicinal purposes since Pedanius Dioscorides’s (a 
Greek physician, pharmacologist and botanist) period (40-90 A.D.). Among these, Sambucus 
nigra lectins are the most relevant species researched (Tejero et al., 2015). However, its 
application has been restricted to some extent due to the fact that the proteins are bioactive 
and the ingestion of these compounds could result in deleterious effects. In the last few years, 
the chemical and pharmacological characteristics of Sambucus species have been investigated. 
SNA-V (Nigrin b) can be used for the construction of conjugates which target the transferrin 
receptor, and this receptor is over-expressed in cancer cells (Citores et al., 2002). Although 
the biological role of proteins derived from Sambucus remains unclear, they are speculated to 
be involved in helping plants against insects and viruses (Tejero et al., 2015). Therefore, 
these SNAs could be potentially used in agriculture to protect crops against plant insects and 
viruses.  
This study reports for the first time the glycolipid glycans in NHDF cells by MALDI-TOF 
MS and MALDI-TOF/TOF MS/MS. Although a paper reported N- and O-glycan profile of 
NHDF in 2012 (Engelstaedter et al., 2012), half of their sample amount was used and 31 
more complex N-glycans were detected in this glycomic analysis. Therefore the analysis here 
is more sensitive and complete, In addition, the detection of the potential sialyl-Lewis X in 
the N-glycans from HeLa cells supports the accuracy of the glycomic analyses as sialyl-
Lewis X is expressed in cervical cancer (Engelstaedter et al., 2012). More work is required 
for uncovering the veil of the biological role and the mechanism of SNA proteins. For 
instance, plants can be genetically modified (being transfected with the gene that encodes 
SNA-I or SNA-II) to express the SNA. Theoretically, these transformants should possess 
enhanced insect resistance as these two SNAs can cause insect midgut cell apoptosis 
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(Shahidi-Noghabi et al., 2010). If this is working, it can be applied to tobacco plants, which 
will bring great profits.       
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4. Mass spectrometric investigation of glycosylation in patients with 
muscular diseases 
 
4.1. Introduction to the project  
 
This project is in collaboration with Professor Hanns Lochmuller and Dr. Juliane Mueller at 
Newcastle University. 
To test the hypothesis which is mutations in GFPT1 may cause N-glycan branching 
variations and thus have an influence on protein glycosylation (see section 1.7.1), glycomic 
analysis was performed to determine whether protein glycosylation is generally impaired or 
modified in CMS patients with GFPT1 mutations. The N-glycomes in myoblasts from 
healthy controls and patients with GFPT1 mutations, as well as myotubes obtained by in vitro 
differentiation were rigorously characterised. Simultaneously, myoblasts and myotubes from 
other patients were also investigated in the same way to check whether this possible 
impairment or modification is unique in the GFPT1 patients. Specifically, MS analyses could 
give general structural information of the glycans from healthy controls and patients. Since 
the focus is on glycan branching variations, potential branched glycans from the controls and 
patients were further analysed with MS/MS as this technique can determine glycan branch 
structures. Sialidase S digestion was only carried out in the myoblast and myotube samples 
from the DOK7 patient to determine the sialic acid linkage due to the fact that the cell pellets 
(myoblast and myotube) from this patient were visually greater than others.  
This investigation would provide a better understanding of glycosylation in neuromuscular 
junction disorders with the long term objective of establishing structure/function relationships. 
Additionally, potential glyco-biomarkers of congenital myasthenic syndrome (CMS) may be 
discovered when comparing glycan profiles of healthy controls, GFPT1 patients and other 
muscular disease patients. 
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4.2. Sample details and sample processing 
 
The detail of three batches of samples is shown in the following 3 Tables. Cell culture details 
are described in section 2.1.3.2. 
Table 4.1 Detail of myoblasts and myotubes  
“GFPT1 patient” means a CMS patient with GFPT1 mutations; similarly for DOK7 and MTND5 
patients. Each of the cell lines, except for GFPT1 patient 3, has three pellets. The myotubes were 
differentiated from myoblasts. (The table has been changed as required: previous three tables have 
been combined) 
First batch 
Myoblasts are from Cell number Number of samples 
GFPT1 patient 1 Estimated to be 10 million 3 
GFPT1 patient 2 Estimated to be 10 million 3 
GFPT1 patient 3 Estimated to be 10 million 1 
DOK7 patient Estimated to be 10 million 3 
MTND5 patient Estimated to be 10 million 3 
Second batch 
Myoblasts are from Cell number Number of samples 
GFPT1 patient 1 Estimated to be 10 million 1 
GFPT1 patient 2 Estimated to be 10 million 1 
GFPT1 patient 3 Estimated to be 10 million 1 
DOK 7 patient Estimated to be 10 million 1 
MTND5 patient Estimated to be 10 million 1 
Healthy control 1 Estimated to be 10 million 2 
Healthy control 2 Estimated to be 10 million 2 
LGMD2A patient Estimated to be 10 million 2 
Pompe disease patient Estimated to be 10 million 2 
Third batch 
Myotubes are from Cell number Number of samples 
GFPT1 patient 1 unknown 1 
GFPT1 patient 2 unknown 1 
GFPT1 patient 3 unknown 1 
Healthy control 1 unknown 1 
Healthy control 2 unknown 1 
DOK 7 patient unknown 1 
MTND5 patient unknown 1 
LGMD2A patient unknown 1 
Pompe disease patient unknown 1 
 
All samples were analysed using glycomic methodologies which have been described in 
section 2.2.  
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4.3. Results 
 
4.3.1. Determination of optimal conditions for cell culture 
 
Because sufficient sample for glycomic analysis could not be provided by human muscle 
biopsies, suitable cell culture conditions for producing cells are required to be established 
whilst the amount of FCS used in the culture medium should be minimised. The latter was 
important as it is known that glycans derived from FCS are frequently co-purified with cell-
derived glycans during glycomic analyses (Monk et al., 2006). 
 
4.3.1.1. MALDI-TOF MS analysis of the N-glycans of the myoblasts cultured in the medium 
containing 5%, 10% and 15% serum 
 
Myoblast samples listed in Table 4.1 were analysed using glycomic methodologies. These 
myoblasts were cultured in medium with different FCS concentrations. Good quality 
MALDI-MS spectra were only yielded from myoblasts cultured in 15% FCS. Representative 
data are shown in Figure 4.1. The spectra demonstrate the presence of high mannose (m/z 
1580, 1784, 1988, 2192 and 2396) and complex glycans (bi-, tri- and tetraantennary, e.g. m/z 
2966, 3777 and 4587) in the cell line. The relative abundance of all complex glycans in top, 
middle and bottom panels which were obtained from myoblasts cultured in the medium 
supplemented with 5%, 10% and 15% FCS respectively accounted for approximately 9.5%, 
29.6% and 45.4% respectively of all detected glycans. Especially, Top and middle panels 
showed that the high mass glycans were not as abundant compared to that in bottom panel. 
More detailed interpretations of figures will be shown in the next section. 
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Figure 4.1 Annotated MALDI-TOF MS spectra of permethylated N-glycans from DOK 7 patient 
myoblast cultured in the medium containing 5% (A), 10% (B) and 15% (C) FCS 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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4.3.1.2. Summary 
 
According to the hypothesis (see section 1.7.1), the focus of this project is on N-glycan 
branching variation. Therefore, glycans with at least 2 LacNAc units are required to check the 
variation. Glycans with at least 2 LacNAc units were sufficiently abundant when cells grew 
in the medium containing 15% FCS, which enabled us to make firm conclusions about 
branching. In addition, one cell line (GFPT1 patient 3) grew extremely slowly in the medium 
containing 5% and 10% FCS.Therefore, all cells that analysed in this project afterwards were 
cultured in the medium containing 15% FCS.  
The glycans which lack core fucose shown in the spectra (Figure 4.1) are probably derived 
from FCS (Monk et al., 2006) and these glycans do not seem to be a problem as they are not 
dominating the spectra, thus the contamination will not have too much influence on the final 
result. In all the comparisons carried out afterward, the non-core fucosylated glycans are 
excluded. 
 
4.3.2. Myoblast N-glycans 
 
4.3.2.1. MALDI-TOF MS analysis of the N-glycans of the myoblasts from healthy controls and 
GFPT1 patients and other muscular disease patients 
 
Myoblast samples listed in Table 4.1 were analysed. High quality MALDI data were obtained 
for the N-glycans from all myoblast samples with the exception of GFPT1 patient 3 whose 
myoblasts were difficult to culture. Combining with the five MALDI MS spectra (myoblasts 
cultured in 15% FCS containing medium) from the previous section a total of eighteen 
MALDI MS data sets were generated which included duplicate experiments. Representative 
MALDI-TOF MS spectra from a healthy control, a GFPT1 patient and the DOK7 patient are 
shown in Figure 4.2 top, middle and bottom panel, respectively.   
The N-glycans comprised high mannose and complex glycans. High mannose glycan 
structures were the same as the ones mentioned in section 4.3.1.1. In addition to being bi-, tri- 
and tetraantennary (see section 4.3.1.1), the complex N-glycans in the myoblasts (Figure 4.2 
and Figure 4.3) could be nonsialylated (e.g. m/z 2244, 2693 and 3143), monosialylated (e.g. 
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m/z 2605, 3055 and 3504), disialylated (e.g. m/z 2966, 3416 and 3865), trisialylated (e.g. m/z 
3777 and 4226) and tetrasialylated (m/z 4587). No disease-unique glycan structure was 
identified. Some common characteristics of mammalian cell N-glycomes (Dell and Morris, 
2001; Antonopoulos et al., 2012) were observed, such as core fucosylated GlcNAc, LacNAc 
antenna building blocks which in some cases are tandemly repeated to produce oligo-LacNAc 
extensions, and NeuAc capped antennae. The number of LacNAc units observed in the 
detected glycan was up to nine (m/z 5389, Figure 4.2 middle). Significantly, the N-glycan 
profile of healthy control 1 showed a broadly similar pattern to those of GFPT1 patient 1 and 
DOK7 patient. 
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Figure 4.2 Annotated MALDI-TOF MS spectra of permethylated N-glycans of myoblasts from 
healthy control 1 (top), GFPT1 patient 1 (middle) and the DOK7 patient (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. The number indicated in the spectra is the mass to charge ratio (m/z) of the corresponding 
ion. Since the ion is monocharged, the value of m/z is equal to the molecular weight value of the 
glycan. Annotations are based on the molecular weight, N-glycan biosynthesis pathway and MS/MS 
data. Glycans at m/z 2966, 3777 and 4587 are clearly annotated, this is due to the fact that their 
structures are unequivocal because each antenna is capped with a sialic acid and thus they are 
homogeneous bi-, tri- and tetraantennary glycans. However, the glycan structure is not always as 
unequivocal as the glycan at m/z 2966 as biosynthetically non-fully sialylated glycan molecular ion 
species could be made up of mixtures of structural isoforms. Therefore, for those heterogeneous 
multiantennary structures with extended LacNAc repeats, the annotations are simplified throughout 
by using biantennary structures with the extensions and NeuAcs listed outside a bracket.  GlcNAc, 
 Man,  Gal,  Fuc,  NeuAc.   
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Figure 4.3 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) of 
myoblasts from healthy control 1 (top), GFPT1 patient 1 (middle) and the DOK7 patient 
(bottom) 
This figure amplifies the mass range (m/z 2900-4700) where the majority of tri- and tetra-antennary 
glycans are found in Figure 4.2. Profiles were obtained from the 50% acetonitrile fraction from a C18 
Sep-Pak column. All ions are [M+Na]+. See legend to Figure 4.2 for explanation of structure assign-
ments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
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MALDI data for the other patients and control are shown in Figure 4.4, Figure 4.5, Figure 4.6 
and Figure 4.7; there was also no significant difference in the N-glycan profile among these 
samples.  
 
Figure 4.4 Annotated MALDI-TOF MS spectra of permethylated N-glycans from myoblasts of 
healthy control 2 (top), GFPT1 patient 2 (middle), the MTND5 patient (bottom)  
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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Figure 4.5 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) 
from myoblasts of healthy control 2 (top), GFPT1 patient 2 (middle), the MTND5 patient 
(bottom) 
This figure amplifies the mass range (m/z 2900-4700) where the majority of tri- and tetra-antennary 
glycans are found in Figure 4.4. Profiles were obtained from the 50% acetonitrile fraction from a C18 
Sep-Pak column. All ions are [M+Na]+. See legend to Figure 4.2 for explanation of structure assign-
ments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
 
146 
 
 
 
 
Figure 4.6 Annotated MALDI-TOF MS spectra of permethylated N-glycans from myoblasts of 
healthy control 2 (top), LGMD2A patient 2 (middle), Pompe disease patient (bottom)  
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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Figure 4.7 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) 
from myoblasts of healthy control 2 (top), LGMD2A patient 2 (middle), Pompe disease patient 
(bottom) 
This figure amplifies the mass range (m/z 2900-4700) where the majority of tri- and tetra-antennary 
glycans are found in Figure 4.6. Profiles were obtained from the 50% acetonitrile fraction from a C18 
Sep-Pak column. All ions are [M+Na]+. See legend to Figure 4.2 for explanation of structure 
assignments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
 
In addition, MALDI spectra for biological replicates are shown in Figure 4.8; the result 
shows that there is no significant difference in the N-glycan profile of biological replicates. 
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Figure 4.8 MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) from two 
batches of healthy control 1 myoblasts (top) and two batches of GFPT1 patient 1 myoblasts 
(bottom) 
See legend to Figure 3.1 for explanation of spectra arrangement. In healthy control 1, the average peak 
variation between the spectra from different batches is approximately 18%. In GFPT1 patient 1, the 
average peak variation between the spectra from different batches is approximately 14%.  
 
To check whether the GFPT1 patients exhibited impaired N-glycan branching, the N-glycans 
were classified into families with different levels of sialylation and then glycan abundances 
within these families were compared. Sialylation levels were determined to be similar in the 
various myoblast samples, which was achieved by calculating abundance ratios of pairs of 
glycans in which one glycan of the pair possessed one more sialic acid than the other but 
otherwise other compositions in the pair are identical. The results of these calculations are 
displayed in Figure 4.9 for the various myoblast samples. The data show that there is no 
significant difference in the glycan sialylation between these samples and sialylation patterns 
are broadly similar.  
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Figure 4.9 Comparison of N-glycan sialylation in the myoblasts 
Each point in the graph indicates a ratio which was obtained by comparing the relative intensity (RI) 
of one glycan to that of another glycan which possesses one fewer NeuAc. The numbers in the 
brackets correspond to the m/z of the comparing glycans. 
 
The N-glycans were classified into nonsialylated, monosialylated, disialylated, trisialylated 
and tetrasialylated families. For each family of glycans, the abundance ratios of pairs of 
glycans varying in composition by a single LacNAc unit were determined. For instance, 
Figure 4.10 shows comparative data for nonsialylated (Panel A) and monosialylated (Panel B) 
glycans possessing from two to six LacNAc units. All samples showed a similar profile of 
abundance ratios, albeit there is a two to three-fold divergence of ratios when comparing four 
LacNAcs with three LacNAcs (m/z 3143 and 2693, Panel A), with the GFPT1 patient 
samples displaying somewhat higher levels of the former than observed in the other samples. 
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Figure 4.10 Comparison of the relative intensities of a family of nonsialylated glycans with 
different numbers of LacNAc (A) in myoblasts, comparison of the relative intensities of a family 
of monosialylated glycans with different numbers of LacNAc (B) in myoblasts 
Each point in the graph indicates a ratio which was obtained by comparing the relative intensity (RI) 
of one glycan to that of the corresponding glycan which possesses one fewer LacNAc moiety. The 
number under the glycan structure is the m/z value of the glycan; the number is increasing with the 
addition of LacNAc moiety. In each comparison, the numbers in the brackets correspond to the m/z of 
the comparing glycans.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
 
4.3.2.2. MALDI-TOF/TOF MS/MS analyses of the N-glycans of the myoblasts from healthy 
controls and GFPT1 patients and other muscular disease patients  
 
No significant difference between the MS spectra of the GFPT1 patients and healthy controls 
and other muscular disease patients was observed, and this unexpected result could not 
support the initial hypothesis (see section 1.7.1) that branching might be impaired in GFPT1 
myoblasts. On the contrary, the result suggested that multiantennary glycans were likely to be 
slightly more abundant in GFPT1 patients than in controls. However, it is important to realise 
that increasing numbers of LacNAc units does not mean increased branching because these 
units can be present in extended oligo-LacNAc antennae rather than as additional antennae. 
For instance, when a LacNAc is added to the glycan at m/z 2244, this LacNAc could be an 
extra antenna or an extension of an existed antenna, no matter where this LacNAc is, the m/z 
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value of the resulting glycan should be 2693. In this case it will be difficult to determine 
branching alteration via only MS analyses. Indeed the MALDI data in Figure 4.2, Figure 4.4 
and Figure 4.6 confirm that the N-glycans are able to extend their antennae due to the fact 
that many of the glycans at high mass have more than four LacNAc moieties which are the 
basis of a tetra-antennary glycan. Fortunately isomeric glycans varying in oligo-LacNAc 
extensions and branching can be distinguished and their abundances can be compared via 
analysing characteristic fragment ions in MS/MS analyses. Therefore additional MS/MS 
investigations were carried out. 
In the MS/MS analyses, it is not very accurate to compare the relative abundance of an 
identical glycan isoform in two different samples as the isoform may account for a greater 
proportion of the glycan mixture in one sample but the corresponding relative abundance may 
be lower than the same isoform in the other sample. Therefore glycan isoform ratios were 
compared within the same MS/MS analysis. Because the amounts of sample were limited, it 
was not practicable to characterise all components by MS/MS. Therefore only peaks that 
were expected to be most informative for comparative purposes were analysed with MS/MS. 
Note, though, that analysing every glycan peak is usually unnecessary because the N-glycans 
are closely related since they share a biosynthesis pathway.  
For example Figure 4.11 shows MS/MS spectra acquired from the monosialylated glycan at 
m/z 3055 that contains three LacNAc units in the MALDI data (see Figure 4.2) for healthy 
control 1, GFPT1 patient 1 and the DOK7 patient. There are two antennae arrangements 
which are consistent with this composition: triantennary and biantennary with one of the 
antennae possessing one LacNAc extension. As shown in Figure 4.11, the MS/MS spectra are 
dominated by fragment ions arising from loss of a single terminal LacNAc, with or without a 
NeuAc. These fragment ions can be obtained from both the bi- and tri-antennary structures. 
Nevertheless there are several fragment ions that are characteristic for the biantennary 
structure with extended LacNAc. These ions are observed at m/z 935, 1781 and 2142. The 
peak signals of them in the spectra are weak. Importantly their relative abundances to the 
major fragment ions are similar in the three samples. It is estimated from abundance 
comparisons that the ratios of the biantennary glycan is in myoblasts from healthy control 1, 
GFPT1 patient 1 and the DOK7 patient are approximately 10.6%, 13.1% and 10.4%, 
respectively. 
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Figure 4.11 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated N-glycan at m/z 
3055 in myoblasts from healthy control 1 (top), GFPT1 patient 1 (middle) and the DOK7 patient 
(bottom) 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
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The analyses of other glycans with similarly ambiguous compositions gave similar results as 
described above. One more example is shown in Figure 4.12 which was obtained from the 
glycan at m/z 2693 which contains one fewer NeuAc than the previously mentioned glycan 
m/z 3055 (see Figure 4.11) in the MALDI data (see Figure 4.2) for the same three subjects. 
There are also two antennae arragements which are consistent with this composition: 
triantennary and biantennary with one extended antenna. As shown in Figure 4.12, the 
fragment ion (m/z 2230) arising from loss of a single terminal LacNAc can be derived from 
both the bi- and tri- antennary structures, in addition to that, there is no characteristic ion for 
triantennary structure but there are two characteristic ions for the biantennary structure. These 
are observed at m/z 935 and 1781. The peaks of them in the spectra are also minor and their 
relative abundances to the major fragment ion (m/z 2230) are similar in the three samples. 
Similarly, the ratios of the biantennary glycan in myoblasts from healthy control 1, GFPT1 
patient 1 and the DOK7 patient are estimated to be approximately 9.2%, 14.1% and 12.3% 
respectively. 
Taken together, the MS and MS/MS results provide strong evidence that the patterns of 
glycan antennae are very similar amongst the myoblasts from healthy controls, GFPT1 
patients, and other muscular disease patients. 
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Figure 4.12 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated N-glycan at m/z 
2693 in myoblasts from healthy control 1 (top), GFPT1 patient 1 (middle) and the DOK7 patient 
(bottom) 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GlcNAc,  Man,  Gal,  Fuc. 
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4.3.2.3. Sialidase S digestion of N-glycans of the myoblasts from the DOK7 patient  
 
The myoblast sample from DOK7 patient in the second batch was split into two aliquots. One 
aliquot was used for normal glycomic analysis, and the other could be used for sialidase S 
digestion to determine the NeuAc linkages in myoblast N-glycome, which could give us more 
information concerning the myoblast N-glycome. This enzyme is specific for α2,3 linked 
sialic aicd. 
As shown in Figure 4.13 (bottom), sialidase S digestion of N-glycans from the DOK7 patient 
myoblast resulted in nearly complete desialylation of all of the core fucosylated N-glycans. A 
handful of sialylated glycans were still shown at m/z 2431, 2880 and 3242. These α2,6 linked 
sialylated glycans are lacking core fucose and are likely to be derived from FCS in the culture 
medium (Monk et al., 2006). Therefore, I can conclude that the NeuAc in the myoblast N-
glycans is predominantly α2,3 linked. 
 
Figure 4.13 Annotated MALDI-TOF MS spectra of permethylated N-glycans (top) and sialidase 
S treated N-glycans (bottom) of myoblasts from DOK7 patient, second batch 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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4.3.3. Myotube N-glycans 
 
4.3.3.1. MALDI-TOF MS analysis of the N-glycans of myotubes from healthy controls and 
GFPT1 patients and other muscular disease patients 
 
Myotube samples listed in Table 4.1 were analysed. These myotubes were obtained via in 
vitro differentiation of the myoblasts that used in the previous experiment. They were 
subjected to the same glycomic analysis that used in the myoblasts. Most of the myotube 
samples showed good quality data. However, the high m/z glycans were not always observed 
due to the fact that myotube sample quantities were more limited than for myoblasts. 
Representative MALDI-TOF MS spectra from healthy control 1, a GFPT1 patient 1 and the 
DOK7 patient are shown in Figure 4.14 and Figure 4.15.  
Some common characteristics of mammalian cell N-glycomes were observed in Figure 4.14 
and Figure 4.15 (see section 4.3.2.1 for detailed describtion). However, there is a difference 
in the myotube data between healthy control 1 and the GFPT1 patient 1 and the DOK7 
patient, the difference is that although all showed minor signals for glycans with more than 
four LacNAcs, healthy control 1 and the GFPT1 patient 1 showed a predominance of 
biantennary glycans and relatively high levels of glycans with three and four LacNAcs 
(Figure 4.15, top and middle panels) while the  DOK7 patient showed more abundant glycans 
with three and four LacNAcs (e.g. m/z 3055, 3143, 3504 and 3865) (Figure 4.15, bottom 
panel). 
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Figure 4.14 Annotated MALDI-TOF MS spectra of permethylated N-glycans of myotubes from 
healthy control 1 (top), GFPT1 patient 1 (middle) and the DOK7 patient (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.   GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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Figure 4.15 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) of 
myotubes from healthy control 1 (top), GFPT1 patient 1 (middle) and the DOK7 patient (bottom) 
This figure amplifies the mass range (m/z 2900-4700) where the majority of tri- and tetra-antennary 
glycans are found in Figure 4.14. Profiles were obtained from the 50% acetonitrile fraction from a 
C18 Sep-Pak column. All ions are [M+Na]+. See legend to Figure 4.2 for explanation of structure as-
signments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
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MALDI MS data for the other patients and control are shown in Figure 4.16 to Figure 4.19; 
they all showed generally similar glycan profiles as those shown in healthy control 1 and the 
GFPT1 patient 1 (Figure 4.14 and Figure 4.15). 
 
Figure 4.16 Annotated MALDI-TOF MS spectra of permethylated N-glycans from myotubes of 
healthy control 2 (top), GFPT1 patient 2 (middle), the MTND5 patient (bottom)  
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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Figure 4.17 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) 
from myotubes of healthy control 2 (top), GFPT1 patient 2 (middle), the MTND5 patient (bot-
tom) 
This figure amplifies the mass range (m/z 2900-4700) where the majority of tri- and tetra-antennary 
glycans are found in Figure 4.16. Profiles were obtained from the 50% acetonitrile fraction from a 
C18 Sep-Pak column. All ions are [M+Na]+. See legend to Figure 4.2 for explanation of structure as-
signments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
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Figure 4.18 Annotated MALDI-TOF MS spectra of permethylated N-glycans from myotubes of 
healthy control 2 (top), LGMD2A patient 2 (middle), the MTND5 patient (bottom) 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
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Figure 4.19 Annotated MALDI-TOF MS spectra of permethylated N-glycans (m/z 2900-4700) 
from myotubes of healthy control 2 (top), LGMD2A patient 2 (middle), the MTND5 patient 
(bottom) 
This figure amplifies the mass range (m/z 2900-4700) where the majority of tri- and tetra-antennary 
glycans are found in Figure 4.18. Profiles were obtained from the 50% acetonitrile fraction from a 
C18 Sep-Pak column. All ions are [M+Na]+. See legend to Figure 4.2 for explanation of structure as-
signments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc.   
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In order to check whether the GFPT1 patients exhibited impaired N-glycan branching in 
myotubes, the N-glycans were also classified into families with different sialylation levels 
and then the glycan abundances within these families was compared. The sialylation levels 
were determined to be similar in the various myotube samples, which was achieved via using 
the same method employed in section 4.3.2.1. The results of these calculations are shown in 
Figure 4.20 for the various myotube samples. In the figure, the red line which stands for 
MTND5 patient is obviously different from other lines at two comparison points (m/z 3055 
and 2693, m/z 3504 and 3143), especially when comparing the abundance of the glycan with 
three LacNAcs and one NeuAc (m/z 3055) to the that of the glycan with three LacNAcs (m/z 
2693), the resulting ratio is two to seven-fold of others. In addition, at the same comparison 
point (m/z 3055 and 2693) somewhat higher level of ratios (two to three-fold) are shown in 
GFPT1 patient 1 and the DOK7 patient. Except for these differences, there is no other evident 
difference in the glycan sialylation between the samples and sialylation patterns are broadly 
similar. 
 
Figure 4.20 Comparison of N-glycan sialylation in the myotubes  
See legend to Figure 4.9 for explanation of structure assignments. 
 
Then the N-glycans were compared in the same way as described in section 4.3.2.1 (same 
sialylation level, but different number of LacNAc). Figure 4.21 shows myotube comparative 
data for nonsialylated (Panel A) and monosialylated (Panel B) glycans containing from two 
to six LacNAc units. The result is similar to that of myobolasts which has been described in 
section 4.3.2.1, except for a two to four-fold divergence of ratios when comparing 4 LacNAcs 
with 3 LacNAcs (m/z 3143 and 2693 in Panel A, m/z 3504 and 3055 in Panel B) shown in the 
DOK7 patient. 
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Figure 4.21 Comparison of the relative intensities of a family of nonsialylated glycans with 
different numbers of LacNAc (A) in myotubes, comparison of the relative intensities of a family 
of monosialylated glycans with different numbers of LacNAc (B) in myotubes 
See legend to Figure 4.10 for explanation of structure assignments.  GlcNAc,  Man,  Gal,  Fuc, 
 NeuAc.   
 
Except for the differences mentioned previously, there was no significant difference between 
the myotube MS spectra of the GFPT1 patients and healthy controls and other muscular 
disease patients, and this unexpected result was similar to the myoblast result described in 
section 4.3.2.1.  
 
4.3.3.2. Sialidase S digestion of N-glycans of the myotubes from the DOK7 patient 
 
The myotube sample from DOK7 patient was split into two aliquots. One aliquot was used in 
section 4.3.3.1, and the other was used for sialidase S digestion to determine the NeuAc 
linkages in myotube N-glycome. 
Digestion of N-glycans from DOK7 patient myotubes with sialidase S resulted in a nearly 
complete desialylation on all core fucosylated N-glycans (Figure 4.22). Several minor 
sialylated glycans were observed at m/z 2431 and 2792. These sialylated glycans are 
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probably α2,6 linked sialylated glycans and they are likely to be derived from FCS (see 
section 4.3.2.3). Therefore, I conclude that the NeuAc linkage in myotubes is not changed 
upon differentiation. 
 
 
Figure 4.22 Annotated MALDI-TOF MS spectra of permethylated N-glycans (top) and sialidase 
S treated N-glycans (bottom) of myotubes from DOK7 patient 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 4.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc.   
 
4.3.4. Myotube O-glycans 
 
4.3.4.1. MALDI-TOF MS analysis of the O-glycans of the myotubes  
 
In addition to analysing N-glycans, the analysis of O-glycans was also performed; however, 
MALDI MS data were only obtained from myotubes of 2 healthy controls and 4 muscular 
disease patients. The O-glycan profiles are shown in Figure 4.23 and Figure 4.24. The figure 
showed the presence of both core 1 (m/z 534, 895 and 1257) and core 2 (m/z 779, 984, 1345 
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and 1706) structures. The profiles of healthy controls, the DOK7 patient, MTND5 patient, 
LGMD2A patient and Pompe disease patient are broadly similar. This result was obtained via 
comparing the relative abundance of glycans within the same family in each sample. In the 
core 1 containing glycan family, all samples showed that the relative abundance of 
nonsialylated glycan (m/z 534) was higher than monosialylated (m/z 895) which was higher 
than disialylated (m/z 1257). In the core 2 containing glycan family, all samples showed that 
there was no significant difference between the relative abundance of the nonsialylated 
glycan (m/z 984) and the monosialylated (m/z 1345).  
 
 
 
Figure 4.23 Annotated MALDI-TOF MS spectra of permethylated O-glycans of myotubes from 
healthy control 1 (top), the DOK7 patient (middle), MTND5 patient (bottom) 
These profiles were obtained from the 35% acetonitrile fraction from a C18 Sep-Pak column. All ions 
were obtained in the form of [M+Na]+. See legend to Figure 3.13 for explanation of structure 
assignments.  GalNAc,  GlcNAc,  Gal,  NeuAc. 
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Figure 4.24 Annotated MALDI-TOF MS spectra of permethylated O-glycans of myotubes from 
healthy control 2 (top), LGMD2A patient (middle) and Pompe disease patient (bottom)  
These profiles were obtained from the 35% acetonitrile fraction from a C18 Sep-Pak column. All ions 
were obtained in the form of [M+Na]+. See legend to Figure 3.13 for explanation of structure 
assignments.  GalNAc,  GlcNAc,  Gal,  NeuAc.   
 
According to the O-glycan biosynthesis pathway, all O-glycan structures displayed in Figure 
4.23 and Figure 4.24 are unambiguous except the structure of the glycan at m/z 895 and 1345. 
The MS/MS spectra of these glycans gave same results as described in section 3.3.2.1. 
Glycan cartoons were assigned accordingly. 
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4.3.4.2. Sialidase S digestion of O-glycans of the myotubes from the DOK7 patient 
 
Sialidase S digestion was also carried out on O-glycans to determine the NeuAc linkage. As 
shown in Figure 4.25 (bottom), digestion of O-glycans from DOK7 patient myotubes with 
sialidase S resulted in a nearly complete desialylation on O-glycans, and with the sialylated 
O-glycan at m/z 895 being observed. This indicated that the NeuAc in myotubes is mainly 
α2,3 linked. 
 
 
Figure 4.25 Annotated MALDI-TOF MS spectra of permethylated O-glycans (top) and sialidase 
S treated O-glycans (bottom) of myotubes from DOK7 patient  
Profiles were obtained from the 35% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.13 for explanation of structure assignments.  GalNAc,  GlcNAc, 
 Gal,   NeuAc. 
 
4.4. Discussion 
 
It has been reported that CMS patients  with GFPT1 mutations shared clinical features with 
CMS patients  with DPAGT1 mutations (Belaya et al., 2012; Guergueltcheva et al., 2012). In 
addition, both GFPT1 and DPAGT1 play important roles in N-glycan biosynthesis pathway, 
and their mutations could result in muscle endplate AChR instability (Zoltowska et al., 2013; 
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Belaya et al., 2012; Freeze et al., 2015). These indicate faulty N-glycosylation of the 
receptors. Muscle specimens from CMS patients  with GFPT1 mutations showed that their 
endplates were poorly developed, ans this implied that the endplate specific glycoproteins, 
such as MuSK and dystroglycans, could be hypoglycosylated (Engel et al., 2015; Selcen et al., 
2013). This thesis for the first time reports N-glycan profiles of in vitro cultured human 
myoblasts and N- and O-glycan profiles of human myotubes  that differentiate from 
myoblasts in vitro.  
Employing ultrasensitive MALDI-TOF MS combined with MALDI TOF/TOF MS/MS, I 
observed that more high mass glycans were detected when the cells were grown in the 
medium containing FCS with higher concentration (see section 4.3.1.1). FCS possesses N-
glycans (Monk et al., 2006), however, their N-glycans which are non-core fucosylated can be  
distinguished from the ones I am interested in which are core fucosylated (see section 4.3.2). 
More importantly, in this project the FCS derived glycans do not seem to be a problem as 
they are not dominating the spectra, thus the contamination will not have too much influence 
on the conclusion that I made. In all the comparisons carried out in this project, the non-core 
fucosylated glycans are excluded. 
The data of cells  from GFPT1 patient 3 gave  less information (only high mannose glycans 
and three complex N-glycans were detected) than the other patients. This is in accordance 
with the fact that the cells grew more slowly than the others (see section 2.1.3.2). 
The main findings of this project are: the N-glycan profiles of myoblasts (Figure 4.2 and 
Figure 4.4) and myotubes (Figure 4.14 and Figure 4.16) from healthy controls, GFPT1 
patients and other patients are broadly similar, the O-glycan profiles of myotubes seem to be 
broadly similar as well, the absence of core 2 containing glycans in healthy control 1 is 
probably caused by the smaller amount of the analyte. 
Sialidase S digestion demonstrated the presence of α2,3 linked NeuAc in both myoblast and 
myotubes from DOK7 patient; and this implies that the NeuAc in the myoblasts and 
myotubes from healthy controls and other patients is probably also α2,3 linked (Figure 4.13, 
Figure 4.22 and Figure 4.25). Indeed, selective expression of sialyltransferase is common, for 
instance, Galβ1,3(4)GlcNAcα2,3-sialyltransferase is specifically expressed in human K562 
leukemia cells (Kitagawa and Paulson, 1994). Therefore I can reasonably conclude that my 
data indicate 2-3 sialyl  transferases, not 2-6, are mainly expressed in myoblasts and 
myotubes. This could be tested using SNA-I which is an important tool in glycoconjugate 
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research as it possesses binding specificity to α2,6 linked NeuAc not α2,3 linked NeuAc 
(Shang and Van Damme, 2014; Shibuya et al., 1987). SNA-I will probably not bind or show 
low binding affinity to myoblasts and myotubes.    
The differences observed in the DOK7 patient and MTND5 patient between other samples in 
Figure 4.20 and Figure 4.21 respectively implied that these two patients did not appear to be 
the same as the others and so perhaps they are not good “controls” for GFPT1 patients and 
healthy controls. Another  explanation for the difference is that it might be caused by 
individual differences between the samples, even biological replicates could show difference 
(see Figure 4.8). Except for these differences, there was no other difference in the comparison 
of the relative abundances of the bi-, tri- and tetraantennary N-glycans in all myoblast and 
myotube samples. These findings are unexpected as the original hypothesis (see section 1.7.1) 
that GFPT1 mutations in the cells would result in changes in the N-glycan branching. This 
hypothesis was made based on a recent glycomic analysis concerning N-glycosylation of 
leukocytes from patients with mutations in the PGM3 gene which encodes a protein 
immediately after GFPT1 in the hexosamine biosynthesis pathway (Sassi et al., 2014). A 
reduced level of tri- and tetraantennary N-glycans was observed, and this was rationalized by 
the fact that the initiations of four antennae are catalysed by 4 different enzymes which are 
GlcNAc-T І (medial Golgi-branching N-acetylglucosamine transferase І), GlcNAc-T II, 
GlcNAc-T ІV and GlcNAc-T V, the Km values of which are 0.04, 0.96, 5.0 and 11.0 mM 
UDP-GlcNAc respectively (Lau et al., 2007). In Michaelis-Menten kinetics, the value of Km 
is a measure of the substrate concentration needed for effective reaction to occur and is an 
important characteristic of enzyme-substrate interactions (Berg et al., 2002a). Higher Km 
value corresponds to lower substrate affinity and thus a lower catalytic activity. Therefore, by 
requiring higher substrate concentration the tri- and tetraantennary N-glycans will be most 
impaired by a reduction in UDP-GlcNAc concentration. However, the glycomic results did 
not support this hypothesis.  
Although the glycomic result of the myoblasts and myotubes implies that the gene (GFPT1) 
mutations do not result in global glycan alterations, it does not rule out the possibility that 
individual glycoproteins have altered glycosylation. It could be that alterations in N-
glycosylation are subtle and such subtle differences are lost in the general glycomic profiling 
or are difficult to identify. Additionally, it could be that the original glycosylation in the 
patient muscle is different from that in the in vitro cultured cells or the glycosylation might 
have changed during the muscle tissue regeneration. Therefore, detailed glycoproteomic 
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analysis of specific glycoproteins, such as acetylcholine receptor and agrin, could be carried 
out as future work. Indeed phenotypic similarities between CMS caused by GFPT1 mutations 
and CMS caused by DPAGT1 mutations would suggest that reduced endplate acetylcholine 
receptor in GFPT1 CMS patients might at least partially be due to abnormal glycosylation 
(Zoltowska et al., 2013). It could also be that there is a bypass of the reaction catalysed by 
GFPT1 existing in humans, and this bypass has diminished or eliminated the effects caused 
by GFPT1 mutations. The observation of the clinical features of CMS patients with GFPT1 
mutations suggests that this bypass could only partially replace GFPT1. 
Bearing in mind that not only could N-glycan antenna initiation be affected by the yield of 
UDP-GlcNAc, but also O-GlcNAcylation. O-GlcNAcylation is the transfer of GlcNAc to a 
serine or threonine residue of nuclear or cytoplasmic proteins (Hart et al., 2011). O-
GlcNAcylation has been long postulated to be a unique intracellular modification (Ogawa et 
al., 2015; Hurtado-Guerrero et al., 2008) and the cell surface glycans seem to be more 
important in this study. In addition, I did not have electron transfer dissociation (ETD) MS 
which is an essential tool for O-GlcNAcylation analysis (Myers et al., 2013) when this 
project was launched, therefore I did not analyse O-GlcNAcylation in myoblasts and 
myotubes. However, extracellular O-GlcNAcylation has been reported (Matsuura et al., 
2008). It is therefore reasonable to investigate O-GlcNAcylation in myoblast and myotubes in 
the future. The Km values of the enzymes related to O-GlcNAcylation, such as intracellular 
O-GlcNAc transferase (OGT) and epidermal growth factor O-GlcNAc transferase (EOGT), 
are much smaller than those of Golgi-resident GlcNAc transferases (Ogawa et al., 2015; 
Haltiwanger et al., 1992; Ma et al., 2013; Lau et al., 2007). This indicates that the O-
GlcNAcylation is  expected to be more easily impaired by a reduction in UDP-GlcNAc 
concentration than N-glycans. In addition, the EOGT-catalysed O-GlcNAcylation responds to 
stimulation of the hexosamine biosynthesis pathway (Ogawa et al., 2015). It is likely that O-
GlcNAcylation level has been affected by the GFPT1 mutations. One function of O-
GlcNAcylation in cells is to act as a sensor to regulate signalling, transcription and translation 
(Lau et al., 2007; Hart et al., 2011). As signalling is closely related to neuromuscular junction 
function it is possible that the GFPT1 mutations might result in abnormal O-GlcNAcylation 
which might contribute to the human neuromuscular junction defect. This might be an 
explanation for the mechanism  by which GFPT1 mutations cause CMS.  
The reason why O-glycans were not detected in the myotubes from GFPT1 patients was 
probably that the amount of cells for analysis was limited. This explanation can be supported 
172 
 
by the phenomenon that fewer high mass N-glycans were observed in the GFPT1 patient 
myotube samples (Figure 4.14 and Figure 4.16). 
My collaborators chose other muscular diseases,  namely CMS caused by DOK7 mutations, 
and myopathy caused by MTND5 mutations, Limb girdle muscular dystrophy type 2A 
(LGMD2A) caused by CAPN3 mutations and Pompe disease caused by GAA mutations, as 
exemplars of muscular diseases which have not been previously found to show defective N-
glycosylation. However, a very recently published paper reported that Pompe disease can 
result in a Golgi-based glycosylation deficit in human skin fibroblast-derived induced 
pluripotent stem cells which were differentiated in culture to cardiomyocytes (iPSC-CMs) 
(Raval et al., 2015). Employing a similar glycomic strategy to ours, Raval et al. have found 
that there is a decreased diversity of multiantennary structures and hyposialylation in Pompe 
disease iPSC-CMs. However, my results did not show any obvious glycosylation defect, and 
the multiantennary N-glycans that I observed in my results are not evident in their control 
cells. This might be due to the fact that the glycosylation defects in Pompe disease are cell-
specific or dependent on culture conditions.  
The underlying mechanism by which GFPT1 mutations cause CMS remains unknown. 
Elucidation of the mechanism could help the development of new treatment options.  
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Chapter 5 
 
Glycomic profiling of trophoblasts  
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5. Glycomic profiling of trophoblasts  
 
5.1. Introduction to the project 
 
This project is in collaboration with Professor Gary F. Clark at University of Missouri and Dr. 
Sandra M. Blois at University Medicine of Berlin. 
In order to further investigate the hu-FEDS hypothesis described in section 1.8.2 and test our 
hypothesis which is that functional glycan structures on human gametes (Lewis X, sialyl-
Lewis X and bisecting GlcNAc) could also be detected on human trophoblasts. The N-
glycomes of three trophoblast populations (CTB, STB and evCTB) were rigorously 
characterised. Specifically, MS analyses provided general structural information of the 
glycans; sialidase S digestion and MS/MS analyses were used to check whether sialyl-Lewis 
X structure was present; MS/MS analyses and endo-β-galactosidase digestion were employed 
to check whether there was Lewis X structure; linkage analysis and β1, 4-
galactosyltransferase treatment were applied to verify the presence of bisecting GlcNAc.   
 
5.2. Sample details and sample processing 
 
The four sets of samples which were obtained from four donors were labelled as 86, 96, 114 
and 117. In each set, there were one cytotrophoblast (CTB) sample and one 
syncytiotrophoblast (STB) sample. The detail of these samples is shown in Table 5.1. 
Table 5.1 Detail of CTB and STB received from University of Missouri 
Cell Type Cell number in each sample Number of samples 
CTB86 Approximately 3 million 2 
STB86 Approximately 3 million 2 
CTB96 Approximately 3 million 2 
STB96 Approximately 3 million 2 
CTB114 Approximately 3 million 2 
STB114 Approximately 3 million 2 
CTB117 Approximately 3 million 2 
STB117 Approximately 3 million 2 
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The extravillous cytotrophoblast (evCTB) samples were more authentic as they were less in 
vitro cultured and thus were closer to the real human tissues. To reduce the costs of shipping 
and for safety reasons, the protein extraction was carried out following the methods 
mentioned in section 2.2.2.1 in Germany. The detail of these evCTB samples is shown in 
Table 5.2. 
Table 5.2 Detail of evCTB protein samples received from University Medicine Berlin 
First batch 
Sample ID Origin Cell number Number of samples 
evCTB pool of samples 12 to 15 million 1 
evCTB1 pool of samples 12 to 15 million 1 
evCTB3 pool of samples 12 to 15 million 1 
Second batch 
Sample ID Origin Cell number Number of samples 
evCTB9W pool of samples Approximately 6 million 1 
evCTB10W pool of samples Approximately 24 million 1 
evCTB11W Individual patient Approximately 25 million 1 
evCTB10 5/7 Individual patient Approximately 18 million 1 
 
All samples were analysed using glycomic methodologies which have been described in 
section 2.2: the processing of CTB and STB samples started with section 2.2.1 while the 
handling of evCTB samples began with section 2.2.3.   
 
5.3. Results 
 
5.3.1. CTB and STB N-glycans 
 
5.3.1.1. MALDI-TOF MS analyses of the N-glycans of CTB and STB 
 
High quality MALDI data were obtained for the N-glycans of all the CTB and STB samples. 
Representative MALDI-TOF MS spectra of N-glycans of each cell type, CTB86 and STB86, 
are shown in Figure 5.1. The spectra show that high mannose (e.g. m/z 1580, 1784 and 1988) 
and complex glycans (e.g. m/z 2693 and 4226) are present in both CTB and STB. The 
antenna number and sialic acid numer of these complex glycans are similar to that described 
in section 4.3.2.1. Some common characteristics of mammalian cell N-glycomes were 
observed in Figure 5.1 (see section 4.3.2.1 for detailed description). In addition to the 
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common structures, some potentially more interesting structures, such as sialyl-Lewis X  
and/or A, Lewis X and/or A and bisecting GlcNAc, were observed. The sialylated N-glycans 
accounted for approximately 57%, 40%, 63% and 43% of the complex glycans in CTB86, 
CTB96, CTB114 and CTB117 respectively, and approximately 64%, 67%, 64% and 67% of 
the complex glycans in STB86, STB96, STB114 and STB117 respectively. 
 
 
Figure 5.1 Annotated MALDI-TOF MS spectra of permethylated N-glycans from CTB86 (top) 
and STB86 (bottom)  
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments. The NeuGc in the minor 
glycan at m/z 2635 is likely diet-derived (Tangvoranuntakul et al., 2003; Banda et al., 2012).  
GlcNAc,  Man,  Gal,  Glc,  Fuc,  NeuAc,  NeuGc. 
 
The method described in section 4.3.2.1 was employed to compare fucosylation between 
CTB and its corresponding STB. Fucosylation level is higher in CTB when comparing the 
relative intensity of m/z 2779 to m/z 2605, but this difference is not observed when 
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comparing the relative intensity of m/z 3025 to m/z 2850 (see Table 5.3). Therefore, a firm 
conclusion could not be made on this fucosylation comparison. 
Table 5.3 Comparisons of N-glycan fucosylation between CTB and STB 
The fucosylation comparison was achieved via comparing the relative intensity (RI) of one glycan to 
that of the previous glycan which possesses one fewer Fuc.  
Modification RI comparison CTB 
86 
STB 
86 
CTB 
96 
STB 
96 
CTB 
114 
STB 
114 
CTB 
117 
STB 
117 
 
Fucosylation 
RI(2779)/RI(2605) 0.79 0.32 0.29 0.15 0.65 0.35 0.53 0.36 
RI(3025)/RI(2850) 0.13 0.12 0.18 0.17 0.09 0.09 0.09 0.11 
 
5.3.1.2. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 2592 
 
MALDI-TOF/TOF MS/MS analyses were carried out to further characterize structures of 
peaks of interest, i.e. those glycans containing potential Lewis structures and sialyl-Lewis 
structures. Here the MS/MS data for the glycan at m/z 2592 which contains potential Lewis 
structures are described as an example.    
As shown in Figure 5.2, the fragment ion at m/z 1955 corresponds to loss of a Lewis structure 
which can be either Lewis A [Galβ1,3(Fucα1,4)GlcNAc] or Lewis X 
[Galβ1,4(Fucα1,3)GlcNAc] or a mixture of both, and its concurrent ion is also observed at 
m/z 660. The signals of these two ions dominate the two spectra. These demonstrate the 
presence of Lewis A and/or X structure. In addition, in Figure 5.2 (bottom) the fragment ion 
at m/z 1781 corresponds to loss of a Lewis B [(Fucα1,2)Galβ1,3(Fucα1,4)GlcNAc] or Lewis 
Y [(Fucα1,2)Galβ1,4(Fucα1,3)GlcNAc] or a mixture of both, its concurrent ion is also 
observed at M/Z 834 though the peak signal is weak. These demonstrate the presence of 
Lewis B and/or Y in STB86. Fuc is confirmed to be 3-linked in the Lewis moiety as the 
signal at m/z 2386 corresponds to the loss of a Fuc from the C3 position of GlcNAc via beta 
elimination. This 3-linked Fuc is either come from the Lewis X or the Lewis Y or both. This 
provides evidence for the presence of potential Lewis X and/or Y. In addition, there is no 
detectable characteristic ion for Lewis A or B, and this can rule out the possibility that Lewis 
A and Lewis B are present in the CTB and STB. Therefore, these data demonstrate the 
presence of Lewis X in CTB and Lewis X and Y in STB. 
More detailed annotation of these two spectra is shown in Figure 5.3. 
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Figure 5.2 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated N-glycan at m/z 
2592 in CTB86 (top) and STB86 (bottom) 
Data were acquired in the form of [M+Na]+ ions. Peaks were annotated with putative fragment ions 
according to the molecular weight.  GlcNAc,  Man,  Gal,  Fuc. 
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Figure 5.3 Fully annotated MALDI-TOF/TOF MS/MS spectra of permethylated N-glycan at 
m/z 2592 in CTB86 (top) and STB86 (bottom) 
Data were acquired in the form of [M+Na]+ ions. Peaks were annotated with putative fragment ions 
according to the molecular weight. The glycan m/z values and their corresponding fragment ions are 
labelled in the same colour (red, green, black or blue).  GlcNAc,  Man,  Gal,  Glc,  Fuc,  
NeuAc,  NeuGc. 
 
5.3.1.3. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 3143 
 
The MS/MS data for the glycan at m/z 3143 which contains potential sialyl-Lewis X and/or 
A are described as another example. 
As observed in HeLa cells (section 3.3.1.2), the isotope peaks of the glycan at m/z 3143 span 
a wider mass range than expected for one single sugar composition. This implies that this 
peak cluster may also include LacNAc containing glycans as well as potential sialyl-Lewis X 
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and/or A containing glycans which differ by 2 Da. MS/MS analyses were carried out to check 
this. 
The spectra shown in Figure 5.4 are similar to that in Figure 3.5 (top), see section 3.3.1.2 for 
detailed explanation. This figure provides evidence for the presence of potential sialyl-Lewis 
X. A comparison of the relative intensity of characteristic fragment ions (m/z 847, 1021, 
2142, 2316, 2765 and 2934) of potential sialyl-Lewis X containing glycan to the sum of all 
fragment ions shows that the potential sialyl-Lewis X containing glycan accounts for 
approximately 60% and 56% of the glycan mixture in CTB86 and STB86 respectively. 
Similary, a comparison of the relative intensity of the characteristic fragment ions (m/z 935, 
1781 and 2230) to the sum of all fragment ions shows that the polyLacNAc containing glycan 
accounts for approximately 7% of the glycan mixture in both CTB86 and STB86. The 
remaining should be tetraantennary glycan with each antenna possessing one LacNAc. 
To further check the presence of sialyl-Lewis X, it is necessary to determine the linkage of 
NeuAc, and this can be achieved via sialidase S digestion. 
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Figure 5.4 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated N-glycan peak 
centred at m/z 3142 in the CTB86 (top) and STB86 (bottom) 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
 
5.3.1.4. Sialidase S digestion of the N-glycans of CTB and STB 
 
Digestion of both CTB and STB with sialidase S resulted in partial desialylation, with only a 
handful of minor sialylated N-glycans at m/z 2431, 2605 and 2850 being observed (Figure 
5.5). The glycan at m/z 2489 is the major component in the complex N-glycans. Comparison 
of this figure and Figure 5.1 indicated that both CTB and STB mainly contain α2,3 linked 
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NeuAc, which could be observed via a significant but not complete loss of NeuAc residues 
from the assigned structures. After the digestion, the isotope peak cluster around m/z 3142 in 
both CTB and STB was consistent with a single composition, which was the same as 
described in section 3.3.1.4. In addition, some high mass glycans, such as m/z 4041, 4490 and 
4939, were not detected previously but observed after the enzymatic digestion. Their putative 
structures suggest the existence of α2,3 sialylated polyLacNAc in both CTB and STB. The 
desialylated high mass components were checked by MS/MS analyses. 
 
 
Figure 5.5 Annotated MALDI-TOF MS spectra of permethylated sialidase S treated N-glycans 
from CTB86 (top) and STB86 (bottom)  
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments. See legend to Figure 5.1 
for explanation of the NeuGc containing glycan.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc,  
NeuGc. 
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5.3.1.5. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 3143 after sialidase S 
digestion 
 
As shown in Figure 5.6, the fragment ions corresponding to loss of LacNAc, diLacNAc and 
triLacNAc were observed at m/z 2679, 2230 and 1781 respectively, while fragment ions 
corresponding to loss of NeuAc or NeuAc related structure were not detected. The fragment 
ion at m/z 2691 corresponds to the loss of a fucosylated GlcNAc. This fragment ion has been 
previously observed in Figure 5.4. There is no other fragment ion corresponding to Fuc or 
Fuc containing residues. This suggested that the NeuAc in the previous potential sialyl-Lewis 
X glycan (m/z 3141) had been cleaved and thus the NeuAc should be α2,3 linked, after 
sialidase S digestion the m/z valude of the glycan has shifted. This demonstrates the presence 
of sialyl-Lewis X in both CTB and STB. 
 
 
Figure 5.6 Annotated MALDI-TOF/TOF MS/MS spectra of permethylated sialidase S treated 
N-glycan at m/z 3143 in CTB86 (top) and STB86 (bottom) 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of 
assignments.  GlcNAc,  Man,  Gal,  Fuc. 
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5.3.1.6. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 4939 after sialidase S 
digestion 
 
As mentioned previously, high mass glycans, such as such as m/z 4041, 4490 and 4939, may 
contain polyLacNAc. Therefore, MS/MS analyses were carried out on these glycans. As an 
example, data obtained from the sialidase S digested glycan at m/z 4939 are shown in Figure 
5.7. The fragment ions corresponding to loss of LacNAc, diLacNAc, triLacNAc, 
tetraLacNAc and pentaLacNAc were observed at m/z 4476, 4027, 3578, 3129 and 2679 
respectively. These fragment ions  dominate the spectra. Some of their concurrent ions were 
also observed at m/z 486, 935, 1385 and 1834. These clearly demonstrate the presence of 
polyLacNAc. The maximum number of the LacNAc repeating unit observed in the CTB and 
STB MS/MS data is six (see Figure 5.7 bottom), although the signal is weak. 
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Figure 5.7 Annotated MALDI-TOF MS/MS spectra of permethylated sialidase S digested N-
glycan at 4939 in CTB114 (top) and STB114 (bottom) 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of 
assignments.  GlcNAc,  Man,  Gal,  Fuc. 
 
5.3.1.7. Linkage analysis of the N-glycans of CTB and STB 
 
In addition to Lewis X, Lewis Y, sialyl-Lewis X and polyLacNAc, bisecting GlcNAc may 
also exist in the CTB and STB. However, MS/MS analysis is not able to check the presence 
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of bisecting GlcNAc as its fragment ion cannot be distinguished from that of a truncated 
antenna. 
As shown in Figure 1.6, bisecting GlcNAc is linked to 3, 4, 6-linked Man, therefore the 
presence of 3, 4, 6-linked Man can reflect the existence of bisecting GlcNAc. GC-MS is able 
to check the presence of 3, 4, 6-linked Man. Table 5.4 summarizes the result of GC-MS 
linkage analysis of the glycan derivatives from CTB117 and STB117 and demonstrates the 
presence of 3, 4, 6-linked Man, and this provides evidence for the existence of bisecting 
GlcNAc.     
Table 5.4 Summary of GC-MS linkage analysis of partially methylated alditol acetates derived 
from the 50% acetonitrile fraction of permethylated N-glycans of CTB117 and STB117 
The elution time is indicated in minutes and the relative abundance is normalised to the abundance of 
2-linked mannose (major component) which is designated as 1. 
Elution 
time, min 
(CTB117) 
Elution 
time, min 
(STB117) 
Characteristic fragment ions Assignments Relative 
abundance 
(CTB117) 
Relative 
abundance 
(STB117) 
16.95 16.90 102, 115, 118, 131, 162, 175 Terminal Fuc 0.16 0.14 
18.45 18.40 102, 118, 129, 145, 161, 205 Terminal 
Man 
0.68 0.62 
18.71 18.67 102, 118, 129, 145, 161, 205 Terminal Gal 0.15 0.17 
19.62 19.56 129, 130, 161, 190, 234 2-linked Man 1 1 
19.90 19.85 118, 129, 161, 203, 234 3-linked Gal 0.07 0.10 
21.18 21.14 87, 88, 129, 130, 189, 190 2,6-linked 
Man 
0.05 0.05 
21.34 21.30 118, 129, 189, 202, 234 3,6-linked 
Man 
0.33 0.34 
21.80 21.76 118, 139, 259, 333 3,4,6-linked 
Man 
0.08 0.07 
22.27 22.23 117, 129, 145, 205, 247 Terminal 
GlcNAc 
0.04 0.04 
23.15 23.12 117, 159, 233 4-linked 
GlcNAc 
0.22 0.39 
24.00 23.96 117, 159, 346 3,4-linked 
GlcNAc 
0.03 0.03 
24.46 24.42 117, 159, 261 4,6-linked 
GlcNAc 
0.04 0.08 
 
5.3.1.8. The N-glycans of CTB and STB treated with β1, 4-galactosyltransferase 
 
In addition to GC-MS linkage analysis, β1,4-galactosyltransferase incubation was also 
carried out to prove the presence of bisecting GlcNAc. β1,4-galactosyltransferase can transfer 
a Gal from UDP-Gal to a GlcNAc producing the disaccharide unit, Galβ1,4GlcNAc. 
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However, if the GlcNAc is bisecting, it will not be modified by this enzyme (Qasba et al., 
2008; Narasimhan et al., 1985). This incubation was carried out on the same samples (117C 
and 117S) which had been investigated by linkage analysis. Glycans at m/z 2489, 2850 and 
3212 were chosen as the research subjects in this experiment as all of them have a GlcNAc 
which could be either truncated or bisecting. Figure 5.8 shows that after β1,4-
galactosyltransferase incubation, the relative intensities of glycans at m/z 2489, 2850 and 
3212 in both CTB and STB did not alter significantly compared to that of glycans at m/z 
2693, 3055 and 3416 respectively. This indicates that β1,4-galactosyltransferase could not 
modify the GlcNAc in these glycans and thus the GlcNAc present in these glycans are 
bisecting.    
A
 
B
 
Figure 5.8 Annotated MALDI-TOF MS spectra of permethylated N-glycans from CTB117 (A, 
top) and STB117 (B, top) and permethylated β1,4-galactosyltransferase incubated N-glycans 
from CTB117 (A, bottom) and STB117 (B, bottom)  
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc. 
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The bisecting GlcNAc-containing N-glycans account for approximately 32%, 15%, 50% and 
59% of the complex glycans in CTB86, CTB96, CTB114 and CTB117 respectively, and 
approximately 15%, 22%, 41% and 49% of the complex glycans in STB86, STB96, STB114 
and STB117 respectively.   
 
5.3.2. evCTB N-glycans 
 
5.3.2.1. MALDI-TOF MS analysis of the N-glycans of evCTB 
 
There were seven evCTB samples in total. They were in turn labelled as evCTB, evCTB1, 
evCTB3, evCTB9W, evCTB10W, evCTB11W and evCTB10 5/7. All the samples were 
analysed using the same method described in section 2.2. High quality MALDI data were 
obtained for the N-glycans of evCTB. The MALDI-TOF MS spectrum of N-glycans of one 
representative sample, evCTB10 5/7 is shown in Figure 5.9. The spectrum shows that high 
mannose and complex glycans are present in evCTB. Common characteristics of mammalian 
cell N-glycomes and potentially more interesting structures were observed in Figure 5.9 (see 
section 5.3.1.1 for detailed description). The sialylated N-glycans accounted for 
approximately 65%, 68%, 40%, 48%, 14%, 12% and 72% of the complex glycans in evCTB, 
evCTB1, evCTB3, evCTB9W, evCTB10W, evCTB11W and evCTB10 5/7 respectively.  
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Figure 5.9 Annotated MALDI-TOF MS spectrum of permethylated N-glycans from evCTB10 
5/7 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Glc,  Fuc,  NeuAc. 
 
There was no significant alteration when comparing the fucosylation in evCTB (Table 5.5) to 
that in CTB and STB (Table 5.3). 
Table 5.5 Comparisons of N-glycan fucosylation 
See legend to Table 5.3 for explanation of the comparison. NA, not available, which is due to the fact 
that the RI of the glycan is too low to be used in the calculation.   
Modification RI comparison 
evCTB evCTB1 evCTB3 
evCTB
9W 
evCTB
10W 
evCTB
11W 
evCTB
10 5/7 
 
Fucosylation 
RI(2779)/RI(2605
) 1.10 0.57 0.45 0.25 0.68 0.56 0.82 
RI(3025)/RI(2850
) 0.28 0.14 0.38 0.49 NA NA 0.06 
 
5.3.2.2. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 3143 
 
In evCTB the isotope peaks of the glycan at m/z 3143 also span a wider than expected, which 
is the same as the observation in section 3.3.1.2, therefore MS/MS analysis was carried out. 
The MS/MS spectrum shown in Figure 5.10 is similar to that in Figure 3.5 (top), see section 
3.3.1.2 for detailed explanation. The following figure provides evidence for the presence of 
potential sialyl-Lewis X. Following the calculation method described in section 5.3.1.3, the 
potential sialyl-Lewis X containing glycan accounts for approximately 15% of the glycan 
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mixture, the poly-LacNAc containing glycan also accounts for approximately 15%. 
Compared to Figure 5.4 (CTB and STB), the relative abundance of sialyl-Lewis X to 
polylacNAc is decreased in evCTB (approximately 9.22 in CTB, 8.33 in STB, 1.00 in 
evCTB).  
 
Figure 5.10 Annotated MALDI-TOF/TOF MS/MS spectrum of permethylated N-glycan peak 
centred at m/z 3142 in the evCTB10 5/7 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
 
5.3.2.3. Sialidase S digestion of the N-glycans of evCTB 
 
The MALDI spectrum of sialidase S digested evCTB N-glycans is shown in Figure 5.11. 
Comparison of this figure with Figure 5.9 indicated that the all NeuAcs in N-glycans of 
evCTB were α2,3 linked as a complete loss of NeuAc was observed. Unlike the spectra in 
Figure 5.5 (sialidase S digested N-glycans of CTB and STB) which are dominated by high 
mannose and biantennary glycans, the following spectrum is dominated by glycans at m/z 
2693 and 3143.  
As observed in CTB and STB (section 5.3.1.4), the high mass glycans, such as m/z 4041, 
4490 and 4939, were not detected previously (in Figure 5.5) but observed after the enzymatic 
digestion in evCTB. This suggests the existence of polyLacNAc, which was checked by 
MS/MS analyses. 
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Figure 5.11 Annotated MALDI-TOF MS spectrum of permethylated sialidase S treated N-
glycans from evCTB10 5/7 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc. 
 
5.3.2.4. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 3143 after sialidase S 
digestion 
 
After the digestion, the isotope peak cluster around m/z 3142 in evCTB was consistent with a 
single composition, and this was consistent with the description in section 3.3.1.4 in HeLa 
cells. The MS/MS spectrum shown in Figure 5.12 is similar to that in Figure 3.8, see section 
3.3.1.4 for detailed explanation. 
 
Figure 5.12 Annotated MALDI-TOF/TOF MS/MS spectrum of permethylated sialidase S 
treated N-glycan at m/z 3143 in evCTB10 5/7 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of structure 
assignments.  GlcNAc,  Man,  Gal,  Fuc. 
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5.3.2.5. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 4041 after sialidase S 
digestion 
 
The MS/MS spectrum shown in Figure 5.13 is similar to that in Figure 5.7; detailed 
explanation could be found in section 5.3.1.6. This figure clearly provides evidence for the 
presence of polyLacNAc in evCTB N-glycans. The maximum number of the LacNAc unit in 
a polyLacNAc observed here is four. 
 
Figure 5.13 Annotated MALDI-TOF MS spectrum of permethylated sialidase S digested N-
glycan at 4041 in evCTB 10 5/7 
Data were acquired in the form of [M+Na]+ ions. See legend to Figure 3.5 for explanation of 
assignments.  GlcNAc,  Man,  Gal,  Fuc. 
 
5.3.2.6. The N-glycans of evCTB and STB treated by endo-β-galactosidase 
 
Whether polyLacNAc is present in the evCTB can also be verified using endo-β-
galactosidase which is an enzyme hydrolysing internal β1,4 galactosidic linkage in this 
favored repeating unit [GlcNAcβ1,3Galβ1,4]n (Scudder et al., 1983). In addition, digestion of 
glycans with this enzyme can reveal the relative abundances of the non-reducing terminal 
structures to the core structures. N-glycans from sample evCTB11W were treated with this 
enzyme; some of the small resulting glycans were washed out by 35% acetonitrile, the MS 
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spectrum of which is shown in Figure 5.15 (top). A comparison of Figure 5.14 with Figure 
5.15 shows that endo-β-galactosidase treatment gives rise to signals at m/z 518, 722, 896 and 
1084. These structures could be the middle part of an antenna (m/z 518) Gal-terminated 
terminal (m/z 722), sialylated terminal (m/z 1084) or fucosylated terminal (m/z 896). These 
data provided firm evidence for the presence of polyLacNAc capped with NeuAc or Fuc, 
however, the terminal structure sialyl-Lewis X was not detected.  
 
 
Figure 5.14 Annotated MALDI-TOF MS spectra of permethylated N-glycans from evCTB11W 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are 
[M+Na]+. See legend to Figure 3.2 for explanation of structure assignments.  GlcNAc,  Man,  
Gal,  Fuc,  NeuAc. 
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Figure 5.15 Annotated MALDI-TOF MS spectra of permethylated endo-β-galactosidase treated 
N-glycans from evCTB11W 
Glycan profile shown in the top panel was obtained from the 35% acetonitrile fraction from a C18 
Sep-Pak column, profiles shown in middle and bottom panels were obtained from the 50% acetonitrile 
fraction from a C18 Sep-Pak column,  All ions are [M+Na]+. See legend to Figure 3.2 for explanation 
of structure assignments.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
 
5.3.2.7. MALDI-TOF/TOF MS/MS analysis of the N-glycan at m/z 896 after endo-β-
galactosidase digestion 
 
The signal of the glycan at m/z 896 in Figure 5.15 (middle) was very weak and it was only 
observed in Figure 5.15 (middle), so it was necessary to check whether it was a glycan. 
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Therefore MS/MS analysis was carried out. As shown in Figure 5.16, the fragment ion at m/z 
660 corresponds to loss of a Gal, and its concurrent ion at m/z 259 was observed. The ion at 
m/z 660 corresponds to the B ion of Lewis structure. In addition, the signal at m/z 690 
corresponds to the loss of a Fuc via elimination. All these provide evidence for the existence 
of the Lewis X structure. 
 
Figure 5.16 Annotated MALDI-TOF/TOF MS/MS spectrum of permethylated N-glycan at m/z 
896 from evCTB11W 
Data were acquired in the form of [M+Na]+ ions. Peaks were annotated with putative fragment ions 
according to the molecular weight.  GlcNAc,  Gal,  Fuc. 
 
5.3.3. CTB, STB and evCTB 
 
The following table summarizes the difference between CTB, STB and evCTB. 
Table 5.6 A summary of the difference between CTB, STB and evCTB 
Cell type CTB STB evCTB 
Locus Foetal part Foetal part Maternal part 
Sialic acid linkage  Mainly α2,3 linked Mainly α2,3 linked all α2,3 linked 
Ratio of sialylated N-glycans in 
complex glycans 
 
51% 
 
65% 
 
59% 
Relative abundance of sialyl-Lewis 
X to polyLacNAc 
 
Higher than evCTB 
 
Higher than evCTB 
Lower than CTB 
and STB 
Ratio of glycans with at least three 
LacNAc units (could be potential 
polyLacNAc) 
 
Lower than evCTB 
 
Lower than evCTB 
Higher than CTB 
and STB 
Ratio of bisecting GlcNAc-
containing N-glycans 
 
39% 
 
32% 
 
19% 
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5.4. Discussion 
 
The human placenta is an interface between mother and foetus. It is responsible for not only 
nutrient exchange but also protecting the foetus from being injured by maternal immune cells. 
However, the mechanism underlying the protection is still not clear. Knowing the glycans 
expressed by the CTB, STB and evCTB could help us to better understand how glycans 
might be involved in this protection. 
Useful information was obtained from MALDI-TOF, MALDI-TOF/TOF, GC-MS linkage 
analysis, sialidase S digestion, endo-β-galactosidase digestion, β1,4-galactosyltransferase 
incubation experiments and the knowledge of N-glycan biosynthesis pathway. Although 
sample quantity limitations prevented the observation of very high mass glycans, an 
abundance of good quality data were still obtained. These data provide evidence for the 
presence of α2,3-linked NeuAc, Lewis X, sialyl-Lewis X, polyLacNAc and bisecting 
GlcNAc in CTB, STB and evCTB.  
CTB and STB were obtained from normal term placenta (approximately 39-40 weeks) and 
evCTB were isolated from 10-12 weeks old placenta. 
In CTB, STB and evCTB, the NeuAcs in N-glycans are mainly α2,3 linked (Figure 5.1, 
Figure 5.5, Figure 5.9 and Figure 5.11). The sialylated N-glycans accounted for 
approximately 51% (mean value of four samples) of the complex glycans in CTB and 
approximately 65% (mean value of four samples) in STB. It has been observed that two of 
the evCTB samples have virtually no sialic acid (evCTB10W and 11W), and this could be 
caused by the loss of NeuAc during sample handling prior to sending to our laboratory. 
Excluding these two samples, the sialylated N-glycans accounted for approximately 59% 
(mean value of five samples) of the complex glycans in evCTB. This shows that the 
sialylation has not significantly changed among these three types of trophoblasts. More than 
half of the N-glycans in these trophoblasts are sialylated indicates the important role of 
sialylation. 
Lewis structures (Lewis and sialyl-Lewis) were present in CTB, STB and evCTB, and this is 
supported by Figure 5.2, Figure 5.4, Figure 5.6 from CTB and STB and Figure 5.10, Figure 
5.12, Figure 5.16 from evCTB. A comparsion of Figure 5.4 and Figure 5.10 showed that the 
relative abundance of sialyl-Lewis X (from the glycan at m/z 3141) to polyLacNAc (from the 
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glycan at m/z 3143) was higher in CTB and STB; this implied that both of sialyl-Lewis X and 
polyLacNAc were essential for these trophoblasts. The relative abundance variation in CTB, 
STB and evCTB suggested their different glycan-related functions. 
PolyLacNAc antennae were observed in CTB, STB (Figure 5.7) and evCTB (Figure 5.13). A 
comparison of MALDI MS spectra of sialidase S digested N-glycans of CTB and STB 
(Figure 5.5) to that of evCTB (Figure 5.11) showed that evCTB possessed higher levels of 
multiantennary and/or polyLacNAc N-glycans.  
In CTB and STB, the results of linkage analysis (Table 5.4) and β1,4-galactosyltransferase 
incubation (Figure 5.8) have confirmed that some glycans, such as m/z 2489, 2850 and 3212, 
possess bisecting GlcNAc. N-glycans with the same m/z value were observed in evCTB 
(Figure 5.9). There is no obvious evidence for the existence of truncated GlcNAc, for 
instance, the loss of two separate HexNAcs or two HexNAcs lost as a whole in the MS/MS 
analysis of the glycan in evCTB. In addition, it has been reported that evCTB expresses 
integrins (Tarrade et al., 2001; Orozco and Lewis, 2010), and integrins possess bisected N-
glycans (Isaji et al., 2010; Zhang et al., 2015). All these imply that bisecting GlcNAc is also 
present in evCTB. Therefore I can reasonably conclude that bisecting GlcNAc is present in 
CTB, STB and evCTB. The bisecting GlcNAc-containing N-glycans accounted for 
approximately 39% (mean value of four samples) of the complex glycans in CTB and 
approximately 32% (mean value of four samples) of the complex glycans in STB. The 
bisecting GlcNAc-containing N-glycans accounted for approximately 19% (mean value of 
seven samples) of the complex glycans in evCTB. This shows that there are relative more 
abundant bisecting GlcNAc-containing N-glycans in CTB and STB. 
Fucosylation was also compared among these trophoblasts, and no variation was observed 
(Table 5.3 and Table 5.5). 
 
5.4.1. The potential function of NeuAc  
 
The α2,3-linked NeuAc is formed between the C2 position of NeuAc and C3 position of Gal 
under the catalysis of α2,3-sialyltransferase. As shown in all the MS spectra, NeuAc is 
typically found to be the terminal residue. Its exposed terminal position in the carbohydrate 
chains make it function as a protective shield for the penultimate galactose residue. In 
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addition to protecting the monosaccharide, sialic acid can protect cells. For instance, 
erythrocytes are masked by a layer of sialic acid molecules which can prevent erythrocytes 
from being degraded by macrophages via phagocytosis. Sialic acids will be gradually 
removed from the surface by serum sialidase and spontaneous chemical hydrolysis during the 
cell life span which is usually 120-day. Finally, erythrocytes without sialic acid layer will be 
degraded as the surface uncapped galactose residues present signals for the degradation 
(Bratosin et al., 1995). In CTB, STB and evCTB, more than 50% of the complex N-glycans 
are sialylated (see section 5.3.1.1 and 5.3.2.1), it is therefore possible that NeuAcs in CTB, 
STB and evCTB may function in the same way to protect the trophoblasts against 
macrophages, especially when evCTB invades the maternal decidua and myometrium as 
macrophages represent approximately 20% of the decidual leukocytes at the maternal-foetal 
interface (Lessin et al., 1988; Houser et al., 2011). 
It is reported that STB and CTB do not express HLA class I and II antigens (Murphy et al., 
2004; Clark and Schust, 2013; Hunt et al., 1987; Hunt et al., 2005; Apps et al., 2009). The 
absence of HLA antigens would make these trophoblasts potential targets for NK cells. 
However, CTB and STB are resistant to NK cells due to the presence bisecting GlcNAc on 
their cell surfaces. Moreover, researchers found that NeuAc also contributes to this resistance: 
the siglec-7 (sialic acid-binding Ig-like lectin-7) is expressed predominantly on NK cells 
(Nicoll et al., 1999). It functions as an inhibitory receptor on human NK cells (Crocker and 
Varki, 2001), therefore interactions between siglec-7 and its ligands, sialic acid, can influence 
NK cell activity. This implies that the α2,3-linked NeuAc in CTB and STB is the potential 
ligand for this siglec. Siglec-7 shows similar binding affinity towards terminal α2,3-linked 
and α2,6-linked NeuAc (Yamaji et al., 2002).  
In addition, due to the negative charge of NeuAc, it is involved in the repulsion phenomena 
between cells. For instance, the negative charge repulsion is a possible explanation for tumor 
cell detachment from the tumour mass and entering the blood stream (Fuster and Esko, 2005). 
This also provides possible explanation for evCTB movement from foetal part into the 
maternal decidua. 
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5.4.2. The potential biological roles of Lewis structures 
 
Lewis, the term, derives from a family, the members of which suffered from an erythrocyte 
incompatibility that helped in the discovery of blood group substances. The blood group 
antigens are composed of a related series of glycans possessing α1,3-linked or α1,4-linked 
Fuc residues. 
Although it had been reported that Lewis B structure is present on human eggs (Lucas et al., 
1994), it could not be confirmed physicochemically as the structure was not observed in the 
MALDI-MS spectra of human zona pellucida (Pang et al., 2011). However, it has been 
physicochemically confirmed that Lewis X/Lewis Y terminated N-glycans are expressed on 
human sperm (Pang et al., 2007).  
The Lewis X/Lewis Y terminated N-glycans that are expressed on human sperm are thought 
to suppress immune responses directed against the gamete (Pang et al., 2007; Clark, 2014). 
This proposal was made based on a study of phase variation of Helicobacter pylori which is a 
human gastric pathogen. Variants of H. pylori that express Lewis X and Lewis Y structures 
on their lipopolysaccharides can regulate antigen related responses. This regulation is 
achieved via the interaction between these lipopolysaccharides and DC-SIGN (dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin) on dendritic cells; this 
regulation has an influence on T helper cell 1/ T helper cell 2 balance (Bergman et al., 2004).  
However, variants of H. pylori that do not express Lewis structures cause strong T helper cell 
1 response, as a result of which peptic ulcer may occur (Bergman et al., 2004; Bergman et al., 
2006). These suggest that the presence of Lewis structure on lipopolysaccharides play an 
essential role in triggering the immune tolerance. This triggering of immune tolerance may 
not be limited in H. pylori. Indeed, schistosomes, a type of helminthic parasites, express both 
Lewis X and a pseudo-Lewis Y that can also interact with DC-SIGN (Meyer et al., 2005). 
Thus, it is possible that human sperm could follow the same pathway that H. pylori employs 
to trigger immune tolerance as the sperm also expresses Lewis structures. Similarly, this 
pathway may be passed on to CTB, STB and evCTB with the expression of Lewis structures.   
The oligosaccharide sialyl-Lewis X can function as a ligand for L-, E- and P-selectin which 
are important cell adhesion molecules (Phillips et al., 1990; Polley et al., 1991; Foxall et al., 
1992; Julien et al., 2011). The interactions between the adhesive molecules from foetus and 
mother are essential for the successful implantation. It is reported that sialyl-Lewis X/L-
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selectin adhesion system mediates adhesion in implantation model (Liu et al., 2011). This 
implies that the importance of sialyl-Lewis X on CTB and STB. It is known that leukocyte 
tethering and rolling is related to the interaction between the selectins and sialyl-Lewis X: 
selectins promote the tethering and subsequent rolling of leukocytes along the vessel wall via 
the sialyl-Lewis X, and this is a prelude to the extravasation into the underlying tissue 
(Somers et al., 2000). Since evCTB expresses sialyl-Lewis X, it is possible that sialyl-Lewis 
X could play an important role when evCTB are extravasated and spread out in the maternal 
part.  
 
5.4.3. The potential function of polyLacNAc 
 
The signals of the polyLacNAc containing glycans become more obvious after sialidase S 
digestion, which implies that the real amount of these glycans is substantial.  
It is probably easier for polyLacNAc to be involved in galectin binding as single LacNAc 
may be limited by its length.   Galectins are a subfamily of glycan-binding proteins that 
possess carbohydrate recognition domain (CRD) with specific affinity for β-galactoside 
(Barondes et al., 1994). Galectins are able to act both extracellularly and intracellularly to 
control cell fate: extracellularly, they cross link glycan ligands to transmit signals that result 
in death or affect other signals influencing cell fate; intracellularly, they direct regulate 
signals controlling cell fate (Hernandez and Baum, 2002; Yang et al., 2008).  
Galectins was not identified in the eutherian uterus until 1999. From then on galectins started 
to attract a lot of attention due to the fact that human placental protein (PP13) is a galectin 
(Than et al., 1999). It has been confirmed that PP13 is expressed on STB (Than et al., 2004). 
Therefore, CTB probably also expresses PP13 as STB is originally differentiated from CTB. 
PP13 can induce apoptosis of T cells in vitro and kill macrophages in the maternal decidua in 
situ (Than et al., 2014). However, the underlying mechanism is still not clear. It is possible 
that CTB and STB could kill the immune cells via the expressed PP13 and thus suppress 
immune responses. In addition, it is reported that in humans 16 different galectin genes are 
expressed at the maternal-foetal interface (Than et al., 2009). These suggest important 
immune functions of galectins. Indeed, in mice galectin-3 has been reported to form lattices 
on cell surfaces by cross-linking glycoproteins on T cells that possess polyLacNAc moiety in 
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their tri- and tetraantennary N-glycans and thus blocking immune responses (Demetriou et al., 
2001). Therefore, in humans the blocking is probably achieved via erecting a “galectin shield” 
around CTB and STB. 
In addition, overexpression of polyLacNAc is one of the most common types of aberrant 
glycosylation observed in human cancers (Hakomori, 1996). The reason why cancer cells can 
evade human immune system might be related to the polyLacNAc overexpression.  
Compared to CTB and STB, polyLacNAc in evCTB is overexpressed (Figure 5.5 and Figure 
5.11), and this could enable evCTB to evade the maternal immune system. 
 
5.4.4. The potential function of bisecting GlcNAc 
 
Bisecting GlcNAc is a structure that is also expressed on sperm (see section 1.8.3). Sperm 
expresses bisected N-glycans to inhibit NK cell cytotoxicity (see section 1.8.3). As explained 
in section 5.4.1 CTB and STB are the targets for NK cells due to the absence of HLA 
antigens on their surface, and CTB and STB also express bisected N-glycans (see sections 
5.3.1.7 and 5.3.1.8). It is possible that these bisected N-glycans are expressed for the same 
purpose to inhibit NK cell cytotoxicity. However, the mechanism underlying the inhibition is 
not clear.  
 
All these results provide more support for the human fetoembryonic defense system 
hypothesis which links the expression of functional glycan groups to the protection of 
gametes and foetus in utero. 
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6. Concluding remarks 
 
This thesis documents three separate but similar research projects. The first project (Chapter 
3) used a glycomic strategy to show differences in glycan profiles between HeLa cells and 
NHDF. The second project (Chapter 4) employed the same strategy to identify difference in 
glycosylation among two healthy controls, three CMS patients caused by GFPT1 mutations, 
one CMS patient caused by DOK 7 mutation, one myopathy patient caused by MTND5 
mutation, one LGMD2A patient and one Pompe disease patient, though the quality of the 
results are good no significant link was found. The third project (Chapter 5) employed highly 
sensitive mass spectrometry and various enzymatic digestions to demonstrate the presence of 
α2,3-linked NeuAc, Lewis structures, sialyl-Lewis X, polyLacNAc and bisecting GlcNAc in 
CTB, STB and evCTB. These three projects are all about investigating glycosylation using 
MS, especially the first two projects which are focusing on glycosylation investigation 
between normal cells and abnormal cells.  
Several contributions to the field of glycobiology have been made during the research:  
1. It reports, for the first time, the glycolipid glycan profile of in vitro cultured normal human 
dermal fibroblasts (NHDF). Dermal fibroblasts are usually used in wound healing studies 
(Sorrell and Caplan, 2004; Froget et al., 2003). In addition, they are also important models for 
tissue regeneration and engineering studies and cancer research (Wong et al., 2007; Kalluri 
and Zeisberg, 2006). Glycolipid glycosylation has attracted a lot of attention due to its 
importance in wound healing and developing cancer therapeutic approaches (Wang et al., 
2014; Daniotti et al., 2013). Therefore, knowing the glycolipid glycan profile of the 
fibroblasts might shed light on these research areas.  
 2. It also for the first time reports the N-glycan profile of in vitro cultured human myoblasts 
and myotubes differentiating from in vitro cultured myoblasts, the O-glycan profile of in vitro 
cultured human myotubes. Myoblasts and myotubes are precursors of mature muscle cells, so 
glycan profile of myoblasts and myotubes would be similar to that of muscle cells. Muscle 
cells are essential in musculoskeletal system (locomotor system) as they receive signals from 
motorneurons and then execute contraction (Bentzinger et al., 2012; Abmayr and Pavlath, 
2012; Senderek et al., 2011). To achieve receiving signal, muscle cell surface receptors, such 
as acetylcholine receptors, are required. Acetylcholine receptors are glycoproteins and are 
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concentrated at neuromuscular synapses. In addition, many vital neuromuscular proteins, 
such as agrin and dystroglycan, are also glycosylated (Sanes and Cheney, 1982; Conti-
Tronconi and Raftery, 1982; Senderek et al., 2011; Martin, 2002). However, the structures of 
the glycans on these glycoproteins are not clear. Therefore, knowing the glycan profile of 
myoblasts and myotubes could provide possible structures for those glycans, and thus explain 
how these glycans function. 
3. It is the first report of  N-glycan profile of in vitro cultured human CTB, STB and more 
authentic evCTB. N-glycan structures that expressed on human gametes could be found in the 
N-glycan profile of the three types of trophoblasts, which supports the human fetoembryonic 
defense system hypothesis. The preeclampsia that arises in the placenta is hypothesized to 
have an immune etiology (Laresgoiti-Servitje et al., 2010). Comparing the N-glycan profile 
of trophoblasts from normal pregnant woman with preeclampsia patient may provide an 
explanation for the etiology. 
 
Chapter 3 describes the comparative glycomic analysis of HeLa cells and NHDF cells. The 
aim of the project was to find whether the cytotoxicity difference was caused by the 
difference in the glycan patterns of the cell surface. Not only were the glycans from 
glycoproteins of HeLa cells and NHDF analysed, but also the glycolipid glycans. The 
glycomic results showed a clear correlation with the results from Van Damme and Shang, 
which indicates the importance of protein-carbohydrate interactions for the proteins entering 
the cells. It might provide valuable insights into delivering drugs into cancer cells. For 
instance, the glycomic results show that HeLa cells express sialyl Lewis X structure while 
NHDF cells do not, therefore the sialyl Lewis X structure could be a potential target for the 
anticancer drug and thus enhance the deliver efficiency of the drug and avoid normal cells 
being killed by the drug. Simultaneously, this project provides the reader with a general 
understanding of currently commonly used glycomic methodology handling glycans derived 
from both glycoproteins and glycolipids and how mass spectrometry data are analysed and 
annotated. However, there are still some unsolved problems which are associated with this 
research project; for instance, the mechanism of the cytotoxicity of the proteins under study 
still needs to be uncovered. In addition, if there were sulphated glycans in HeLa and NHDF 
cells, their information was missing due to the permethylation strategy employed. The 
permethylation of sulphated glycans needs to be carried at 4 °C due to the thermal instability 
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of the bond(s) formed between the sulphate group(s) and the glycan, and the reaction time 
will be approximately 3 hours (Khoo and Yu, 2010). Following the permethylation strategy 
employed (see section 2.2.8), sulphated glycans will probably not be permethylated, and thus 
their information was lost.     
  
Chapter 4 describes the comparative glycomic analyses of in vitro cultured myoblasts and 
myotubes from healthy controls, CMS patients caused by GFPT1 mutations and other 
muscular disease patients. GFPT1 is the first enzyme of the hexosamine biosynthesis 
pathway (see section 1.7.1) and it catalyses the reaction providing the precursor for UDP-
GlcNAc synthesis. In humans, it has a redundancy, GFPT2 which is proposed to have the 
same function as GFPT1 due to the fact that their amino acid sequences share approximately 
75% identity (Oki et al., 1999; Nakaishi et al., 2009). However, it is reported that GFPT2 is 
mainly expressed in the central nervous system (Oki et al., 1999). Therefore, it is not 
necessary to consider GFPT2 here. Mutations in GFPT1 were expected to cause N-glycan 
branching variations and have an influence on protein glycosylation. However, the results 
showed that there was little difference among the glycan profile of healthy controls, GFPT1 
mutations caused CMS patients and other patients. This does not rule out the possibility that 
individual glycoproteins have altered glycosylation. The only way to look for this possibility 
is to target candidates and purify them. Current glycoprotein isolation and purification 
techniques cannot provide enough material for the glycomic analysis of glycoproteins of 
interest, which means that glycoprotein sample quantity limitations remain a challenge for 
glycomic studies. Therefore, these techniques still need to be further improved or developed. 
Future experiments aimed at the investigation of O-GlcNAcylation in the cells may enable 
the discovery of alternations in the glycosylation.  
 
Chapter 5 identifies the presence of several functionally important glycan structures (Lewis X, 
Lewis Y, sialyl-Lewis X, polyLacNAc and bisecting GlcNAc) in CTB, STB and evCTB. 
This chapter is a test of the human fetoembryonic defense system hypothesis (hu-FEDS). The 
results support the concept that the glycosylation patterns in these three types of trophoblasts 
could play a role in the suppression of immune responses at the pregnant uterus, and thus 
supports the hypothesis. The limitations of sample quantity remain a challenge in this project 
as usually multiple experiments are required on the same sample to provide full structural 
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information. In addition, more research is required to determine the function of these glycan 
structures. 
The NeuAc on trophoblasts (CTB, STB and evCTB) is proposed to contribute to NK cell 
resistance (see section 5.4.1), this could be tested by removing all NeuAc on CTB, STB and 
evCTB using sialidase A and then checking their NK cell resistance.  
A mouse model could be set up to test the potential function of Lewis structures mentioned in 
section 5.4.2. Since Lewis structures have a common point: they all have an extra fucose 
which is either α1,3-linked or α1,4-linked. These linkages are different from the core fucose 
linkage which is α1,6-linked. Therefore, it is possible to knock down the expression of α1,3 
and α1,4-fucosyltransferases (Gallego et al., 2003; Prohaska et al., 1978; Witte et al., 1997) 
and then compare the embryo development in the knock down mouse and normal mouse. It is 
expected that the knock down mouse would suffer abortion which could be caused by 
immune responses.  
PolyLacNAc is proposed to be easier than LacNAc to be involved in galectin binding (see 
section 5.4.3), this can be tested via a control experiment: two batches of CTB (or STB) cells 
need to be prepared, one batch will be treated with endo-β-galactosidase which is an enzyme 
hydrolysing internal β1,4 galactosidic linkage in this favoured repeating unit 
[GlcNAcβ1,3Galβ1,4]n (Scudder et al., 1983) (see section 2.2.7.4 for details), then the cells 
were extracted, washed and treated with UDP-Gal and β1,4-galactosyltransferase (see section 
2.2.7.3 for details); the other will not be treated. After that, same amount of fluorescence 
labelled galectin (e.g. galectin-3) will be added to the cells. The cells and labelled galectin 
will be incubated. After incubation iced cold PBS will be used to wash away the isolated 
galectin. The cells will be checked using fluorescence microscope. It is expected to see that 
the non-treated cells have stronger fluorescent signals than the cells treated with endo-β-
galactosidase and β1,4-galactosyltransferase as the N-glycans in the untreated cells have 
polyLacNAc while the N-glycans in the treated cells only have LacNAc. 
An experiment can be set up to test the potential function of bisecting GlcNAc in the 
trophoblasts mentioned in section 5.4.4.. Before the experiment, it is necessary to know that 
erythroagglutinating phytohemagglutinin (E-PHA) lectin preferentially binds to bisecting 
G1cNAc in N-glycans (Cummings and Kornfeld, 1982; Yoshimura et al., 1996). Firstly, CTB 
cells will be cultured with E-PHA (group 1) or cultured without E-PHA (group 2). In group 1, 
E-PHA will bind to CTB cells due to the fact that the cells express bisecting GlcNAc 
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containing N-glycans. Then cells from group 1 and group 2 will be resuspended and mixed 
with NK cells. Since the bisecting GlcNAc in group 1 is cryptic due to the presence of E-
PHA, CTB cells should be killed by NK cells. While in group 2 the bisecting GlcNAc will 
probably prevent CTB cells being killed. 
Although the three projects documented are separate, they all demonstrate the biomedical 
importance or potential biomedical importance of glycosylation.  
It is hoped that information obtained from the first project will be helpful for seeking cervical 
cancer treatment. Over the last thirty years, RIPs have been applied in the construction of 
targeted drugs against cancer cells. These drugs are usually designed to possess two portions, 
one portion (lectin portion) is used for binding to cancer cells and the other (toxin portion) is 
used for killing them (Tejero et al., 2015; Kreitman, 2006). If the drug can bind to HeLa cells 
specifically, then only HeLa cells will be killed. To achieve the specific binding, it is 
necessary to know surface glycan structures of HeLa cells and then design the corresponding 
lectin portion for the drug. The glycan profiles of HeLa cells in Chapter 3 can provide clues 
for the lectin design. Similarly, when design lectin portion for targeted drugs against other 
cancers, it would be better to perform glycomic analyses of the corresponding cancer cells as 
the glycan profiles would be useful for the lectin design. Information obtained from the 
second project has ruled out the possibility that GFPT1 mutations would cause global glycan 
alterations in in vitro cultured myoblasts and myotubes. This provides further impetus to 
elucidate the underlying mechanism of how GFPT1 mutations cause CMS as future 
researchers will only need to focus on some particular glycoproteins, such as acetylcholine 
receptor and agrin. In this situation, other techniques, such lectin binding and immunoblot, 
could be used to investigate the glycosylation variation of those proteins of interest. For 
instance, RL2 antibody which binds to single GlcNAc at serine or threonine residues can be 
applied to check the variation of O-GlcNAcylation in glycoproteins (Tashima and Stanley, 
2014). 
Results obtained from the third project provide support for the human fetoembryonic defense 
system hypothesis which links the expression of functional glycan groups to the protection of 
gametes and foetus in utero. It is possible that when implantation occurs, the same protection 
system that was used to protect sperm and eggs are incorporated into trophoblasts. Therefore, 
this may provide a possible explanation for some of those couples who cannot make babies: 
their gametes may have deficient glycosylation, and thus the trophoblasts also have deficient 
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glycosylation, which could not induce immune tolerance. This can be checked via comparing 
the N-glycan profiles of their gametes to the normal couples.   
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